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Enzymes play important roles in the functioning of any living system and regulating 
cellular processes. Within the 20,000-25,000 genes in human, only around 18-29% 
encode enzymes. However, due to lack of efficient technologies, little is still understood 
about the physiological roles, substrate specificity and downstream targets of these 
enzymes or proteins. Besides, it is also of great importance and interest to identify the  
specific enzymes or proteins associated with cancer states, which are called biomarkers. 
This kind of research is now named as “Catalomics”, which is an emerging “-omics” 
field focusing on high-throughput studies of enzymes or proteins by using advanced 
chemical proteomics approaches. Main challenge in the “Catalomics” field is how to 
develop robust and efficient platforms for following-up high–throughput screenings. This 
thesis examines and addresses these challenges by combining microarrays, microplates 
and other enabling platforms. Chapter 2 and 3 respectively present an affinity and activity 
based microarray approach for mapping the substrate specificity of PTPs. With these 
approaches, potent and specific substrates as well as new phosphatase/substrate pairs 
could be discovered. Chapter 4 demonstrates an array based systematic approach for 
high-throughput discovery of potent and selective SH2 domain binders, which will shed 
light on potent and selective SH2 domain inhibitor design in the future. Chapter 5 
presents a systematic microarray approach for comparative proteomic profiling of 
mammalian cell lysates and cancer biomarker candidates discovery, which will have the 
potential and be of great use and benefit for cancer diagnosis and treatment in the future.   
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1.1 Summary  
 
The complete decoding of human genes was regarded as one of the greatest scientific 
accomplishments of mankind.
1
 However, for most of those who work in related fields, it 
is only the beginning of a longer and much more challenging journey to identify all 
proteins expressed in humans and to elucidate the functions which they carry, as well as 
the mechanisms they impose so as to precisely control different aspects of cellular 
activities.
2 
Proteomics aims to identify and characterize protein products expressed by the 
genome of an organism, or the proteome.
3
 Although it was concluded from the human 
genome project (HGP) that there are only about 20,000-25,000 genes in human, it has 
been estimated that the human proteome could contain from as few as 100,000 different 
proteins, to as many as a few million.
4
 By studying the dynamic description of gene 
regulation, proteomics offers a powerful tool to unravel gene functions, holding promises 
to significantly impact our understanding of the molecular composition and function of 
cells. Furthermore, by studying the whole array of proteins in a cell, tissue, or an 
organism, it provides a global, integrated view of disease states and cellular processes.
5  
The alteration of the protein profiles upon perturbation by different signals, such as viral 
infection, and change of metabolic substrates, environmental or hormonal influences, 
may also be monitored and quantified, thereby providing a powerful tool to identify 
proteins that are potential targets or biomarkers for therapeutics/ interventions. An 
2 
emerging area, which is introduced as “Catalomics” in our group( Figure 1.1 ), is the 
development of high-throughput efficient platforms/techniques for high-throughput study 
and discovery of substrate and inhibitor specificities (e.g. substrate and inhibitor 
fingerprinting, respectively) of enzymes, as well as novel protein functions inside the 
cells, new protein-protein interactions, and biomarkers for diseases (such as cancers).
6-21
 
Main challenge in the “Catalomics” field is how to develop robust and efficient platforms 
for following-up high–throughput screenings. 
Enzymes play very important roles in the functioning of all living systems and in 
regulating cellular processes and metabolic transformations.
22
 As is well known, many 
human diseases (e.g. cancers) are caused by the aberrant regulation of enzymes inside 
cells.
23 
Consequently, enzymes account for >20% of all drug targets.
24
 However, little is 
known about the exact roles of these important enzymes, for example, what kinds of 
substrates they prefer, and what kinds of functions they perform inside the cells. 
Therefore, it is greatly imperative for chemical biologist to develop robust platforms 
which allow the unraveling of the role of enzymes in normal and diseased cellular 
processes, as well as in the discovery of new biomarkers for different kinds of cancers. 
Amongst a huge number of methods available to accelerate the functional 
annotation of enzymes and biomarker discovery, microarrays have become a powerful 
and versatile platform as they are compatible with many of the traditional solution-based 
enzyme assays. Besides, the outstanding features of microarray technology, i.e. 
miniaturization, parallelization and automation, make it very easy and convenient to 
perform thousands of enzyme assays simultaneously. A more detailed description of the 





Figure 1.1 Overview of Catalomics. This is focusing on high-throughput studies of 
enzymes using the chemical proteomics approaches, and its platform technologies and 
applications. 
 
1.2 Most of Important Enzymes Are Drug Targets  
Enzymes are important biocatalysts which are intimately involved in every 
cellular process and metabolic exchange. These proteins are suitable candidates for the 
directed perturbation of cellular functions and thus serve as valuable therapeutic targets.
26
 
Minor imbalances in enzymatic activities are known to cause debilitating diseases such as 
haemophilia and phenylketonurea, and even promote cancer and tumor metastasis.
27, 28a
 
Consequently, much attention has been paid to a better understanding of the activity, their 
substrates in vivo, new protein-protein interactions pairs, biochemistry and cellular 
pathways controlled by these enzymes, as well as in seeking novel pharmaceutical leads 
4 
to modulate their activities. 
Amongst the different classes of enzymes, phosphatases and kinases are 
responsible for the phosphorylation/dephosphorylation of biomolecules (shown in Figure 
1.2), which play important roles in cell cycle regulation, signal transduction and cellular 
communication.
28b
 It is normally agreed that protein tyrosine phosphorylation is regulated 
by the equal and balanced action of protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases (PTPs); However, much more attention has been paid to PTKs, partly 
because historically, the first PTP was purified 
29
 and cloned 
30




Protein kinases are considered to be the second most important group of drug 
targets after G-protein-coupled receptors. 
31b, 31c
 Aberrant kinase activity is reported in a 
variety of human diseases, in particular those involving inflammatory or proliferative 
responses, such as cancer and so on. So far, there are more than 400 kinds of human 
diseases, which have been directly or indirectly linked to protein kinases. The ability to 
modulate kinase activity therefore represents an attractive therapeutic strategy for the 
treatment of human illnesses. However, despite the wealth of potential targets, the most 
advanced compounds currently on the market or in clinical development target only a 
handful of the best-characterized kinases. The modulation of kinase activity can be 
achieved through several strategies: inhibition of phosphorylation activity by blocking 
ATP binding; disruption of protein–protein interactions; and downregulation of kinase 
gene expression by antisense or RNA interference approaches.
31d
 As kinases are not the 










For PTPs, recent findings have led to the discovery that PTPs play specific, active 
and even dominant roles in regulating the levels of tyrosine phosphorylation in cells and 
in the regulation of many physiological processes.
32-37
 In contrast to kinases which differ 
in the structure of their catalytic domains, many phosphatases gain specificity by binding 
protein cofactors which facilitate translocation and binding to specific phosphoproteins. 
The active phosphatase usually contains a phosphatase catalytic subunit and a regulatory 
subunit. Regulatory subunits for Tyr phosphatases may contain a SH2 domain allowing 
6 
binding of the binary complex to autophosphorylated membrane receptor Tyr kinases.
38
  
Tyrosine phosphorylation accounts for only 0.01-0.05% of total protein phosphorylation 
in normal tissues.
39
 However, upon oncogenic transformation or growth factor 
stimulation, the level of tyrosine phosphorylation increases to 1–3% in the cell.40 
Together with protein tyrosine kinases (PTKs), PTPs, and their corresponding substrates 
are integrated within elaborate signal transduction networks that are essential for cell 
growth, differentiation, and transformation. As PTPs as well as their regulatory subunits 
play so many functional roles inside the cells and are also linked to many cancers 
41b, 42a
, 
it will be of great importance to develop efficient platforms to identify potent and 
selective substrates/inhibitors candidates/binding partners for inhibitor design for the next 
generation drugs. 
43
 In the following sections, we shall review more detailed information 
about the PTPs and SH2 domains background and their recent developments, which are 
related to the main topic of this thesis.  
1.2.1 Protein Tyr Phosphatases (PTPs) 
One important group of the enzymes is protein tyrosine phosphatases (PTPs), and 
we will discuss more in the following sections, starting with their classification as below.  
1.2.1.1 Classification of Different PTPs 
Protein phosphatases (PPs) comprise a large family of enzymes that hydrolyze the 
phosphoester bonds of phosphoserines, phosphothreonines or phosphotyrosines. Therefore, 
for protein phosphatases, they are classified into three subgroups: the protein Tyr 
phosphatases (PTPs), protein Ser/Thr phosphatases, and those that cleave both. Among all 
these phosphatases, PTPs which are the subject of study in this thesis, together with PTKs, 
play more and more important roles in the key signalling pathways that are involved in 
7 
the control of cell proliferation, adhesion and migration, thus serving as oncogene or 
non-oncogene addiction genes that contribute positively to the initiation and maintenance 
of human cancer.
 42
 The PTPs inhibitor development field is still in infancy, especially for 
the potent and selective PTPs inhibitors.
44
 Especially recent findings have led to the 
discovery that PTPs play even key and dominant roles in control the levels of tyrosine 
phosphorylation in cell and in the regulation of many physiological processes. Therefore, 
PTPs including development of of their potent and specific small molecule inhibitors 
have attracted considerable attention in both basic research and pharmaceutical 
investigations, while PTKs inhibitors have been commercially and routinely developed 
for cancer treatment.  
To better investigate PTPs, one of most important things is to know all kinds of 
PTPs and their classification. If the classification is based on the amino acid sequence of 
all published PTPs, the list contains 107 human PTP genes, 105 of which have a mouse 
ortholog (one of the genes missing in a mouse has a rat ortholog). Based on the amino acid 
sequences of their catalytic domains, the PTPs can be grouped into four separate families, 
each with a range of substrate specificities (summarized in Figure 1.3).  
1.2.1.1.1 Class I Cysteine-Based PTPs 
Class I cysteine-based PTPs constitute by far the largest family (99 members),  
and can be further classified into several subfamilies based on domain architecture and 
the degree of homology between catalytic domains. Among the 99 members of class I 
cysteine-based PTPs, there are 38 strictly tyrosine-specific “classical PTPs”, which can 
then be divided into trans-membrane, receptor-like enzymes (RPTPs), and the 
8 
intracellular, non-receptor PTPs (NRPTPs). These 38 PTPs are represented in the human 
genome by 21 and 17 genes, respectively.
45 
Similar to protein kinases, the number of PTP 
catalytic domains encoded by the genome is greater than the number of PTP genes 
because many of the RPTPs have tandem catalytic domains. For the other 61 members of 
class I cysteine-based PTPs, they are grouped as VH1-like, or “dual-specific” protein 
phosphatases (DSPs), which is the most diverse group in terms of substrate specificity. 
All Class I enzymes have evolved from a common ancestor, based upon their similar 








1.2.1.1.2 The Class II Cysteine-Based PTPs 
This group of PTPs is represented in the human genome by a single gene, and is 
referred to as ACP1, which encodes the 18 kDa low molecular phosphatase (LMPTP). 
Related class II enzymes are widely distributed in living organisms with most bacterial 
genomes encoding at least one member of this family, which are remarkably well 
conserved through evolution. The single class II cysteine based PTP in humans is a 
tyrosine-specific low molecular enzyme, the origin of which appears to be more ancient 
than class I PTPs. Although the human LMPTP can also dephosphorylate a number of 
tyrosine kinases and their substrates, its physiological function is still not clear so far. The 
preservation of a class II PTP through evolution to humans and the correlation of allelic 
variants of LMPTP with many common human diseases, 
46 such as diabetes, Alzheimer’s 
disease, indicate that LMPTP likely is involved in the regulation of one or several 
fundamental processes in cell physiology.  
1.2.1.1.3 The Class III Cysteine-Based PTPs  
Class III cysteine based PTPs are tyrosine/threonine-specific phosphatases that 
most likely evolved from a bacterial rhodanese-like enzyme. They are only represented 
by the three cell cycle regulators (named CDC25A, CDC25B, and CDC25C) in humans. 
Their function is to dephosphorylate Cdks at their inhibitory dually phosphorylated 
N-terminal Thr-Tyr motifs, a reaction that is required for activation of these kinases to 
drive progression of cells through the cell cycle.
47
 Interestingly, a group of class I PTPs 
also contain a catalytically inactive rhodanese-like domain, referred to as the CDC25 
homology (CH2) domain. 
1.2.1.1.4 Asp-Based PTPs 
10 
Despite similarities in catalytic mechanism 
48
 and active site structure, 
49, 50, 51, 52
 
class I, II, and III cysteine-based PTPs evolved independently. Nevertheless, a structural 
comparison indicates that they may have originated from an ancestral fold by 
re-arrangement of elements. In contrast, the fourth family of PTPs use a different 
catalytic mechanism with a key aspartic acid and dependence on a cation. This family 
contains the Eya proteins, which were recently discovered to be tyrosine-, or dual serine- 
and tyrosine-specific protein phosphatases.
53, 54, 55
  
1.2.1.2 General Catalysis Mechanism of PTPs for Dephosphorylation  
The crystallographic structures of more than 20 PTPs have been solved and, 
together with mutagenesis experiments, have strongly contributed to our understanding of 
catalysis and substrate recognition. PTPs are a/β proteins composed of β-barrels flanked 
by a helix. The catalytic site is located in a groove at the protein surface which is deeper 
for classical PTPs (9 Å) than for DSPs (6 Å), a difference which explains the higher 
substrate selectivity of the classical PTPs. The characteristic motif (H/V)C(X)5R(S/T) 
and a surface loop rich in acidic residues are further elements common to the PTP 
domain. 
The general mechanism is explained herein using PTP1B as an example (Figure 
1.4), a phosphatase important in the insulin cascade, whose mechanism is likely reflective 
of that for most PTPs. The negatively charged phosphate substrate is stabilized by 
hydrogen bonds to residues of the phosphate-binding loop (P loop) and a highly 
conserved Arg group (Arg221 of PTP1B). Furthermore, a nearby α-helix dipole stabilizes 
the phosphate. Upon substrate binding, the enzyme undergoes a conformational change 
that brings the WPD loop over the substrate-binding pocket and generates further 
11 
stabilizing interactions, which are essential for substrate selectivity and catalytic activity. 
In the closed state, Asp181 is positioned near the substrate and forms a hydrogen bond 
with the phenolic oxygen atom of phosphotyrosine. Furthermore, the phenyl ring of 
phosphotyrosine is sandwiched by and forms hydrophobic interactions with Tyr 46 and 
Phe182. The central step of catalysis is a nucleophilic attack by a deprotonated cysteine 
residue (Cys215), which results in the formation of a covalent thiophosphoryl 
intermediate. Mutational analysis has shown that substitution of the active-site cysteine 
totally abolishes enzymatic activity. The active-site cysteine is particularly acidic in PTPs, 
as the thiolate anion is stabilized by several hydrogen bonds, one of which is formed with 
the proximal OH group of a conserved Ser/Thr moiety. The geometry of the 
pentacoordinate intermediate is stabilized by ionic interactions with the positively 
charged Arg221. The acidic Asp181 stabilizes the formation of a negative charge by 
protonation. In a second step, the intermediate is attacked by a water molecule that is 
deprotonated by Asp181 (at this point in its basic form), thereby releasing the cysteine 
and regenerating the enzyme after dissociation of the product. Besides, the conserved 
Ser/Thr group found proximal to the conserved Arg residue (Arg221) in the catalytic loop 
facilitates the hydrolysis of the enzyme-phosphoryl adduct, possibly through 
hydrogen-bond stabilization of a negative charge on the sulfur atom in the hydrolysis step 






Figure 1.4 General catalytic dephosphorylation mechanism of the PTPs against their 
substrates. 
 
1.2.1.3 Recent Advances of Protein Tyrosine Phosphatases (PTPs)  
 
 
Figure 1.5 Phosphorylation is balanced inside the cells by PTPs and PTKs. Loss of the 
balance will cause diseases including cancers. 
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Protein phosphorylation and dephosphorylation reactions are employed by living 
organisms for the regulation of innumerable cellular processes. The protein tyrosine 
phosphatases are the class of enzymes that act as catalysts in the dephosphorylation of the 
phosphotyrosine residues in their protein substrates. More than 100 PTPs are encoded in 
the human genome. PTPs play a crucial physiological role in variety of mammalian tissues 
and cells. Tyrosine phosphorylation accounts for only 0.01-0.05% of total protein 
phosphorylation. However, upon oncogenic transformation or growth factor stimulation, 
the level of tyrosine phosphorylation is clearly elevated inside the cells as well as cancer 
cells.
56
 Defective regulation of PTPs leads to various human diseases like cancer, diabetes, 
and immune disorders
 
(seen in Figure 1.5).
57
 PTPs have increasingly become important 
therapeutic drug targets. Therefore, in recent years, there have been numerous examples of 
extensive biochemical and structual studies on PTP family, which leads to a better 
understanding about the molecular mechanism of PTP catalysis. However, the molecular 
basis by which PTP distinguish and recognize the diverse substrates in cellular 
environment remains largely unknown. Currently, there are few methods which allow 
high-throughput and comprehensive studies on substrate specificity of PTPs. We admit 
that there has been some progress in the study of PTPs and some inhibitors targeting PTPs 
have been made and investigated in recent years. However, because the PTP active site is 
highly conserved, it is still a daunting task as well as significant challenge to design and 
develop selective and potent inhibitors targeting to a given PTP. Therefore, since PTPs are 
so important and linked to many diseases, it is of great importance to develop efficient 
screening tools as platforms to high throughput screening of potent and selective PTPs 
inhibitors or substrates candidates for drug development. As for the comparision of the 
14 
platform developed in our lab to other available screening tools, to avoid overlapping, 
please refer to the detailed introduction  parts in Chapter 2 and Chapter 3 respectively.         
1.2.2 SH2 Domains -One kind of Phosphotyrosine Binding Domains 
Signalling events that are initiated at the plasma membrane of eukaryotic cells 
control the reversible assembly of protein complexes to regulate cell motility, patterns of 
gene expression and so on through the cell cycle and programmed cell death. Much of 
this regulation is achieved through phosphorylation and dephosphorylation of important 
protein or enzymes. It is well known that reversible tyrosine phosphorylation is an early 
step in the transduction of many types of signals in multicellular organisms. 
Phosphorylated signaling proteins on tyrosine residues are usually specifically recognized 
by Src Homology 2 (SH2) domain modular proteins.
41c, 58
 SH2 domains are about 100 
amino acids long and they are found to be contained in many important proteins 
including PTPs, PTKs, growth factors receptors and adaptor proteins.
59
 Each SH2 domain 
recognizes a specific subset of pY peptide sequences.
60
 The specificity is determined by 
the interactions between amino acids adjacent to pY and the less conserved regions of the 
SH2 domain surface. Since SH2 domain modular proteins play very important roles in 
the signal transduction inside the cells/human body, mapping the SH2 domain binding 
specificity will help us predict/control the signaling state of the cell, thus facilitating us in 
developing treatment for human disease caused by the aberrant signaling. Different SH2 
domains select distinct phosphopeptides, and the function of a given SH2 domain is often 
determined by the specific motifs that it recognizes. Therefore, deciphering the 
phosphotyrosyl peptide motif recognized by an SH2 domain is the key to understanding 
its cellular function. A more detailed description about SH2 domains will be given in the 
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following sections.  
1.2.2.1 Discovery and Advances of SH2 Domains  
      The first modular signalling domain that was recognized to bind to its ligands in a 
phosphorylation-dependent manner was the Src-homology-2 (SH2) domain. 
The SH2 domain was originally identified from insertional mutagenesis experiments on 
the p130gag–fps tyrosine-kinase fusion protein of Fujinami sarcoma virus.61 Two of the 
inserts that were found to lie ~90 amino acids amino-terminal to the beginning of the 
kinase domain resulted in impaired kinase activity and defective cell transformation in 
Rat-2 cells, but when the mutant fps polypeptides were expressed in bacteria, they 
showed the same kinase activity as the wild-type fps polypeptide. Analysing the v-fps 
sequence by eye showed that these mutations were located within a ~ 100 amino-acid 
block that was conserved in numerous cytoplasmic tyrosine kinases, including Src. 
Therefore, Pawson and his colleagues
61
 named this region Src-homology-2 (SH2). SH2 
domains have subsequently been identified in a wide range of signalling proteins, often 
together with other modular signalling domains.  
SH2 domains were firstly discovered to bind to phosphotyrosine containing 
peptides or proteins (such as activated growth factor receptors and cytoplasmic 
phosphoproteins).
62-66
 Subsequent study indicated that binding depended on the sequence 
that flanks the phosphotyrosine residue.
67, 68, 69
 Oriented peptide library screening has 
been performed to identify the specific sequence motifs that are selected by various SH2 
domains.
 60, 71
 This information has been used to design synthetic peptides that modulate 
normal SH2-domain function, to select optimal phosphopeptides for structural studies
72-76
 
and to predict probable in vivo targets of individual SH2 domains.
 72, 77
 In most cases, 
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SH2 domains strongly favor particular amino acids that encompass the canonical 
phosphotyrosine and residues that lie 3–5 amino acids carboxy-terminal to it. 78, 79       
Although these methods mentioned above have contributed a lot for the SH2 
domains study, it is still a daunting challenge to design and develop selective and potent 
inhibitors targeting to a given SH2 domain, because there are so many members of 
conserved SH2 domains (more than 100) but with limited efficient tools for 
high-throughput and comprehensive studies of the binding specificity of SH2 domains. 
Therefore, it will be of great importance to develop high throughput and efficient tools to 
study any given SH2 domains proteins. 
1.2.2.2 Cellular Function of SH2 Domains 
As SH2 domains fulfill various cellular and molecular functions, mutations that 
occur within the SH2 domains of various proteins often result in defects in signalling 
pathways that manifest as several known diseases including cancers. 
A main function of SH2 domains is the recruitment of numerous signalling 
molecules to autophosphorylated receptor tyrosine kinases. As discussed above, 
particular tyrosine residues bind to different SH2-domain-containing proteins, depending 
on the amino-acid sequence that is adjacent to the phosphorylated tyrosine. Mutational 
studies have shown that the binding of some SH2-domain-containing molecules in 
isolation to the activated PDGF receptor is sufficient to transmit downstream signals that 
trigger DNA synthesis and immediate-early-gene expression.
80, 81
  
Besides, activated receptor tyrosine kinases also recruit SH2 domain containing 




 and NCK 
84
). GRB2 binds to receptor 
tyrosine kinases through its SH2 domain, but uses two SH3 domains to bind to the Ras 
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guanine-nucleotide exchange factor son-of-sevenless (SOS), which facilitates the 
production of GTP-bound Ras and the subsequent activation of the mitogen-activated 
protein kinase (MAPK) pathway.
82, 85, 86, 87, 88
 In this manner, tyrosine kinase and MAPK 
signalling pathways become coupled and linked. If other SH2-containing cytoplasmic 
signalling molecule except GRB2 is bound, it will result in negative regulation of 
receptor-tyrosine- kinase signalling.  
Active c-Src kinase                              Inactive c-Src kinase 
-open conformation                              -close conformation 
                           
 
Figure 1.6 c-Src protein tyrosine kinase activation mechanisms. The right panel shows a 
model of the structure of inactivated c-Src PTK that is phosphorylated on the C-terminal 
tyrosine Y527 by addition of CSK and ATP. The right panel shows possible mechanisms 
involved in activation of Src PTKs. Intramolecular interactions of the SH3 and SH2 
domains are disrupted in this open conformation. 
 
As for the SH2 domains’ function inside these cytoplasmic tyrosine kinases, most 
evidence indicates that they have two main functions: one in maintaining the kinase in an 
inactive state, and another in substrate targeting and processive phosphorylation after 
kinase activation (shown in Figure 1.6). In the absence of stimulation, Src is maintained 
in an inactive state through an intra-molecular association between its SH2 domain and a 
tyrosine-phosphorylated residue (Tyr527 in chicken Src) in the carboxy-terminal tail. The 
inactive state is further stabilized by an interaction between the SH3 domain and a type II 
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poly-proline helix in the segment that links the SH2 domain with the kinase domain. 
Concurrently, the SH2 and SH3 domains in the inactive enzyme remain rigidly coupled 
through the highly structured SH2–SH3 linker. 89, 90, 91, 92 Src activation by ligand binding 
to the SH2 or the SH3 domain, 
93, 94
 or by dephosphorylation of Tyr527, melts the 
SH2–SH3 linker, which allows the kinase subunit to become active. 91, 92 The release of 
the SH2 and SH3 domains from their intra-molecular associations therefore allows the 
Src SH2 domain to be recruited to a preexisting phosphotyrosine motif, at the same time 
as presenting an un-phosphorylated tyrosine to the kinase active site. This results in 
enhanced and processive phosphorylation of substrates.
 95, 96, 97
  
As for the SH2 domains appearing in tandem SH2 repeats, it will be more 
complicated. Mechanistic insight into the function of tandem SH2 domains has emerged 
from the structure of SHP-2. The amino-terminal SH2 domain packs tightly against the 
phosphatase catalytic domain (PTP domain) so that the loop that connects the SH2 βD′ 
and βE strands directly blocks access to the catalytic cleft of the enzyme. This maintains 
the phosphatase in an inactive state. Furthermore, the PTP–SH2 interaction deforms the 
amino-terminal SH2 domain, so that it cannot bind phosphotyrosine-containing ligands. 
By contrast, binding to the PTP does not occur when the amino-terminal SH2 domain 
binds to a tyrosine- phosphorylated ligand. So, the amino-terminal SH2 domain of SHP-2 
functions as an ‘allosteric switch’—it inhibits the enzyme in its unbound state, and 
activates it in its tyrosine-phosphorylated state. However, as the amino-terminal SH2 
domain has a diminished affinity for phosphopeptides when it is bound to the PTP, how 
can it be efficiently activated by phosphotyrosine- containing ligands? This is where the 
carboxy terminal SH2 domain comes in. By binding to one site of a dually 
19 
phosphorylated ligand, the carboxy-terminal SH2 domain both provides further binding 





1.3 Microplate Technology----Conventional Tool for Screening  
A microtiter plate is used mostly in laboratories and pharmacies. A microtiter 
plate could have 6, 24, 96, 384 or even sometimes 1536 wells arranged in rows. Each 
well of a microplate can only hold small amounts of liquid for screening. As is well 
known to chemists and biologists, microplate readers (also known as plate readers) are 
common laboratory instruments for the detection of biological, chemical, or physical 
events of samples in microtiter plates. Microplate technology is widely used in research, 
drug discovery, bioassay validation, quality control and manufacturing processes in the 
pharmaceutical and biotechnological industry and academic organizations. Sample 
reactions can be assayed in 6-1536 well format microplates. The most common 
microplate format used in academic research laboratories or clinical diagnostic 
laboratories is 96-well plates (8×12 matrix) with a typical reaction volume between 100 
and 200 µL per well. Higher density microplates (384- or 1536-well microplates) are 
commonly used for screening applications, when throughput (number of samples per day 
processed) and assay cost per sample become critical parameters, with a typical assay 
volume between 5 and 50 µL per well. Common detection modes for microplate assays 
are absorbance, fluorescence intensity, luminescence, time-resolved fluorescence, and 
fluorescence polarization. Among these methods, absorbance detection has been available 
in microplate readers for more than 3 decades, and is widely used for assays such as 
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ELISA assays, protein and nucleic acid quantification or enzyme activity assays (i.e. in 
the MTT assay for cell viability). A light source illuminates the sample using a specific 
wavelength (selected by an optical filter, or a monochromator), and a light detector 
located on the other side of the well measures how much of the initial (100 %) light is 
transmitted through the sample: the amount of transmitted light will typically be related 




1.4 Microarray Technology 
Miniaturization of fingerprinting (and screening) down to the scale of a few 
nanoliters per spot is possible with microarrays printed on glass slides. By combining a 
number of advantageous features, microarrays have emerged as one of the most 
prominent and revolutionary technologies currently available for multiplexed 
detection.
100, 101
 The cutting edge is provided by the ability of microarrays to miniaturize, 
parallelize and automate high throughput screening.
102 
 
1.4.1 Functionalization of the Glass Slides 
In recent years, researchers have overcome practical hurdles to now enable the 
stable immobilization of virtually any type of biomolecule on planar supports (typically 
glass/coated slides). The versatile immobilization chemistries developed have opened 









 small molecules 
109, 110
 or carbohydrates 
111
 may be presented on 
microarrays for simultaneous assessment. Cells and tissues have also been studied as 
microarrays, and benefit from the diverse manipulations (for example plasmid 




  These diverse platforms have matured rapidly, and are increasingly 
being channeled towards more extensive studies; accelerating the rate information may 
be assimilated for such “-omics” driven research. For the general method for the 
functionalization of avidin glass slides developed in our lab, it has been described in 
detail in Scheme 1.1.  
 
 
Scheme 1.1 Functionalization of the avidin coated slides for the microarray: (I) Normal 
glass slide for functionalization; (II) Amine functionalized glass slides; (III) COOH 
(carboxylic group) functionalized glass slides; (IV) NHS functionalized glass slides; (V) 
Avidin functionalized glass slides. 
 
 
1.4.2 Recent Advances of the Microarray Technology 
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      Microarray-based technologies were originally introduced by Fodor et al.
114
 in 
1991 in the form of peptide microarray. In 1995, Schena et al.
115
 firstly created the now 
highly popular DNA microarray. Small-molecule and protein microarrays were 
subsequently developed by MacBeath et al., 
116, 117
 and for the first time, the array-based 
detection of kinase activity using peptide substrates was also demonstrated. In essence, 
these pioneering studies set the precedent for development of various types of 
microarray-based enzyme assays capable of sensitive characterization of different 
enzyme classes.
1c, 25
 At present, four key microarray-based platforms, namely protein, 
peptide, small molecule and cell based microarrays, have been successfully developed for 
catalomics or the high-throughput study of enzymes. Irrespective of the platform type, a 
capture, or bait molecules (such as proteins, peptides or small molecule and so on) are 
immobilized on a substrate, and then analytes in a solution are incubated on the spotted 
array. With the activity or interaction between the bait molecules and analytes, the 
microarray fingerprints are generated based on the activity 
118, 119
, or based different types 
of interaction for microarray application, such as protein–lipid interaction,105  
protein–protein interaction, 120, 121, 122 protein–peptide Interaction,123 protein–DNA 
interaction, 
124
 protein–small-molecule interaction, 125 Protein–RNA Interaction, 126  
protein–glycan Interactions.127  
 
1. 5 Solid Phase Peptide Synthesis and IRORI Sorting 
Technology 
      Merrifield’s idea of the synthesis of peptides on solid support128, 129, 131, 132  
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fundamentally changed the thinking of peptide chemists (even though, depending on the 
personality of the scientists, the adoption of the solid phase methodology sometimes 
required a very long “induction period”). Later, as it became apparent that the 
transformation of sometimes unpredictable behavior of synthetic intermediates into 
predictable behavior of solid support with attached organic moieties makes synthetic 
process and purification of intermediates very simple, organic chemists worked hard to 
show that almost all types of organic transformations can be performed on solid support 
and solid phase synthesis was broadly embraced by chemists in all fields. Solid supports 
allow an easy realization of parallel synthesis. It requires just the compartmentalization of 
solid phase and the individualized delivery of reactants. This concept of 
compartmentalization was later pushed to its limit by the realization that each particle of 
solid support can serve as an individual compartment in which individual peptides can be 
produced to create libraries of millions of peptides or any other molecular species. 
133
  
This one-bead–one compound concept is covered in detail elsewhere 133, 134 and will not 
be discussed here. When some new technologies (such as IRORI™) 135 were developed, 
high throughput peptide synthesis became feasible (seen in Scheme 1.2). For the detailed 












Scheme 1.2 Simplified scheme for the IRORI™-assisted high throughput 
phosphopeptides library synthesis. (a)The phosphopeptides are individually synthesized 
inside each microreactor with the assistance of IRORI™ directed sorting combinatorial 
technology; (b) Description for one cycle coupling for peptide synthesis. 
  
 
1.6 Post Translational Modifications (PTMs) 
Post-translational modifications (PTMs) modulate protein function in most 
eukaryotes and have a ubiquitous role in diverse range of cellular functions. The 
interpretation of proteome data obtained from the high-throughput methods cannot be 
deciphered unambiguously without a priori knowledge of protein modifications. An 
in-depth understanding of protein PTMs and their physiological roles (such as their 
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substrates, binding proteins and so on) is important not only for gaining a perception of a 
wide array of cellular functions but also towards developing drug therapies for many 
life-threatening diseases including cancer and neurodegenerative disorders.  
The common modifications include phosphorylation, acetylation, glycosylation, 
ubiquitination, acetylation, and hydroxylation. Posttranslational modifications (PTMs) of 
proteins influence the enzyme activity, protein turnover and localization, protein-protein 
interactions, modulation for various signaling cascades, DNA repair, and cell division. 
Given the important roles of PTMs in the regulation of cellular environment, there is a 
constant effort to develop novel, highly sensitive, and sophisticated PTM techniques to 
identify, study these proteins as well as related proteins
.136, 137, 138, 139
 Most of these 
commonly observed PTMs are routinely tracked as disease markers while many others 
are used as molecular targets for developing target-specific therapies.  
Herein we introduce one of most important PTMs-phosphorylation, which is also 
one of most important and related topic in this thesis. Phosphorylation, addition of a 
phosphate group to an amino acid, is one of the central reversible, post-translational 
modifications that regulate cellular metabolism, protein-protein interaction, enzyme 
reactions, and protein degradation for a myriad of proteins, which results in intracellular 
signaling cascades.
140, 141
 This reaction is mediated by a number of protein kinases (PKs) 
in the cell. Conversely, dephosphorylation or removal of a phosphate group is an 
enzymatic reaction catalyzed by various phosphatases (PPs).
140
 Dysregulated 
phosphorylation has been implicated in neurological diseases like Parkinson’s and 
dementia that harbor the accumulation of the Lewy bodies.
142
  Besides, the role of 
protein phosphorylation/dephosphorylation in cancers and their huge impact in disease 
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pathophysiology has been extensively reviewed multiple times over the years, with a 
steady stream of new discoveries of protein phosphorylation and their effects in disease 
pathology.
143, 144, 145, 146 
  
All above clearly show that post-translational modifications play important roles 
insides the cells/human bodies. Once losing balances, they will be linked to many 
diseases including cancers. 
 
1.7 Biomarkers and Their Identification 
A biomarker is a measurable indicator of a specific biological state, particularly 
one relevant to the risk of contraction, the presence or the stage of disease. Biomarkers 
can be used clinically to screen for, diagnose or monitor the activity of diseases and to 
guide molecularly targeted therapy or assess therapeutic response.
147
 Though historically 
often a physical trait or physiological metric, the term is now typically shorthand for a 
molecular biomarker. Molecular biomarkers can take many forms, and as a consequence 
a variety of strategies have been adopted for their discovery. Transcriptional profiling and 
DNA methylation studies have shown strong potential for biomarker discovery in 
cancer
148
, and metabolomics approaches are beginning to show promise for metabolic 
disease, drug and toxicity studies.
149
 Indeed, since 1998, the rate of introduction of new 
protein analytes approved by the US Food and Drug Administration has fallen to an 
average of one per year (personal communication, Leigh Anderson, Plasma Proteome 
Institute). The reasons for this disjunction are many fold and reflect the long and difficult 
path from candidate discovery to clinical assay, and the lack of coherent and 
comprehensive processes for efficient biomarker development.
150, 151, 152 
 
27 
The principal enabling technology of proteomic tools for biomarker discovery is 
MS. All mass spectrometers, regardless of type, ionization mode or performance 
characteristics, produce mass spectra, which plot the detected ion abundance (Y axis) 
versus mass-to-charge ratio of the ions observed (X axis). Subsequent interpretation of 
spectra, using characteristics such as isotope distribution, accurate mass and amino acid 
sequence information (in tandem MS (MS/MS) experiments), may allow portions of the 
spectrum to be labeled with a protein or peptide identity. However, whether a peptide or 
protein has been identified or not, what gives it the status of a candidate biomarker is its 
consistent variation in some fundamental characteristic, such as abundance, between two 
states of disease.
152
 Although a lot of progress have been made by this strategy, it also has 
its own limitation. It has intrinsic limitation in discriminating the structural isomers. 
Besides, it also requires expensive equipment, and time-consuming for sample 
preparation and separation, and annotation techniques.
153 
 
The use of protein microarrays in biomarker discovery has recently received 
particular attention from researchers in cancer medicine. A biomarker can be understood 
as a molecule or set of molecules linked to a defined biological state of a cell, organ, or 
organism; this biological state may, for example, reflect a certain disease state in cancer. 
The identification of biomarkers in early-stage cancers could lead to improved therapies 
and survival rates of patients.
154
 Antibody arrays are the most commonly used protein 
arrays in biomarker discovery and proteomic research.
155 - 163
  
      Besides, autoantigen or proteins microarrays also have enormous impacts on 
clinical diagnosis and prognosis,
164
 high-throughput characterization of monoclonal 
antibody (mAb) target specificity 
165




Although these technologies have made a lot of useful contributions for 
biomarkers identification and discovery, they also have their own limitations. For protein 
and antibody microarrays, it is difficult to maintain protein activity and their 
configuration properly for long time on the microarray. Besides, it will take long time and 
a lot of money to make these specific antibodies. For other platform or technologies 
(Such as MS or 2D-DIGE), they all have their own limitations either in terms of  very 
expensive instruments and taking relatively long time to prepare the samples (For MS), or 
not high throughput (For 2D-DIGE). Therefore, it is necessary and of great importance to 
develop complementary, relatively cheap and efficient platform to identify the useful 
biomarkers candidates in future.  
 
1.8 Project Objectives 
The aim of this thesis is to develop novel high throughput screening technologies, 
which could not only provide the complete fingerprints in terms of their substrate 
specificities, binding potency and kinetic measurements of a given enzymes or proteins, 
but also enable high throughput comparative proteome profiling of mammalian cell 
lysates via global phosphopeptide-protein interactions. The technologies developed 
should ideally be highly scalable and offer a high-throughput insight into enzyme 
biology. 
From the pure enzymes or proteins based screening, the detailed data analysis for 
the fingerprints could be applied to solve the substrate specificity issue of functionally 
and structurally homologous enzymes/proteins on a broad scale, and offer unique insight 
into enzyme catalytic mechanism and new protein-protein interactions, thus providing 
29 
invaluable information for identification of physiological substrates as well as for 
selective inhibitors design in future; from the comparative proteome profiling, the 
fingerprints generated from the peptide microarrays screening results could be used to 
compare different mammalian proteomes, and the selective peptide probes were then 



























High-throughput Screening of Catalytically Inactive 




2.1 Summary  
PTPs have become important therapeutic targets in recent years. However, the PTP 
active site is highly conserved across the whole PTP families, which present a daunting 
task to design selective and potent inhibitors targeting to each PTP. The successful 
development of PTP inhibitors relies on a detailed undertanding about the molecular 
mechanism of PTP catalysis as well as substrate specificity. In our approach, we applied 
the fluorescently labeled PTP mutants onto pTyr peptide array and studied the substrate 
specificities of different PTPs. By using this approach, we were able to 1) generate the 
unique and comparative affinity-based substrate fingerprints against different PTPs, 2) 
obtain quantiative KD values of a given phosphatase against different substrates on a single 
slide, and 3) simultaneously screen multiple PTPs under different fluorescence channels by 




The events of protein phosphorylation and dephosphorylation reactions are used by 
living organisms for the regulation of a lot of cellular processes. During these 
phosphorylation and dephosrylation reactions, the protein tyrosine phosphatases are the 
class of enzymes that behave as catalysts for the dephosphorylation of the phosphotyrosine 
residues in their corresponding substrates. So far, more than 100 PTPs have been found in 
the human genome. PTPs play a crucial physiological role in various mammalian tissues 
and cells. Although tyrosine phosphorylation accounts for only 0.01-0.05% of total protein 
phosphorylation, upon oncogenic transformation or growth factor stimulation, the level of 
tyrosine phosphorylation increases to 1-2% in the cell. 
56
 Defective regulation of PTPs 
leads to various human diseases like cancer, diabetes, and immune disorders. 
57
 PTPs have 
increasingly become important therapeutic drug targets and some inhibitors targeting PTPs 
have been made and investigated in recent years. However, the PTP active site is highly 
conserved which presented a daunting task as well as significant challenge for designing 
selective and potent inhibitors targeting to a given PTP.  
PTP1B shares 74% sequence homology with TCPTP in their catalytic domain, 
however, their substrate specificity has implicated these enzymes in various signaling 
pathways.
167
 SHP1 is implicated as a negative regulator in haemopoietic signalling.
168 
 
SHP2 is very similar to SHP1 in terms of sequence homology. However, their fucntions are 
very different. Deletion of this gene will result in death which indicates SHP2 is critical for 
regulation of cellular function. SHP2 is also implicated in the cancer development as a 
result of mutations.
169
 LMW PTP is a small size PTP which is composed of around 157 
amino acid residues. The little sequence similarity between LMW PTP and other PTPs 




       In recent years, there have been numerous examples of extensive biochemical and 
structual studies on PTP family, which leads to a better understanding about the molecular 
mechanism of PTP catalysis. However, the molecular basis by which PTP distinguish and 
recognize the diverse substrates in cellular environment remains largely unknown. 
Currently, there are few methods which allow high-throughput and comprehensive studies 
on substrate specificity of PTPs. Only in 2007 and 2008, Waldmann and our group 
independently report the feasibility of using peptide microarray for large-scale phosphatase 
substrate specificity studies.
118, 119







 peptide array offers the unique advantages in 
terms of throughput and sensitivity. 
 
Scheme 2.1 The strategy used in this study. The PTP mutants were fluorescently labeled 
and used to probe the binding affinity towards the pTyr array. 
In our approach, we developed an innovative array technique based on PTP 
substrate-trapping mutant 
174
 (Scheme 2.1). The method is based on the ability of PTP to 
bind to its cognate substrate during dephosphorylation. When the critical active site residue 
is mutated, namely Cys to Ser, the substrate retains the ability to bind to PTPs; whereas the 
nucleophile attack on the phosphatae cannot occur. The substrate-trapping mutant 
33 
approach has been utilized extensively for the identification of a number of putative PTP 
substrates both in vitro and in vivo. By integration of microarray and PTP substrate mutant 
approach, it allows one to 1) generate the unique and comparative affinity-based substrate 
fingerprints against different PTPs, 2) obtain quantiative KD values of a given phosphatase 
against different substrates on a single slide, and 3) simultaneously screen multiple PTPs 
under different fluorescence channels by a single doube-labeling assay.  We envisage this 
approach will be able to quickly discern the substrate difference of  highly homologous 
PTP pair, e.g.  PTP1B and TCPTP, SHP1 and SHP2. These information will greatly help 
to design the highly specific inhibitors for a given phosphatase. Unlike the activity based 
assays for high-throughput screening of PTP inhibitors where highly reactive oxidizing 
and alkylating reagents might surface as hits, our approach eliminates the potential false 




2.3 Results and Discussion 
2.3.1 Peptide Library Synthesis 
We synthesized 144 putative peptide substrates of PTPs, each containing 11 
amino acid residues with a central located pTyr moiety flanked by 5 amino acid residues 
on each side. The peptide sequence is derived from potential PTP protein substrates by 
data mining from the website:www.hprd.org. The peptides were individually synthesized 
by standard solid-phase peptide chemistry and characterized by LC-MS. An extra 
hydrophilic linker and biotin were introduced at the N-terminus of each peptide, which 
was then subsequently immobilized onto an avidin-coated glass slide to generate the 
34 
corresponding peptide microarray. To ensure uniform immobilization, spotted slides were 
subject to Pro-Q dye treatment. The image indicated most of the peptides were spotted 





















































































Figure 2.1 The Pro-Q image of 144 pTyr peptide library. (a) The microarray image after 
staining with Pro-Q dye. (b) The spotting format in our study. 
 
2.3.2 Substrate Binding Fingerprinting for PTPs Mutants 
Next the active site mutants of 5 different PTPs (PTP1B, TCPTP, SHP1, SHP2 
and LMWPTP) were mutated by using the commercially available site directed 
mutagenesis Kit. Subsequently, these PTP mutants were expressed, purified, fluorescently 
labeled and applied onto array. Highly reproducible data were obtained across different 
slides. (r>0.9) All PTPs tested showed distinct substrate specificities against our peptide 
microarray (Figure 2.2a). The peptide AELEFpYMDYEA which was previously 
reported as a potent substrate for PTP1B 
176
 showed the strong binding affinity towards 
PTP1B in the array, which indicated the feasibility of our approach for identifying the 
potent substrates. PTP1B and TCPTP displayed very similar binding pattern which 




sequence homology also clustered together (Figure 2.3). LMW PTP is implicated as a 
novel class of PTP which showed the most unique binding pattern among the 5 PTPs 
investigated. SHP1 and SHP2 are well known to bind to ITIM motif.
177
 Further data 
analysis with the frequency of occurrence of a particular amino acid at N-3 and C+2 
positions were carried out with the top 69 binders selected from both SHP1 and SHP2 
binding experiments. Results indicated that SHP phosphatase indeed prefers the amino 
acid residue “Ile”, “Leu”, “Thr” and “Val” at N-3 and C+2 position (Figure 2.2(c)). 
Interestingly, the top binders for SHP1 and SHP2 identified from our array experiments 
closely matched with the literature, which reported the relevant experiments showing 
their interaction in vitro or in vivo (Figure 2.4). Nevertheless, this did not apply to 
PTP1B and TCPTP, which probably could be due to the reason that there might be other 
factors which determine the substrate specificity, e.g. subcellular localization or the 
protein sequence other than catalytic domain which is responsible for binding to occur. In 
the mean time, the denatured fluorescently labeled protein didn’t show any binding 
towards our array which indicated our affinity assay is activity dependent. The 14-3-3 
protein which contains the GST tag served as a negative control and did not show any 
obvious binding towards our array. It indicated that GST tag did not contribute any 
binding to our array. On the other hand, it also proved the pSer/Thr binding proteins did 
not bind to pTyr peptides. The previous reported pSer/Thr peptide array also did not show 













Figure 2.2 Substrate fingerprints of 5 different PTP mutants. (a) Microarray image of 5 
different PTP mutants. (b) Substrate fingerprintof 5 different PTP mutants in “Tree view” 
format. (c) The summary of amino acid frequency at N-2 and C+3 position of Top 69 




Figure 2.3 Calodograms of  PTPs based on substrate fingerprint obtained from pTyr 
peptide array. The panel was clustered according to the fluorescence data set of 144 
























































































































































Figure2.4 The venn diagram from top 59 binders of SHP1 and SHP2. It shows that 32 
peptides which sequence are derived from SHP1 or SHP2 protein substrates are in the list. 
























Figure 2.5 Proof–of-concept experiments with pTyr peptide array. (a) The denatured 
experiment of PTP mutants. The top panel showed the image obtained with denatured 
fluorescently labeled mutants. The bottom panel showed the image obtained with the 
corresponding fluorescently labeled mutants. (Left, SHP1, right PTP1B) (b) The 
microarray image of 14-3-3 protein against pTyr peptide array. 14-3-3 protein, which is 
previously shown to binding to a pSer/Thr peptide microarray, did not show measurable 
specific binding to any of the pTyr peptides on the array, indicating our pTyr peptide is 
highly specific for screening of PTP mutants.  
 
2.3.3 Dual Color Microarrays  
Next we went on further to investigate the substrate specificity difference between 
the highly homologous pairs by using dual labeling approach. Due to the high degree of 
homology between PTP1B and TCPTP, it is extremely challenging to identify the selective 
substrates or inhibitors towards PTP1B or TCPTP. To discriminate the subtle difference 
between these two enzymes, we carried out the dual labeling assay and identified several 

















Figure 2.6 Dual labeling assay with PTP1B and TCPTP. (a) The microarray image of 
PTP1B Cy5 vs TCPTP Cy3, (b) The summary of selectivity ratio results of PTP1B against 
TCPTP. The higher the value, the more selective towards PTP1B. 
Subsequently, we picked up 3 of the selective peptides and verified the selectivity by 
microplate activity assays,which is named malachite green assay for detection of the free 
phosphate group dephosphorylated from phosphopeptides. The results indicated that the 
peptides were indeed specific towards PTP1B (Table 2.1). 
Table 2.1  The kobs of PTP1B-selective peptides against PTP1B and TCPTP. 
Peptide 
NO. 






B15 IESDI-pY-AEIPD Type 12 0.14 0.048 
D12 SSTVQ-pY-STVVH SHP2 0.215 0.11 
D24 YFMTE-pY-VATRW Mitogen kinase 0.040 0.017 
    
SHP phosphatase is known to contain two N terminal SH2 domain and catalytic 
domain. SH2 domain is also known to bind to pTyr containing peptides. To explore 
whether the binding affinity comes from SH2 domain itself or PTP catalytic domain alone, 
we overexpressed proteins of SH2 domain and catalytic domain from SHP2 respectively 
and applied fluorescently labeled proteins onto array. Results indicated that both of SH2 
domain and catalytic domain has the binding affinity towards our pTyr peptide array. 
 
 








Further data analysis also indicated that the full length SHP phosphatase binding affinity 
comes from both SH2 domain and catalytic domain together (Figure 2.7a).  On the other 
hand, SHP1 and SHP2 are interesting homologous PTP pair under our investigation. They 
share 61% homology in their catalytic domain and 64%, 55% similarity in their two N 
terminal SH2 domains respectively;
178
 however,  their cellular functions are very 
different. SHP1 is a potential anti-oncogene and inhibits the growth of tumor by negatively 
regulation of c-Kit gene. Whereas SHP2 was defined as a bona fide oncogene which 
arouses much interest to develop the selective inhibitors targeting to SHP2.
179
  In our dual 
labeling assay , we were able to identify several peptides selective to SHP1 or SHP2 
respectively (Figure 2.7c). As the figure showed, 5 out of them showed the strong 
selectivity towards SHP1 and 7 out of them showed strong selectivity towards SHP2.  
Interestingly, peptide B6 derived from c-Kit Tyr569 was found selective to SHP1. 
Previous reports has identified the Tyr 569 as the major site for binding of SHP1 to c-Kit 
whereas Tyr567 is involved with SHP2.
180
 This agrees well with our results which also 
suggests the Tyr 569 is selective towards SHP1. The cadherin and catenin complex was 
tyrosine phosphorylated and associated with cytosolic SHP1, 
181
 although the detailed 
anchoring part is still unknown. Our studies with peptide A18 indicated that Tyr 654 might 
serve as a specific anchoring site for association with SHP1. FAK2 is demonstrated as a 
direct substrate for SHP1 in vitro.
182 
FRS-2 was reported to form a complex with 
N-terminal SH2 domain with SHP2 in response to FGF stimulation.
183 
Gab-1 is tyrosine 
phosphorylated and forms a complex with SHP2 upon stimulation with gp130 or 
interleukin-3 receptor.
184
 Tyr 1009 phosphorylation in the C-terminus of PDGFR is 
required for the stable association with SHP2.
69e




 Phosphorylated MYELIN PZR was associated with SHP2.
186
 SHP2 
binds to IRS-1 via SH2 domains in response to insulin.
187
 All these reported examples have 
matched with our results pretty well, which might indicate that the particular 
phosphorylation site identified from our studies potentially serve as selective anchoring 
site for differentiation between SHP1 or SHP2 in vivo. 
It was suggested that the catalytic domain directly contributes the substrate 
specificity to the highly conserved SHP1 and SHP2 PTPs.
168, 178 
To explore whether the 
substrate specificity of full length PTP comes from catalytic domain or SH2 domain, both 
catalytic domains of two SHP PTPs were cloned, expressed, fluorescently labeled and 
applied onto our array respectively. The dual labeling experiments showed that the 
selective peptides identified from SHP1 catalytic domain closely matched with those 
peptide previously identified from the full length PTP experiments (Figure 2.8 & Table 
2.2).  Although at current stage we cannot rule out the possbilities that SH2 domain might 
aslo confer substrate specificity to some extent considering the difference between two sets 
of selectivity ratio data, we were able to pinpoint the catalytic domain of PTP contributes 



















1  3  5  7  2  4  6  8  
Figure 2.7 Substrate fingerprints of SH2 domain and catalytic domain of SHP2 mutants 
and dual labeling assay with SHP1 and SHP2 full length mutants. (a) The fingerprinting 
results of SHP2 full length, SHP2 SH2 domain and SHP2 catalytic domain. (b) The 
microarray image of SHP1 full length and SHP2 full length mutants. (c) The summary of 
selectivity ratio results of SHP1/ SHP2 or SHP2/SHP1. 
 





1  3  5  7  2  4  6  8 
Figure 2.8 Dual labeling assay with SHP1 and SHP2 catalytic domain. (a) Microarray 
image of SHP1 catalytic domain Cy5 and SHP2 catalytic domain Cy3. (b) The summary of 





































































































































Table 2.2 The summary of SHP1 catalytic domain-selective peptides. 
384 well Peptide 
Sequence 
Enzyme Protein Source SHP1/SHP2 
Catalytic Domain 
Ratio 
A18 EGVAT-pY-AAAVL SHP1 CATENIN 7.6 
C19 PSFSE-pY-ASVQV SHP2 SIRP 4.3 
E19 AELEF-pY-MDYEA  Alanine scanning 6.6 
B6 GNNYV-pY-IDPTQ SHP1 KIT 4.0 
B15 IESDI-pY-AEIPD Type12  4.5 
 
To study the strength of binding interactions, we next performed the KD 
experiments on the array with three PTPs, namely PTP1B, SHP1 and SHP2. The data 
were fitted to a saturation dynamics reaction, which assumes that when equilibrium is 
achieved, KD information could be extracted from the resulting curves. Upon subjecting 
the data to the stringent filtering criteria (r>0.9) and significant binding intensities, we 
were able to obtain the KD data which showed a good affinity on the array. We also 
compared the KD data with selectivity ratio data obtained from SHP PTPs previously. 
Results indicated that the KD value could also reflect the selectivity between SHP1 and 







Figure 2.9 Microarray image of concentration dependent SHP1 (up) and SHP2 (down) 
binding experiments.  
 















A18 EGVAT-pY-AAAVL SHP1 Catenin 654 0.96 1.1 9.4 
E19 AELEF-pY-MDYEA  Alanine 
scanning 
 0.41 ND 17.7 
E21 GPQDI-pY-DVPPV  P130cas  1.1 ND 12.7 
B6 GNNYV-pY-IDPTQ SHP1 KIT 570 ND ND 5.3 
B15 IESDI-pY-AEIPD Type12 FAK2  0.2 ND 27 
ND the fluorescent value was low and KD was unable to be determined. 
Too high signal means signal reached saturation point at very low concentration. 
 

















A9 DKQVE-pY-LDLDL SHP2 GAB1 657 4.7 0.96 5.1 
A17 EDTLT-pY-ADLDM SHP2 SIRP 470 7.9 4.1 7.0 
A20 ENGLN-pY-IDLDL SHP2, 
PTP1B IRS1 
1179 ND 0.18 4.8 
C22 QGPVI-pY-AQLDH SHP2 MYELIN 241 1.3 0.14 8.4 
B11 HRQLN-pY-IQVDL SHP2 FRS2 436 1.4 0.42 4.5 
D18 TSSVL-pY-TAVQP SHP2 PDGF 1009 ND 0.095 4.1 
 
46 
ND the fluorescent value was low and KD was unable to be determined. 
 
2.4 Conclusion 
In conclusion, we have developed an affinity-based array capable of determination 
of  the substrate specificity against various PTPs. The information obtained should allow 
us to shed light on the molecular mechanism of protein-protein interactions in the 
signalling proteome. More importantly, by using the dual labeling approach, we were able 
to differentiate the subtle differences between the closely homologous PTP pairs, e.g. 
PTP1B and TCPTP, SHP1 and SHP2. We envisage this approach will greatly accelerate 




















Activity Based High-Throughput Determination of 






Protein tyrosine phosphatases (PTPs) constitute a large family of enzymes that play 
key roles in cell signalling. Malfunction of PTPs activity results in aberrant tyrosine 
phosphorylation, which has been linked to several human diseases, including cancer. 
Since phosphate removal by the PTPs can both enhance and antagonize cellular 
signalling, it is essential to elucidate the physiological roles of PTPs in cellular events, 
especially the physiological substrates of PTPs. Herein a library of 144 putative peptide 
substrates against different PTPs was synthesized and immobilized on the array. 
Screening of the phosphopeptide library against various PTPs provided the distinctive 
and comparative substrate fingerprinting against different PTPs. Several potent and 
selective substrates were identified against different PTPs. This information could be 
valuable in the future for the design of the potent and selective PTPs inhibitors. The 
signal-decreased kinetic microarray assay provided a facile and efficient way for 
determining the kinetic constants for many peptides against different PTPs. Furthermore 




Protein tyrosine phosphatases (PTPs) play a critical role in regulation and 
maintainance of cellular functions. Tyrosine phosphorylation accounts for only 
0.01-0.05% of total protein phosphorylation in normal tissues.
39
 However, upon 
oncogenic transformation or growth factor stimulation, the level of tyrosine 
phosphorylation increases to 1-3% in the cell.
40
 Together with protein tyrosine kinases 
(PTKs), PTPs and their corresponding substrates are integrated within elaborate signal 
transducing networks that are essential for cell growth, differentiation, progression 
through the cell cycle, cell-cell communication, cell adhesion and migration, gene 
transcription, ion channel activity, the immune response and apoptosis/survival 
decisions. Malfunction of PTPs could lead to numerous diseases, such as diabetes, 
obesity and even cancers.
43
 PTPs have thus become important therapeutic targets in 
recent years. However, the PTP active site is highly conserved across the whole PTP 
families, which presents the daunting task to design selective and potent inhibitor 
targeting each PTP. The successful development of PTP inhibitors relies on a detailed 
understanding about the molecular mechanism of PTP catalysis as well as substrate 
specificity.  
Although PTPs share a common core catalytic domain and similar catalytic 
mechanism, they do show distinct and often unique biological functions in vivo.
188
  
The ability of phosphatases to selectively dephosphorylate the specific substrates in 
the presence of many other potential substrates in cellular environment is essential for 
maintaining normal cellular processes. Knowledge of the substrate specificity of a 
49 
given phosphatase can therefore be used to facilitate the identification of its 
physiological substrates, which is essential for elucidation of its biological role. 
Moreover, determination of substrate specificity can also aid in the design of potent 
and selective substrates and inhibitors. 
In recent years, there have been numerous examples of extensive biochemical 
and structural studies on PTP families, which lead to a better understanding about the 
molecular mechanism of PTP catalysis.
188, 189
 However, the molecular basis by which 
PTP distinguishes and recognizes the diverse substrates inside the cellular 
environment remains largely unknown. Currently, there are few methods which allow 
high-throughput and comprehensive studies on substrate specificity of PTPs. Only 
recently, Waldmann and our group independently report the feasibility of using 
peptide microarray for large-scale phosphatase substrate specificity studies.
118, 119, 190, 
191







 peptide microarray offers the unique advantages in terms 
of throughput, miniaturization and sensitivity. In this study, we extended the previous 
phosphopeptide microarray approach for activity-based high-throughput studies of the 
PTP substrate specificity (Scheme 3.1). 144 peptides whose sequences were derived 
from the putative PTP protein substrates were synthesized, immobilized onto array 
and screened against various PTPs. Each PTP will dephosphorylated their preferred 
peptides respectively. After Pro-Q treatment, microarray scanner scanning and data 
analysis, we will identify the preferred peptide substrates for each PTP. 7 PTPs 
including PTP1B, TCPTP, SHP1 full length (SHP1), SHP2 full length (SHP2), SHP1 
catalytic domain (ΔSHP1), SHP2 catalytic domain (ΔSHP2) and LMW PTP were 
50 
chosen in our study.  PTP1B and TCPTP are highly homologues protein pairs, which 
share more than 70% identity in sequence within the catalytic domain.
195
 For SHP1 
and SHP2, they also have about 60% homology in their catalytic domain.
196
 By 
investigating these highly homologous PTPs, we sought to explore the sensitivity, 
capability and competency of our microarray platform in differentiating the subtle 
differences of substrate specificity. By using our strategy, we can: 1) generate unique 
and comparative substrate fingerprints with various PTPs; 2) carry out the kinetic 
measurements and obtain the kinetic constants of many peptides against different 
PTPs; 3) identify the potent and selective substrates against PTPs; 4) predict the new 
functional roles of PTPs in vivo by the identificaiton of unknown phosphatase/ 
substrate pair. 
 
      I                 II                  III               IV 
 
Scheme 3.1  Scheme of our activity based screening strategy: (I) Fabrication of the 
putative phosphopeptide substrates microarray; (II) After PTPs incubation, they 
dephosphorylated their preferred peptide substrates respectively; (III) After Pro-Q dye 
treatment (a phospho specific dye) and microarray scanner scanning, only 
non-preferred peptides (still contained PO3
2- 
group) visualized fluorescence; (IV) 
After data analysis, preferred peptide substrate with weaker or no fluorescence in the 
fingerprinting was identified. (P stands for PO3
2- 
in the scheme) 
 
3.3 Results and Discussions  
3.3.1 Peptides Library Synthesis and Microarrays Fabrication 
51 
 
Figure 3.1 The Pro-Q image of 144 phosphopeptides (in duplicate) spotted on a slide 
containing 6 subgrids. 
 
144 putative peptide substrates of PTPs, each containing 11 amino acid residues 
with a centrally located phospho-Tyrosine (pY) moiety flanked by 5 amino acid 
residues on each side were synthesized as previously described.
190
 The peptide 
sequences are derived from potential PTPs substrates by data mining from the 
website:www.hprd.org. An extra hydrophilic linker and biotin were introduced at the 
N-terminus of each peptide, which was then subsequently immobilized (in duplicate) 
onto an avidin-coated glass slide to generate the corresponding peptide microarray. To 
ensure uniform immobilization, spotted slides were subject to Pro-Q Diamond dye 
treatment, which is capable of fluorescence-based measurement of pTyr/Ser/Thr 
residues present in peptides and proteins (Figure 3.1). Compared to other previous 
strategies, the Pro-Q method is advantageous in terms of its safety, non radio activity, 
ease to handle and high sensitivity.  The image indicated most of the peptides were 
52 
spotted uniformly and consistently (r>0.9). We noticed, however, that different 
peptides spotted on the same subgrid despite a uniform spotting concentration, 
registered a bit varying degrees of fluorescence reading after Pro-Q treatment. This 
could be due to the presence of different hydrophobic environments around the 




The spotting format of phosphopeptide library on the slide was summarized in 
Table 3.1. The detailed information of 144 putative phosphopeptides was summarized 
in Table 9.1. On each peptide microarray, 6 identical sub-arrays were fabricated, with 
each containing all 144 putative phosphopeptides individually spotted in duplicate. 
Each subarray comprises approximately 300 different spots, thereby allowing up to 
1800 different enzymatic assays to be simultaneously performed on the same slide 























Table 3.1 Spotting format of the 144 phosphopeptides on the microarray in this study 
(duplicated spots boxed in the same frame). 
 
3.3.2 Single Point Microarrays Fingerprinting of Different PTPs  
After successful fabrication of the phospho-peptide microarray, it was tested 
against seven PTPs, namely PTP1B, TCPTP, SHP1, SHP2, ΔSHP1, ΔSHP2 and LMW 
PTPs. All PTPs tested showed distinctive substrate fingerprinting against our peptide 
microarray (Figure 3.2(a)). 
Briefly, PTP1B and TCPTP showed strong activity and dephosphorylated most 
of the peptide substrates. SHP1 and SHP2 full length PTP showed much weaker 
activity than their respective catalytic domain, which is probably due to the 
auto-inhibition mechanism through their own SH2 domains and their C-terminal 
54 
tails.
197, 198, 199, 200, 201, 202
 LMW PTP which is a nonclassical PTP didn’t show much 
activity towards most of the peptide substrates. This underscores the uniqueness of 












A01: AEKPFpYVNVEF  






(A10: SRC-1) (A09: GAB1) (C05: ABL) (B23: JAK3) 
DSGGFpYITSRT DKQVEpYLDLDL MTGDTpYTAHAG  LISSDpYELLSD 10
(A14: FER kinase) (B08: P130Cas) (F23: CDC42) (F13: CRK)
EDGGVpYSSSGL GWMEDpYDYVHL VSSTHpYYLLPE PEPGPpYAQPSV 9
(B01: SLP76) (A08: PDGF)(D04: VEGF) (A10: SRC-1) 
FEEDDpYESPND DESVDpYVPMLD SDDVRpYVNAFK   DSGGFpYITSRT 8
(A06: GAB2) (A17: SIRP) (D16: SIRP)(A08: PDGF) 
DEKVDpYVQVDK EDTLTpYADLDM TNDITpYADLNL DESVDpYVPMLD 7
(A05: SIGLEC2)(A06: GAB2)(D22: ZAP70)(A11: CD31) 
DEGIHpYSELIQ DEKVDpYVQVDK VYESPpYSDPEE DTETVpYSEVRK 6
(A08: PDGF) (D15: Unknown) (A04: CD33) (A04: CD33) 
DESVDpYVPMLD TGGSVpYTEDND DEELHpY ASLNF DEELHpYASLNF 5
(C03: ZAP 70) (A04: CD33) (A06: GAB2)(A01: BCR) 
MDTSVpYESPYS DEELHpYASLNF DEKVDpYVQVDK AEKPFpYVNVEF 4
(B23: JAK3) (A07: GAB1) (D02: ROS1)(A05: SIGLEC2)
LISSDpYELLSD DERVDpYVVVDQ REGLNpYMVLAT DEGIHpYSELIQ 3
（A04: CD33）(A05: SIGLEC2)(F18: HS1 )(C03: ZAP70)
DEELHpY ASLNF DEGIHpYSELIQ EEEPVpYEAEPE MDTSVpYESPYS 2
(B22: BTK ) (C03: ZAP70) (A10: SRC-1)(D05: PDGF) 
KVVALpYDYMPM       MDTSVpYESPYS DSGGFpYITSRT  SDGHEpYIYVDP  1
ΔSHP2ΔSHP1TCPTPPTP1BRanking
 
Figure 3.2 (a) The substrate fingerprintings of 7 PTPs including PTP1B, TCPTP, 
ΔSHP1, ΔSHP2,SHP1,SHP2,LMW PTPs; Pro-Q image is the control without any 
phosphatases incubation; and selected hits against 4 phosphatases were highlighted; (b) 
Heat map of extracted fingerprint data of 5 PTPs. The scale bar represents the relative 
dephosphorylation ratio; (c) The summary of Top 10 peptide substrates (including ID 
and original protein source) for 4 PTPs identified from dephosphorylation ratio of 
single-point experiments and selective peptides substrates were highlighted in blue 
color. 
 
From the single point fingerprinting experiments, the potent peptide substrates 
could be identified.  To identify the most potent peptide substrates, we analyzed top 
10 peptide substrates for 4 PTPs (PTP1B, TCPTP, ΔSHP1, ΔSHP2) identified from 
the dephosphorylation ratio of single-point experiments (Figure 3.2(c)). Interestingly, 
peptide A01 (AEKPFpYVNVEF) derived from BCR (Y177) which site was 
56 
previously identified as PTP1B dephosphorylation site showed good activity against 
PTP1B in our microarray study. Peptide D14 (TDKEYpYTVKDD) which was 
derived from Janus Family Kinases 1 (JAK1) and was proved to be the substrate of 
TCPTP previously, 
203
 was identified to be greatly dephosphorylated by TCPTP from 
our microarray study. One of the top peptide substrate of SHP1 and SHP2---A04 
(DEELHpYASLNF) identified from our study, which was derived from CD33 (Y340), 
was previously discovered as a good substrate for both SHP1 and SHP2. 
204
 The same 
is true for peptide A08 (DESVDpYVPMLD), which was derived from PDGF (Y751) 
205
 and showed good activity against ΔSHP1 and ΔSHP2.  Additionally, some 
unknown phosphatase/substrate pair was also discovered. A05 (DEGIHpYSELIQ), 
which was derived from SIGLEC2 (CD22, a regulator of B cell signalling), and a 
substrate of SHP1,
206
 was also greatly dephosphorylated by PTP1B from our 
microarray study. This might reveal the novel role and pathway for PTP1B in the 
regulation of the immune response. Recently a novel role of PTP1B in immune cell 
signalling has been demonstrated and received much attention.
207
 All these findings 
strongly advocated the strength of our phosphopeptide microarray platform in 
identifying and discovering known and unknown phosphatasse/ substrate pair, at the 
same time predicting and revealing the new functional role and pathway of 








(a)                                (b) 
 
(c)                               (d) 
 
Figure 3.3  The summary of amino acid position preference from position -5 to +5 
for top 10 peptide substrates against 4 PTPs identified from dephosphorylation ratio of 
single-point experiments: (a) PTP1B; (b) TCPTP; (c) ΔSHP1; (d) ΔSHP2. 
 
Further data analysis of the amino acid preference at each position (namely 
from -5 to +5 position corresponding to N to C terminal, with pY as 0 position) was 
carried out with these top 10 peptides against each PTP (Figure 3.3). Results indicated 
that PTP1B prefers the acidic residues at many positions, especially N terminal 




strong preference for acidic residues at position -4 and -5 was observed based on our 
studies. The basic residues(R and K) were unfavored at most of positions except +4 
and +5 position. It was noticed that the hydrophobic residues were also favored at +3 
position. Similar to PTP1B, TCPTP also prefers the acidic residues at many positions, 
especially -3, -4 and -5 position.
210 
It was noteworthy that the hydrophobic residues 
were also favored at -2 and +3 position. 
SHP1 and SHP2 are well known to recognize the so-called ITIM motifs.
211
 Our 
results strongly indicated that ΔSHP1 and ΔSHP2 prefer I, L or V residues at position 
-2 and +3. It was also observed that ΔSHP1 prefers the acidic residues at position -5,-1, 
+2 and +4, whereas ΔSHP2 prefers the acidic residues at position -5, -4, -1, +1, +5. 
Additionally, there is no much selectivity for particular amino acids at position +4 and 
a high preference of hydrophilic residues at +2 was also observed for ΔSHP2. These 
findings also supported the points which were suggested by previous reports: the 
catalytic domains of PTPs have distinct substrate specificity and their intrinsic 












Table 3.2 Selective peptide substrates uncovered from top 10 dephosphorylation ratio 
of single-point experiments for each PTP. 
 





















































It is a challenging task to design the potent and specific inhibitor targeting a 
given PTP considering the highly conserved PTP catalytic domain. Herein our aim 
was to explore the sensitivity and capability of our microarray platform in 
differentiating the subtle differences among different PTP substrates. To achieve this, 
Venn diagram software was used to remove the overlapping sequences in top 10 lists. 
We were able to identify 4, 7, 5 and 3 selective sequences against PTP1B, TCPTP, 
ΔSHP1 and ΔSHP2 respectively (Table 3.2 ). This information could be valuable for 
designing potent and selective inhibitors for PTPs in the future.  
3.3.3 Microarrays and Microplates Based Kinetic Studies 
While single point data provided a quick way to delineate the substrate 
specificity of PTPs, however, it will be more informative if one could obtain the 
kinetic parameters of PTPs, which are of great importance for the inhibitor design. 
Additionally, the study of enzyme kinetics is important for two basic reasons. Firstly, 
it helps to explain how enzymes work by showing the whole of enzyme working 
process from beginning to end of the catalytic process; and secondly, it may help to 
predict how enzymes behave in living organisms.
214
 The kinetic constants defined in 
this study, kobs, are critical to attempts to understand how enzymes dephosphorylate 
their peptide substrates in the whole process of catalysis. 
We next carried out the kinetic assay of top 5 potential substrates identified 
from single point fingerprinting microarray assay with 4 PTPs including PTP1B, 
TCPTP, ΔSHP1 and ΔSHP2 using  time course signal decreased assay on the 
microarray(Figure 3.4(a)). Results showed that all the top 5 peptides exhibited decent 
kinetic curves (Figure 3.4(b)), and indicated that they could be dephosphorylated by 
61 
their corresponding PTPs respectively, which again confirmed the possibility of our 
microarray platform for the identification of PTPs substrates.  
From the time course microarray images of the kinetic study, most of peptides 
were greatly dephosphorylated by 30 min. Interestingly, by comparison to PTP1B and 
TCPTP, ΔSHP1 and ΔSHP2 exhibited a lagged dephosphorylation activity at 5 min 
and 15min, which was most probably due to the lack of the SH2 binding domain 
helping the recognition of the pY and interaction between phosphopeptides and 
phosphatases to help the dephosphorylation process.
215
 Additionally, based on kinetic 
constants from the kinetic study, it was observed that peptide with the highest 
dephosphorylation ratio didn’t mean they also exhibited a highest kinetic constant of 
Kobs, as dephosphorylation ratio just indicated one time point of the catalytic process, 
while Kobs indicated the whole process of the catalysis. To identify a good substrate 
for PTPs, single point assay was definitely a quick and direct method as it did indicate 
the dephosphorylation or not. However, if we want to design a good and efficient 
inhibitor in future, it was suggested that peptides with higher dephosphorylation ratio 
were important for inhibitor design, and a higher kinetic constant should be also 
considered.  
To further confirm the accuracy of our microarray kinetic data, we also 
subjected top 5 peptides exhibiting highest dephosphorylation ratio identified from 
single-point microarray assay, to the standard solution-phase phosphomolybdate 
colorimetry microplate enzymatic PTP assay. The results were summarized and shown 
in Figure 3.4(c). Good agreements were obtained with both microplate and 
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Figure 3.4 Summary of the kinetic study for top 5 peptides identified from 
dephosphorylation ratio of single-point experiments using microarray and microplate: 
(a) time course signal decreased microarray spot image; (b) kinetic curves from 
microarray; (c) kinetic curves from microplate. 
 
Table 3.3 Summary of kinetic constants from both microarray and microplate 
experiments for top 5 peptide substrates of 4 PTPs identified from dephosphorylation 











D05 0.079 0.067 A10 0.086 0.025 
C03 0.071 0.071 F18 0.132 0.03 
A05 0.088 0.028 D02 0.082 0.025 
A01 0.105 0.068 A06 0.089 0.018 









C03  0.056 0.2 B22 0.037 0.031 
A05 0.044 0.024 A04 0.062 0.018 
A07 0.043 0.15 B23 0.06 0.018 
A04 0.04 0.052 C03 0.028 0.017 






In conclusion, we have extended the previous phosphopeptide microarray 
approach amenable for determing the PTPs substrate specificity in high-throughput 
manner, which could allow up to 1800 different enzymatic assays to be 
simultaneously performed on the same slide. The stratgy is facile and only a minimum 
of enzyme and chemical compounds were used throughout the whole process.  
Additionally, our approach also exhibited several advantages of its own. 
Fristly, we conquered the inherent limitation of previous library design because PTPs 
can interact with 4-5 residues on either side of pY,
216, 217, 218, 219, 220
 and improved our 
design by choosing 5 amino acids in both sides of pY and then summaried the 
preference of amino acids in each postion from -5 to +5, which could be valuable for 
the design of potent and selective inhibitor in future; Secondly, our strategy was based 
on activity based screening, which was better and also much closer to the real case in 
vivo than the “PTP mutant” strategy or a nonhydrolyzable pY analogue;191, 221 Thirdly, 
our study here presented comprehensive fingerprintings by using several kinds of  
PTPs, which could not only confer us some potent peptide substrates for each PTP, 
but also generate some relatively selective peptide substrates against different PTPs; 
Fourthly, our putative phophopeptide microarray strategy could not only identify the 
known subtrates, but also could discover the potential unknown phosphatase 
/substrate pair to predict the new functional roles of PTPs in vivo.We envisage this 
approach should add useful tools for unraveling the PTP substrate specificity and play 






A Phosphopeptide Microarray Based Systematic  
Strategy for High-Throughput Discovery of Potent  




A novel phosphopeptide microarray platform with 144 members was developed to 
rapidly and efficiently high throughput screening of SH2 domains. By using this 
microarray platform, we could not only identify some potent binding partners for these 
SH2 domain proteins, but also could use the dual color microarray system to easily and 
efficiently decipher some selective binding partners for each SH2 domains, which was 
then validated by the lysates proteomes pull down and antibody detection on the 
microarray. These newly uncovered SH2 domain binding partners will be of great 
importance and useful for the potent and selective SH2 inhibitor design in future.  
 
4.2 Introduction 
Signal transduction plays a vital role in cellular functions such as proliferation, 
differentiation, cyto skeletal organization, and cell survival, and aberrant signaling could 
cause many diseases, 
224
 which was mediated by protein-protein interactions (PPI) via the 
assembly of complexes or relocalization of proteins in response to signals.
79
 It is well 
known that reversible tyrosine phosphorylation is also an early step in the transduction of 
many types of signals in multicellular organisms. Phosphorylated signaling proteins on 
66 
tyrosine residues are usually specifically recognized by Src Homology 2 (SH2) domain 
modular proteins.
41c, 58
 Since SH2 domain modular proteins are so important for the 
signal transduction inside the cells /human, mapping the SH2 domain binding specificity 
will help us predict/control the signaling state of the cell, thus facilitating us for human 
disease treatment caused by the aberrant signaling. SH2 domains are about 100 amino 
acids long and they are found to be contained in many important proteins including PTPs, 
PTKs, growth factors receptors and adaptor proteins.
59
 Each SH2 domain recognizes a 
specific subset of pY peptide sequences.
60
 The specificity is determined by the 
interactions between amino acids adjacent to pY and the less conserved regions of the 
SH2 domain surface. Determination of the sequence specificity of these SH2 domains is 
an important first step towards identifying their in vivo binding partners and 
understanding their physiological functions. Such information will also facilitate the 
development of specific SH2 domain inhibitors as research tools and therapeutic 
agents.
225
 Different SH2 domains select distinct phosphopeptides, and the function of a 
given SH2 domain is often determined by the specific motifs that it recognizes. Therefore, 
deciphering the phosphotyrosyl peptide motif recognized by an SH2 domain is the key to 
understanding its cellular function. 
Since protein-protein interactions play a central role in almost all cellular 
responses and specific recognition of signaling domains, such as SH2 and WW domains, 
with peptide motifs found on protein-binding partners is critical for a variety of cell 
signaling pathways, many techniques have been developed to study protein binding to 





 capillary electrophoresis, 
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The former has a low throughput, while the latter requires 
cumbersome filtration manipulations and generates radioactive waste, an increasingly 
difficult product of which to dispose. However, all these methods have their own 
limitations in much sample consumption, throughput, or sensitivity.  
Microarray is a powerful strategy for enzyme based screening for potent and 
selective substrate and inhibitor discovery together with reduced reagent costs, faster 
kinetics, higher throughput, and potentially improved sensitivity. To conquer previous 
limitations and develop better high throughput screening complimentary method, we in 
this report used a novel phosphopeptide microarray platform developed in our lab to the 
high throughput study of SH2 domains proteins, which has the advantages of being 
robust, nonradioactive, and also should be easily extensible to other SH2 domains with 
different peptide binding selectivity. By using the single point microarray experiment, we 
could quickly identify the potent binding partners for each SH2 domains. Besides, when 
using the dual color approach, we could easily identify the selective binding partners for 
each SH2 domain via the naked eyes. What is more, we also could do the concentration 
dependent assay to determine the KD to indicate the binding strength, which would be of 





Scheme 4.1 Schematic representation of this project. (I) Firstly construction of the 
phosphopeptide microarray; (II) Incubation of single optimized concentration of different 
SH2 domain proteins labeled with Cy3 dye on the microarrays for 1 hour, and then 
generation of the single point microarray image for identification of potent SH2 domains 
binders; (III) Performing the dual color microarray assay with two protein labeled with 
different dyes (such as Cy3 and Cy5), and then generation of dual color microarray image 
for identification of selective SH2 domains binders; (IV) Performing concentration 
dependent microarray experiments for generation of kinetic KD; (V) Validation 
experiments to confirm hits identified from the microarray assays. 
 
In Scheme 4.1, by using this microarray strategy, we could: (1) apply our 
phosphopeptide microarray to high throughput study of SH2 domains, which is much 
more direct and better than previous strategy; (2) higher throughput, minimal sample 
(include peptides and proteins) consumed; (3) identify some new phosphopeptide-SH2 
domain interaction pair, which will be not only of great importance for uncovering new 
protein-protein interactions, but also will be helpful for predicting new function of SH2 
domains inside the cells; (4) our microarray platform could also determine the binding 
strength of KD by using concentration dependent microarray assays; (5) identify the 
binding motif for these SH2 domains, which will be of great importance and use for the 
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SH2 domains potent and selective inhibitor design and discovery in future; (6) extend our 
microarray platform to other SH2 domains study or pY binding proteins (such as PTB 
domains or newly discovered pY selective binding proteins.  
 
4.3 Results and Discussion 
4.3.1 Library Synthesis and Microarray Construction 
Firstly, 144-member phosphopeptide library was synthesized by standard Fmoc 
solid phase peptide synthesis as previously described. 
119, 190, 191, 231c, 232
 The peptide 
sequences were derived from important signal pathway proteins with important 
phosphorylation sites, phosphorylation related proteins (kinases, phosphatases, receptors 
and so on), data mining from literature or the website www.hprd.org. Each 
phosphopeptide contained 11 amino acid residues with a centrally located phosphor 
tyrosine (pY) moiety flanked by 5 amino acid residues on each side. An extra hydrophilic 
linker and biotin were introduced at the N-terminus of each peptide, which was then 
subsequently immobilized (in duplicate) onto an avidin-coated glass slide to generate the 
corresponding peptide microarray. To ensure uniform immobilization, spotted slides were 
subject to Pro-Q Diamond dye treatment, which is capable of fluorescence-based 
measurement of pTyr/Ser/Thr residues present in peptides and proteins (Figure 4.1). 
Compared to other previous strategies, the Pro-Q method is advantageous in terms of its 
safety, non radio activity, ease to handle and high sensitivity. The image indicated most of 





Figure 4.1 The Pro-Q
TM 
image of the 144-member pTyr peptide library, spotted on six 
subgrids microarrays, indicating a high degree of slide-to-slide and (duplicated) 
spot-to-spot reproducibility of our microarrays.  
 
Table 4.1 Spotting format of the 144 phosphopeptides on the microarray in this study 





The spotting format of phosphopeptide library on the slide was summarized in 
Table 4.1. The detailed information of 144 putative phosphopeptides was summarized in 
Table 9.1. On each peptide microarray, 6 identical sub-arrays were fabricated, with each 
containing all 144 putative phosphopeptides individually spotted in duplicate. Each 
subarray comprises approximately 300 different spots, thereby allowing up to 1800 
different binding events to be simultaneously performed on the same slide (Figure 4.1). 
4.3.2 Single Color Based SH2 Domains Screening 
So far, there are more than 100 SH2 domains discovered before.
233
 For our study, 
we firstly performed the phosphopeptide microarray screening assays with 3 classical 
SH2 domain proteins named GRB2, LCK and SRC1, which were labeled by Cy3 and 




Figure 4.2 Fluorescence gel image of SH2 domains labeled with Cy3 (in Green) and 
Cy5 (in Red). 
 
Growth factor receptor-bound protein 2 (GRB2) is an adaptor protein made of one 
SH2 domain flanked by two SH3 domains. GRB2 interacts via its SH2 domain with 
activated receptors and via its SH3 domains to the nucleotide exchange factor sos, which 
thus becomes activated as a positive regulator of Ras.
234a, 234d
  Design of molecules that 
block the interaction between the phosphotyrosine-containing activated receptors and the 
SH2 domain of GRB2 should interrupt the Ras signaling pathway and may promise 
therapeutic leads for diseases like cancer, in which the Ras signaling pathway plays a 
major role.
234b
 GRB2 may have other functions as well. Microinjection studies with 
72 
anti-GRB2 antibodies in rat kidney cells suggest that GRB2 may play a role in signaling 




Lymphocyte-specific protein tyrosine kinase (LCK) is a member of the src family 
of non-receptor protein tyrosine kinases
 235
 expressed primarily in T-Lymphocytes and 
natural killer cells.
236 
LCK is essential for T-cell development and function.
237
 It is 
constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface 
receptors and plays a key role in T-cell antigen receptor (TCR) linked signal transduction 
pathways.
238
 Inhibitors of LCK may have potential therapeutic ability in the treatment of 
auto-immune diseases, such as coxsackievirus B3-mediated heart diseases, rheumatoid 
arthritis, multiple sclerosis, lupus, as well as inflammatory diseases, prevention of solid 
organ transplantation and allergic diseases.
239
 
V-sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) (c-SRC) is a 
proto-oncogene, belonging to the non-receptor protein kinases family, which plays a 
prominent role in carcinogenesis. Consistent evidence suggests the involvement of the 
proto-oncogene c-SRC in the development and progression of many human cancers, 
including breast carcinomas.
240
 c-SRC is a non-receptor tyrosine kinase whose deficiency 
in mice affects only bone cell function, with no effects in other organs.
241
 Our previous 
data demonstrated the ability of c-SRC inhibitors belonging to the pyrrolopyrimidine 
class to reduce the malignant activities of prostate cancer cells in vitro.
242 
 c-SRC kinase 
activity is significantly increased in human breast cancer tissues compared with benign 
breast tumors or adjacent normal breast tissues, and this elevated c-SRC activity is 
correlated with poor metastasis-free survival.
243 
A  role for c-SRC in the development of 
73 
breast cancer metastases has been elegantly demonstrated by Myoui et al. in 2003. 
244 
 In 
other study, c-SRC could promote breast cancer metastatic disease affecting various cell 
types and that, as a consequence, pharmacological disruption of its kinase activity could 
be useful for the development of novel therapies for the treatment of both bone and 
visceral metastases arising from breast malignancy. 
245
 
After successfully fabricating the phosphopeptide microarray, single point 
microarray assays were carried out to quickly identify the potent binding partners for 
each SH2 domain proteins. What we did was that we firstly labelled these 3 SH2 domains 
with Cy3 commercial dye following previous procedures,
191, 232b
 and then they were 
applied onto the phosphopeptide microarray. From the results shown in Figure 4.3, all 3 
SH2 domain proteins showed distinct and highly reproducible fingerprintings against the 
144-member phosphopeptide microarray. These bindings were highly specific towards 
only active SH2 domain proteins—phosphortyrosine (pY) binding proteins, while 
denatured proteins (heated by 95C for 10mins ) and other non-phosphor tyrosine binding 
proteins did not bind (Figure 4.4).These results totally proved that our phosphopeptide 
microarray was sensitive and specific to different SH2 domain 














Figure 4.3 (a) Fingerprintings of 3 SH2 domains (GRB2, LCK and SRC1) at 0.5μM; (b) 
Heat map of these 3 SH2 domains screening results. 
 
From the single-point fingerprinting experiments, some interesting and well 
known binding partners as well as some unknown binding partners with specific 
phosphorylation sites against each SH2 domain were efficiently and clearly confirmed 
and uncovered. For example, peptide A01 (AEKPFpYVNVEF), which was derived from 
protein BCR (pY site 177) and was known to be the binding partner of GRB2,
246
 showed 
good binding here to the GRB2 SH2 domain. It had been reported SHC and GRB2 
interacted with each other and form a complex mediated by GRB2 SH2 domain binding 
the SHC at pY 317 (PSpYVNVQNL) to regulate the mammalian Ras signaling 
pathway.
247
 From our microarray results, peptide F11 (PPDHQpYYNDFP), which 
75 
derived from the SHC (pY349) but not the same position as previous one, also showed 
strong binding here, which also not only confirmed the existence of the interaction 
between GRB2 SH2 domain and SHC proteins, but also may predict a possible 
new/uncovered interaction/binding site for GRB2 and SHC protein-protein interaction 
(PPI). Peptide C22 (QGPVIpYAQLDH), which was derived from the myelin (pY241), 
showed decent binding here to the LCK SH2 domain, which was consistent with SMALI 
site prediction and previous report before.
248
 Peptide B15 (IESDIpYAEIPD), which 
sourced from protein tyrosine kinase 2 beta (type12), showed strong binding to SRC1 
SH2 domain here, which was consistent with previous report or SMALI site prediction.
248
 
Besides, some new binding partners could also be uncovered here. For example, 
phosphopeptide E13 (DRFIQpYANPAF), which derived from cAMP phosphodiesterase 
(PDE8A), and E23 (GRETIpYPNASL), which sourced from carcinoembroyonic antigen, 
also showed decent binding to the GRB2 SH2 domain here, both of which, to our 
knowledge, were not reported before. This may be the new interaction partners for GRB2, 
thus suggesting new protein-protein interaction inside the cells as well as predicting the 
new function of GRB2 uncovered before. 
      
Figure 4.4 The 176-member pTyr peptide microarray is shown to bind to SH2 domain 
specifically (protein concentration 0.5 μM). (a) Native Grb2; (b) Denatured GRB2; (c) BSA; 
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(d) Renin-one of Asp protease;  
 
From the single-point fingerprinting experiments results shown in Figure 4.3, the 
potent binders could be also rapidly identified. We analyzed the top-10 binders against 
these 3 different SH2 domains based on the binding strength, which were summarized in 
Figure 4.5a. These strong SH2 domains binders could be very useful for future SH2 
domain inhibitor design in future. Besides, further analysis using Venn diagram to 
compare these top 10 hits indicated that there were 4 hits overlapping shown in Figure 











Figure 4.5 Top 10 hits binders of GRB2, LCK and SRC1 SH2 domains. 
What is more, based on these top 10 SH2 domain binders, further data analysis of 
the amino acid preference at each position (namely from -5 to +5 positions counting from 
the N- to C-terminus with pY defined as the 0 position) was carried out, and the results 
were graphically presented in Figure 4.6.  
From these results, GRB2 showed a good preference for Ser at position -5, Glu at 
78 
position -4, Asp at position -3, His at position -2, Val at position +1, Asn at +2,  Val at 
+3. For other positions, there is no much clear preference. LCK showed a clear 
preference for Ile at position -1, Ala at +1, Val at +2 and +3, Gln at +4. For other 
positions, which agrees well with previous reports and binding motif. SRC1 showed a 
clear preference for Ala at position -5, Glu at position -3, Ile at position -1, Val at position 
+3, which agrees well with previous reports and binding motif. 
(a) Prefered amino acids for GRB2        (b) Prefered amino acids for LCK 
   
(c) Prefered amino acids for SRC1 
     
Figure 4.6 Amino acid preference at each position from top 10 hits from position -5 to 5 
for 3 SH2 domains. X axis stands for 20 normal amino acids, Y stands for positions from 
-5, to 5 and Z stands for the repeating times of the each amino acids in specific position 
from top 10 peptides hits. 
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Besides, we also summarized the bottom 10 peptides and amino acid at each 
positions unprefered by SH2 domains (Figure 4.7). From the results, it was clearly 
shown that, GRB2 showed a bad preference for Asp at position +1, Lys at +2, Ser at +3, 
Lys at +4, Thr at +5. For other positions, there is no much clear bad preference. LCK 
showed a clear bad preference for Ser at position -3, Gly at position -2, Gly at position -1, 
Thr at position +1. For other positions, there is no much clear bad preference. SRC1 
(name) showed a clear bad preference for Lys at position -3, Gln at position -2, Thr at 
position +1, Glu at position +5. For other positions, there is no clear bad preferrence. 






 (a) Unprefered amino acids for GRB2   (b) Unprefered amino acids for LCK 
 
  
(c) Unprefered amino acids for SRC1 
 
 
Figure 4.7 Amino acids unpreferred at each position from bottom 10 peptides for 
position from -5 to 5 for 3 SH2 domains. X axis stands for 20 normal amino acids, Y 
stands for positions from -5, to 5 and Z stands for the repeating times of the each amino 
acids in specific position from botom 10 peptides hits. 
 
Taking together, the information of the detailed preference and unpreference of 
amino acids at each position will be not only of great use and importance for potent and 
selective SH2 domains inhibitor design and discovery in future, but also will be greatly 




4.3.3 Dual Color Microarrays Screening 
 
As there are many families of SH2 domains, which play great important roles in 
the protein-protein interactions and signal transduction, identification of the selective 
SH2 domains binders/inhibitors have been paid much attention to but remains a 
challenging and daunting task to achieve so far, primarily because of the highly 
conserved SH2 domains and limited efficient tools to achieve this goal.
233 
Therefore, 
another objective of our present studies was to explore the capability of our microarray 
platform for uncovering potent and selective binders towards different SH2 domains. To 
achieve this, Venn diagram software and dual color microarray assays were used to 
remove the overlapping sequences from our top 10 hits as shown in Figure 4.5(a). We 
were able to identify several promising peptide sequences that showed clear selectivity 
against each of the 3 SH2 domains and the results are shown in Figure 4.5 (b) & (c). 
This information, though needing to be further substantiated by more thorough and 
detailed biochemical studies, may shed some lights on the design of potent and selective 
inhibitors against different SH2 domains in future. Besides, to provide a valid and general 
complementary methods for the identification of the selective binders for each SH2 
domain protein, we carried out the dual color microarray assays here. What we did was 
that we labeled 2 different proteins with 2 different dyes named Cy3 and Cy5, and mixed 
them together before applying them onto the microarrays. Interestingly and to our 
pleasant surprise, by using this strategy, we could much more easily and efficiently get 
the dual color fingerprintings shown in Figure 4.8, which was much more directly to help 
us identify some selective binding peptides for these 3 SH2 domains. For examples, from 
82 
the dual color fingerprintings, we also summarized the selective phosphopeptides. 
For Cy3-GRB2/Cy5-SRC1 pair, peptides D04, F16, A01, E22, A11, A13, C17, 
B17, F01, were much selectively preferred by GRB2, while peptides A07, A23, A15, C04, 
F23, C22, C10, A06, A04, D08 were selectively preferred by SRC1. 
For Cy3-GRB2/Cy5-LCK pair, peptides F16, A01, D04, F02, F01, C17, D11, F03, 
F19, E22, were much selectively preferred by GRB2, while peptides F10, F09, B08, C18, 
F23, C02, D08, C10, B04, B05, were much selectively preferred by LCK. These 
information will greatly help us design the selective inhibitor in future.  
 
Figure 4.8 Dual color microarray fingerprintings of SH2 domains at protein 
concentration of 1μM. 
4.3.4 Concentration Dependent Microarrays Assays  
 
While the microarray-based single-point experiments provided a quick way to 
delineate the binding specificity of SH2 domains, it will be more informative if one 
could obtain kinetic parameters(such as kD) of SH2 domains which would give a 
better picture of how these enzymes might behave under cellular environments .
 
Previously, our group and some other group showed that peptide/protein microarray is 
a very useful tool well-suited for semi-quantitative measurements of enzyme 
kinetics.
190, 191, 232
 In this study, to further explore /evaluate the binding strength 
83 
between the phosphopeptides binders and SH2 domains, concentration dependent 
microarray assays were carried out here by taking advantage of the six identical 
subgrids spotted on the same slide. Each sub-grid (containing all 144 phosphopeptides) 
was simultaneously incubated with the 6 different concentration  (0 to 2 μM) of the 
SH2 domains for 1hour. At the end, a total of 6 data points were obtained for each of 
the 144 different peptides simultaneously. The 144 kinetic constants derived from this 
single experiment, kD value, enabled us to quantitatively compare the subtle difference 
between different binders against the same SH2 domains. This is very useful 
especially when one compares highly homologous SH2 domains.What we did was that 
we firstly applied different concentration of SH2 domains to the phosphopeptide 
microarray, and then we got the concentration dependent fingerprintings (Figure 4.9). 
After we did the quantitative data analysis, we fitted them on the software and got the 
kinetic binding curve, which will generate the corresponding kD value. Upon getting 
the kD value, we could easily judge the binding strength, which is also another one of 
very important factor for designing the SH2 domains inhibitors. As representative 
examples, results obtained from the concentration-dependent kinetic measurements of 
top-10 potential substrates (identified from single-point fingerprinting assays) with 
the various SH2 domains  were graphically plotted as well as the corresponding KD 




Figure 4.9 Microarray images of concentration-dependent experiments with GRB2 (a), 
LCK (b) and SRC1 (c). Data were extracted and fitted, assuming a saturation binding 
model, to derive the corresponding KD. 
 
(a) GRB2                       (b) LCK 
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Figure 4.10 Representative KD of the strong binder for 3 SH2 domains. (a) E19 for 
GRB2; (b) C23 for LCK; (c) E21 for SRC1. 
4.3.5 Pull Down Assays 
To test the accuracy of our phosphopeptide microarray and further validate the 
probes identified from our microarray screening, lysates pull down assays were carried 
out here. What we did was that, we chose some potent phosphopeptide probes identified 
from the microarray results and then used them as the bait to enrich the proteins from the 
MCF7 cancer cell lysates. After washing the beads and running the SDS gels, western 
blotting was used to confirm the presence of the target proteins shown in Figure 4.11. 
From the results, they clearly and unambiguously showed that our phosphopeptide probes 
could pull down the corresponding proteins from the lysates proteomes, which were 
consistent with our microarray results and further proved the accuracy and competency of 




Figure 4.11 Western blotting for the pull down assay (MCF7 lysates used here) to 
validate the interactions between the peptide binders and their corresponding proteins 
(Neutral avidin beads, 10 μM probles final concentration). 
 
4.3.6 Antibodies Detection on the Microarrays 
(a) Microarray fingerprinting for MCF7 lysates 
     
(b) Anti-GRB2 detection on the array  (c) Anti-LCK detection on the array 
              
 
E19   DMSO       C23   DMSO 





(c)  (d) 
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Figure 4.12 (a) Profiling of the Cy3 labeled MCF7 cell lysates (10μg/subgrid) using the 
144 pY library; (b)Anti-GRB2 detection on the microarray after incubation with MCF7 
lysates; (c) Anti-LCK detection on the microarray after incubation with MCF7 lysates. 
 
Besides, to further prove the existence of the interactions between the 
phosphopeptides and the corresponding proteins, and at the same time generally and 
broadly validate the accuracy of our SH2 domain binding partners as inhibitor candidates 
in future, antibody detection on the microarray assay was employed. What we did was 
that we firstly incubated the MCF7 cell lysates (without being labeled) on the microarray, 
which had been washed and blocked by 1%BSA/TBS in advance. After the incubation, 
the slides were gently washed by H2O and then incubated the Cy3 labeled antibody 
(Anti-GRB2 and Anti-LCK) for 1hour. Subsequently, the slides were gently washed by 
H2O for 2 minutes each for 2-3 times and then scanned in the array scanner. The results 
(Figure 4.12) showed that most of phosphopeptide probes were bright, which proved the 
existence of interactions between the phosphopeptide and the target proteins, and were 
consistent with our microarray results and further proved the accuracy of the discovery 
based on our phosphopeptide microarray screening. 
 
4.4 Conclusion  
In summary, a systematic phosphopeptide microarray based platform (single color 
screening microarray assay, dual color screening microarray assay, concentration 
dependent microarray assay, lysates proteomes pull down and western blotting, lysates 
proteome profiling, antibody detection on the microarray) was developed for high 
throughput study of SH2 domains. By using this biological referencing system 
88 
(phosphorylation, one of most important post transcriptional modifications), we could 
efficiently screen, identify and validate several potent and selective SH2 domains binders 
from a pool of 144-member phosphopeptides library. These new uncovered SH2 domain 
binding partners will be of great importance and use for the SH2 inhibitor design in 
future. This novel strategy developed here should be also applicable for the other post 











 and so on) by changing the phosphopeptides into other small 
molecules. We would expect more applications of this phosphopeptide based system to 




Besides, we also have successfully managed to use the phosphopeptide 
microarray to attempt to do the proteome profiling using one MCF7 cancer cell lysates, 
which may prove and grant the phosphopeptide microarray as a good high throughput 
tool for the next generation of cancer proteomes profiling. Although the systematic 
phosphopeptide microarray platform was developed here for pure proteins screening, it 
will also shed light on and pave the way for cancer proteomes profiling in future, which 
could also lead to cancers biomarkers discovery but is still a challenge now, which would 
be beneficial for cancer differentiation and diagnosis in future. Our lab now is focusing 






Chapter 5.   
 
 
Comparative Proteomic Profiling of Mammalian Cell 




A 176-member dual color reciprocal phospho-peptide microarray was developed 
for high throughput comparative profiling of mammalian cell lysates proteomes. 
Combined with dual color pull down, MS identification, antibody detection on the 
microarray and western blotting, this new systematic strategy could be used to identify 
and preliminarily validate several cancer biomarker candidates named PKM2, PTPN21, 
LDH-B, PRDX1 for MCF7 (breast cancer) and PHB for SW620 (colon cancer).  
 
5.2 Introduction 
Tyrosine phosphorylation is one of the most important and well-studied 
post-transcriptional modifications, which plays critical roles in the regulation of many 
cellular processes including cell cycle, growth, apoptosis and differentiation. Two major 
groups of enzymes are involved in regulating tyrosine phosphorylation: protein tyrosine 
phosphatases (PTPs) and protein tyrosine kinases (PTKs).
39, 41c
 Although the level of 
tyrosine phosphorylation was minor, the phosphorylation of tyrosine residues, in 
particular, is important in signaling pathways.
231
 Aberrant phosphorylation has been 
observed in many cancers,
41b, 251
 thus making the phosphorylation related proteins (PTPs 
90 
and PTKs) and phosphorylation specifically binding proteins (such as SH2 domains, PTB 
domain containing proteins and so on) becoming drug targets and biomarkers for cancer 
diagnosis and treatment.
42 
So far, most of previous study focused on finding substrates of 
these phosphorylation related and binding proteins,
118, 119, 190, 191, 249
  few report focused 
on the global profiling of the whole mammalian cell lysates proteomes. Only recently 
global profiling of the tyrosine phosphorylation state was carried out for a cancer biology 
study, which will help cancer diagnosis and cancer biomarker discovery.
252
 However, 
there is still few report focusing on the proteomic profiling of phosphorylation related 
binding proteomes in mammalian cell lysates. It had been reported that many 
phosphorylation related binding proteins were over-expressed in the cancers (such as 
GRB2, SRC, and so on).
253
 It will be of great use and importance if we could develop an 
efficient and high throughput platform to do the comparative profiling of diseased cells 
(such as cancer cells) to the normal cells to uncover some proteins more related to 
cancers, which most probably could lead to the cancer biomarker discovery in future.  
There are currently a lot of strategies employed for the proteomic studies to 
evaluate protein abundance, define protein-protein interaction and their function 
including direct mass spectrometry, 
254





Although a lot of progress has been made by these strategies, 
they also have limitation of themselves. For mass strategy, it has intrinsic limitation in 
discriminating the structural isomers. Besides, it also requires expensive equipment and 
time-consuming separation and annotation techniques.
257 
For other strategies, they also 
have some limitations in throughput, much sample consumption and so on. Due to the 
reasons above, it is of great importance and imperative to develop a new, efficient, and 
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simultaneously complimentary method to conquer previous limitations for the proteomic 
profiling of tyrosine phosphorylation related binding proteomes in the mammalian cell 
lysates, thus hopefully providing a highly predictive set of signatures that can reliably 
distinguish each diseased cells (such as cancers) from normal, which help cancer 
diagnosis and cancer biomarker discovery.  
      Therefore, we here developed a novel phosphopeptide microarray strategy for the 
comparative proteomic profiling of the mammalian cell lysates together by virtue of a 
dual color approach. Dual color system is a good approach to compare different samples 
at the same time. The dual color strategy originated from 2D-GE system using the 
different dye labeling different samples.
258a
 After that, it was then applied in the DNA 
microarray analysis using this two-color approach.
258b
 Mahal et al in 2007 applied this 
strategy to the analysis of dynamic mammalian glycome using a rationmetric lectin 
microarray.
257a
 Our lab also had applied this strategy to some studies. For example, 
Uttamchandani et al in 2007 
232a
 applied this strategy to avoid the false positive results in 
the pure protein screening; Lu et al in 2008 
232b
 and Sun et al in 2009 
191
 applied this 
strategy for the identification of selective binding partner in the pure protein screening. 
Microarray is a powerful high throughput screening tool for analyzing gene and 
protein expression, developing diagnostic procedures, and discovering new 
pharmacologically active agents, together with reduced reagent costs, faster kinetics, 
higher throughput, and potentially improved sensitivity.
259 
As shown in Scheme 5.1, by 
using the phosphopeptide microarray and the dual color labeling reciprocal approach, we 
can not only improve the protein-ligand interaction specificity by taking tyrosine 
phosphorylation-one of the most important post transcriptional modifications into 
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consideration, but also can self-report to filter the false positive results, which can be 
judged here by naked eyes and should be taken into consideration for microarray studies. 
By using this approach, we could easily compare different proteomic profiling 
fingerprints for different cancers cells, and can also investigate the profiling difference 
between cancer cells and normal cells. Especially, when combined together with dual 
color pull down, MS identification and western blotting, this approach could be 
developed to be a novel and general systematic approach to help identify some cancers 
biomarkers candidates, which could be very useful for the cancer diagnosis and treatment 
in future. By using this novel and general systematic approach, we have:(1) first time 
successfully applied the phosphopeptide microarray to proteomic profiling of the 
mammalian cell lysates; (2) first time developed a systematic strategy (combining dual 
color microarray, dual color pull down, MS, western blotting, antibody detection on the 
microarray) for the cancer biomarker candidates discovery;(3) used a class of proteins as 
our targets based on proteins-phosphopeptide affinity based interactions while not 
depending on specific protein/biomarker-ligand interaction for the profiling, which made 
this approach better in that we do not need to require prior knowledge of expression level 
of the specific target protein in the mammalian cells for the profiling; (4) preliminarily 
identified and validated some novel biomarkers candidates related to some human 
cancers (MCF7: breast cancer ; SW620: colon cancer), which could be very useful for the 
cancer diagnosis and cancer treatment in future;(5) firstly proved that the dual color 
phosphopeptide microarray proteomic fingerprinting may provide a novel 
indicator/strategy to pave the way for the cancer differentiation and diagnosis by 
comparison to normal cell proteomic fingerprintings; (6) developed a high throughput 
93 
proteomic profiling based strategy as well as high sensitivity and the capacity for the 
multiplex quantification. 
 
Scheme 5.1 Schematic representative of this project. (I) Firstly, preparation and labeling 
of the cell lysates, and then construction of the 176-member phosphopeptide microarray; 
(II) Incubation of different proteomes samples labeled with different dyes with the 
microarrays for 1 hour, and then scanned by microarray scanner to generate the 
microarray fingerprintings results for quantitative data analysis to finally choose the 
selective probes for following up dual color pull down assay; (III) Performing the dual 
color pull down assays and run the Pull down samples in SDS-PAGE gel to obtain in-gel 
fluorescence results; (IV) Selective bands and the whole lane were cut for the MS 
identification; (V) Validation experiments were carried out to confirm the MS results for 
biomarkers candidates discovery using western blotting and antibody detection on the 
microarray. (In the scheme, pY stand for phosphotyrosine)  
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5.3 Results and Discussions 










Figure 5.1 Spotting format was used throughout the study for the 176 phosphopeptides 
(each peptide was spotted duplicate). (see Table 9.3 for peptide sequences, ID and source 
proteins). 
 
Firstly, a 176-member phosphopeptides library was synthesized by standard Fmoc 
solid phase peptide synthesis as previously described 
119, 190
 (Scheme 5.2). The peptide 
sequences were derived from important signal pathway proteins with important 
phosphorylation sites, phosphorylation related proteins (kinases, phosphatases, receptors 
and so on), data mining from literature or the website www.hprd.org. An extra 
hydrophilic GG linker and biotin were introduced at the N-terminus of each peptide, 
which was subsequently immobilized (in duplicate spots) onto an avidin-coated glass 
slide to generate the corresponding peptide microarray. To ensure uniform immobilization, 
spotted slides were subjected to Pro-Q
TM
 Diamond dye treatment, which is capable of 
fluorescence-based measurement of pY/S/T residues present in peptides and proteins, 
which previously had been reported.
118, 231c 
Spotting format (Figure 5.1) was used 
throughout the study for the 176 phosphopeptides (each peptide was spotted duplicate). 
As shown in Figure 5.2, the results indicated most of the peptides were uniformly and 





Figure 5.2. The Pro-Q
TM 
images of the 176-member pY peptide library spotted on three 
separate subgrids, indicating a high degree of slide-to-slide and (duplicated) spot-to-spot 
reproducibility of our microarrays. 
 
5.3.2 SH2 Domains Test Screening 
5.3.2.1 SH2 Domain Proteins Expression, Purification and Labeling  
3 SH2 domains (GRB2, LCK and SRC1) overnight expression host bacterial 
cultures were diluted 1:100 in LB media supplemented with 50 μg/mL of kanamycin and 
grown at 37 °C. At OD 600 reaching 0.6-0.8, expression was induced by addition of 
IPTG (isopropyl-β-D-1-thiogalactopyranoside) with final concentration at 0.1mM, and 
cultures were grown further at 15 °C overnight for 18hours. Successful overexpression of 
the proteins was verified by coomassie blue staining and immunoblot analysis with 
anti-His antibody (Amersham Biosciences). After cell harvest and lysis at PBS buffer by 
sonication (6 times pulses of 15 s each at half maximal power, on ice), the solution was 
clarified by centrifugation at 13.2k rpm in eppendorf centrifuge, 30 mins, 4°C and 
affinity purified following vendor’s protocols. Fractions containing the desired fusion 
protein were pooled and dialysed into a suitable buffer, and stored at -20 °C. Protein 
concentration was determined using the Bradford protein assay (Bio-Rad). Protein purity 
97 
was determined by separation on a 15 % SDS-PAGE gel. After getting these 3 puried 
SH2 domains proteins, we then labelled these 3 SH2 domains proteins using Cy3 
commercial available dye following previous protocols.
191, 232
 After that, they were 
performed using the dialysis cassette to remove the unreacted dye to maximally lower the 
background when doing the pure SH2 domains screening. They were then confirmed and 
evaluated using the SDS-PAGE and fluorescence scanner for the successful purification 





Figure 5.3 (a).Coomassie blue stain gel results of 3 SH2 domains proteins;(2) 
Fluorescent gel results of 3 Cy3 labeled SH2 domain proteins (Green color) for pure SH2 
domains proteins screening on the phosphopeptide microarray.0.Protein ladder; 1.GRB2 
SH2 domain; 2. LCK SH2 domain; 3.SRC1 SH2 domain.  
 
 
5.3.2.2 Single Point SH2 Domain Proteins Fingerprints  
Next, to evaluate the sensitivity of our phosphopeptide microarray platform, we 
98 
firstly performed the pure proteins profiling experiments with 3 classical SH2 domain 
proteins (GRB2, LCK, SRC1). SH2 domains are about 100 amino acids long and they are 
found to be contained in many important proteins including PTPs, PTKs, growth factors 











   
 
Figure 5.4 Single-point microarray fingerprintings at 1μM. (a) Microarray 









sequences of the representative peptides mentioned ; (c) Heat map of the 3 SH2 domain 
proteins fingerprintings. 
 
Each SH2 domain recognizes a specific subset of pY peptide sequences.
60
 The 
specificity is determined by the interactions between amino acids adjacent to pY and the 
less conserved regions of the SH2 domain surface. Determination of the sequence 
specificity of these SH2 domains is an important first step towards identifying their in 
vivo binding partners and understanding their physiological functions. Such information 





Figure 5.5 The denatured and non-pY binding proteins microarray experiments     
showed almost no binding here, thus suggesting that the 176-member pY peptide 
microarray relatively specifically binding SH2 domains (all proteins concentration at 
0.5μM).  
 
After successful fabrication of phosphopeptide microarray, we could use these 3 
SH2 domain model proteins to: firstly, test the sensitivity of our phosphopeptide 
microarray platform, which could specifically bind these phosphotyrosine binding 
proteins; secondly, we could find some potent SH2 binders, which would be useful for 
SH2 inhibitor design in future. Upon labeling with commercial Cy3 dye,
191, 232
 they were 
applied onto the peptide microarray (Figure 5.4). All 3 SH2 domain proteins showed 
Native GRB2        Denatured GRB2           BSA         Renin (Asp protease) 
protease) 
100 
distinct and highly reproducible binding profiles against the 176-member microarray. The 
bindings were highly specific towards only active phosphor tyrosine binding proteins, 
while denatured proteins (heated by 95C for 10mins ) and other non-phosphor tyrosine 
binding proteins didn’t bind (Figure 5.5). These results totally proved that our 
phosphopeptide microarray was sensitive to differentiate among different 
phosphotyrosine binding proteins via different binding strength.  
From the single-point fingerprinting experiments, some interesting and well 
known binding partners as well as some unknown binding partners with specific 
phosphorylation sites against each SH2 domain were efficiently and clearly confirmed or 
could be identified from our microarray binding profiles. For example, peptide A01 
(AEKPFpYVNVEF), which was derived from protein BCR (pY site 177) and was known 
to the binding partner of GRB2, 
261
 showed good binding here to the GRB2 SH2 domain. 
Peptide G04 (PSpYVNVQNLD), which was derived from the SHC-transforming protein 
1(pY site 317), also showed decent binding here to the GRB2, which was consistent with 
SMALI site prediction and previous report before.
262 
Peptide G15 (KPpYDGIPASE), 
which sourced from epidermal growth factor receptor (pY site 891), also showed strong 
binding to our SRC1 SH2 domain here, which was consistent with previous report.
263
  
Peptide G09 (VLpYTEVIPML), which was derived from the Olfactory receptor 9Q1 and 
was consistent with binding motif of the LCK,
60
  also showed strong binding to the LCK 
SH2 domain. Besides, based on our microarray results, we could also identify some 
unknown binding partners. For example, peptide H10 (ALpYDNVPECA), which was 
derived from the enhancer of filamentation 1 (pY site 12), a scaffolding protein 
implicated in regulating diverse cellular processes, such as cellular attachment, motility, 
101 
cell cycle progression, apoptosis, and inflammation,
264
 also showed decent binding here 
to the GRB2 SH2 domain from our microarray results, which may predict both the 
existence of  the new protein-protein interaction and undiscovered regulating function of 
GRB2 inside the cells for the signal pathway, as it was reported that GRB2  was 
over-expressed in the inflammatory lesions in infected livers.
265
  
5.3.2.3 Validation of Phosphopeptide-Pure Protein Interactions via Pure Protein Pull 
Down Assays  
To further test the accuracy and evaluate the importance of our microarray 
platform for the SH2 domain profiling, we also chose another 2 selective probes for 
further experiments: peptide D04 (SDDVRpYVNAFK), which had strong binding 
against GRB2 while weak binding against SRC1, and peptide H01 (DIpYAEIPDET), 
which had decent binding against SRC1 but weak binding against GRB2. To validate the 
interactions between selective phosphopeptides and the SH2 domains identified from the 
pure SH2 domain microarray screening, pure protein pull down experiments were carried 
out. 20μL of NeutrAvidin™ agarose beads, 20 μg of pure SH2 domain proteins and 2 
selective phosphopeptide probes (peptide D04 for GRB2, H01 for SRC1) (10μM final 
concentration for the peptide probes) were used here. Next the phosphopeptide probes 
were immobilized onto the avidin beads. After washed by PBS, the avidin beads were 
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Figure 5.6 Fluorescent gel for Probe D04 selectively pulling down GRB2.  
0. Protein marker; 1.Beads+DMSO+Cy3-GRB2; 2.Beads+D04+Cy3-GRB2; 
3.Beads+D04+Cy3-BSA; 4. Beads+D04+Cy3-SRC1; 5. Beads+D04+Cy3-GRB2+ Cy3- 
SRC1; 6.Cy3-GRB2; 7. Cy3-SRC1; 8.Cy3-BSA.  
 
0   1    2   3   4   5   6   7    8 
  
 
Figure 5.7 Fluorescent gel for probe H01 selectively pulling down SRC1.  
0. Protein marker;1.Beads+DMSO+Cy3-SRC1; 2.Beads+H01+Cy3-SRC1; 3.Beads+ 
H01+ Cy3-BSA; 4.Beads+H01+Cy3-GRB2; 5.Beads+H01+Cy3-GRB2+Cy3-SRC1; 6. 
Cy3-SRC1; 7.Cy3-GRB2; 8.Cy3-BSA. 
 
The results showed that they could pull down the corresponding proteins (Figure 
5.6 & 5.7), while the negative control (pull down without probes or other non-pY binding 
protein BSA) did not work (Figure 5.6 & 5.7). Besides, they can also pull down the 
expected protein even in the mixtures of the GRB2 and SRC1 (Figure 5.6 & 5.7), which 
was then validated by the western blotting (Figure 5.8 & 5.9). Similarly both probes 
could also work when MCF7 lysates were used for the proteomic pull down assay 
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(Figure 5.10). Therefore, our phosphopeptide microarray provided the possibility of 
using a novel highly miniaturized, rapid, reliable and efficient high throughput screening 
tool to establish the specificity of the SH2 domains—one kind of phosphor tyrosine 
binding proteins, and also can accurately indicated the interactions between proteins and 
phosphopeptides, which will be not only helpful for the SH2 domain potent and selective 
inhibitor design in future, but also will be of great importance for the prediction of new 
protein-protein interactions (PPI) inside the cell, because PPI was mostly transducted by 
the one protein with the core function fragment peptide in another protein.  
   1     2     3    4     5     6 
 
 
Figure 5.8 Western Blotting for probe D04 selectively pulling down GRB2 pure proteins 
(Anti-GRB2). 1. Beads+DMSO+GRB2; 2.Beads+D04+GRB2; 3. Beads+D04+BSA; 
4.Beads+D04+SRC1; 5.Beads+D04+GRB2+SRC1; 6.GRB2. 
 
 
1      2      3     4     5     6 
 
 
Figure 5.9 Western Blotting for probe H01 selectively pulling down SRC1 pure protein 
(Anti-SRC). 1. Beads + DMSO+SRC1; 2. Beads+H01+SRC1; 3. Beads+H01+ BSA; 4. 
Beads+H01+ GRB2; 5. Beads+H01+GRB2+ SRC1; 6.SRC1. 
 
(a) Anti-GRB2            (b) Anti-SRC 
 
D04   Control                   H01   Control             
                    
             






Figure 5.10 Western blotting to validate the corresponding proteins from lysate 
proteomes pull down assay using 2 selective probes (D04 and H01): (a)Anti-GRB2: 1. 
D04 pull-down; 2. DMSO pull-down (negative control); (b) Anti-SRC: 1.H01 pull-down; 
2.DMSO pull-down (negative control). 
 
5.3.3 Comparative Proteomic Profiling of Mammalian Cell Lysates 
 
5.3.3.1 Validate the Overexpression of Endogenous GRB2 Inside Cancer Cells  
Protein tyrosine phosphatases (PTPs) and protein tyrosine kinases (PTKs), as two 
major groups of enzymes, are involved in regulating tyrosine phosphorylation, which is 
one of mostly important post translational modifications inside the cells and which plays 
critical roles in regulating a lot of cellular process including cell cycle, growth, apoptosis 
and differentiation.
39, 41a, 41c, 231b, 231c, 266
  
Aberrant phosphorylation could lead to many cancers,
267 
which makes the 
phosphorylation related proteins (PTPs and PTKs) and phosphorylation specifically 
binding proteins (such as SH2 domains, PTB domain containing proteins and so on) 
becoming drug targets and biomarkers for cancer diagnosis and treatment.
268
 It was  
reported that many phosphorylated binding proteins were overexpressed in cancers, such 
as GRB2 in breast cancers. As a starting point and an example, we validated and 
confirmed the GRB2 overexpression in 3 classical cancers (HeLa, MCF7 and 


















Figure 5.11 Western blotting for the endogenous GRB2 level in 4 kinds of cells (30μg 
lysates), thus indicating overexpression of GRB2 in many cancers, which is consistent 
with previous report.
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 1.HEK293T; 2.HeLa; 3.MCF7; 4.MDA-MB-231. 
 
5.3.3.2 Test the Dual Color System 
To make sure that the dual color system worked in a good condition, we should 
use a same lysate (MCF7) labeled with both Cy3 and Cy5 dye. After that, we should run 
the fluorescent gel to confirm lysates properly labeled and can form a yellow color when 
mixing the equal amount of these two dye labeled same MCF7 lysates (Figure 5.12 (a)). 
After that, we then went on to apply the mixture of two dye labeled same lysates onto the 
phosphopeptide microarray platform with incubation for 1 hour. Following by washing 
and drying, they were scanned by the array scanner. The result showed that the 
fingerprintings are all yellow color on the microarray with ratio almost 1 (intensity of 
Cy3 channel: intensity of Cy5 channel) (Figure 5.12 (b)), which indicated that the dual 











(a)                               (b) 
0  1   2   3 
       
 
Figure5.12 Test the dual color system.(a) 0. Protein marker; 1.Cy3-MCF7; 2.Cy5-MCF7; 
3.Mixture of Cy3-MCF7 and Cy5-MCF7; (b) Dual color microarray image with 
incubation with 10μg each of Cy3-MCF7 and Cy5-MCF7. 
 
5.3.3.3 Dual Color Microarrays for Comparative Proteome Profiling of the 
Mammalian Cell Lysates 
 




    ( MCF7 + MCF7 ) 
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DAMB231; 7.Cy5-HeLa; 8.Cy5-HEK293T; 9.Cy3-SW480;10.Cy3-SW620; 11. 
Cy5-SW480; 12.Cy5-SW620. 
Next, having established that the phosphopeptide microarray platform provided 
reproducible and distinctive fingerprints against the pure proteins and also dual color 
system working in good condition, we went on to exploit the potential application of 
phosphopeptide microarray in comparative profiling of different mammalian cell lysates 
proteomes based on the proteins-phosphopeptide interactions. It will be of great 
importance and much interest to get different profiling for different cancer cells, which 
will predict the subtle difference of them inside the cells. Similarly, it will be also much 
more critical and important to compare the profiling of the cancer cells to the normal 
cells simultaneously, which will help us identify some differences between the cancers 
cells and normal cells, thus helping the discovery of cancers biomarkers. We 
hypothesized that, since some phosphorylation related proteins (phosphatases, kinases, 
pY binding proteins) were over-expressed inside the cell and linked to many cancers,
254, 
270
 there could be much more phosphopeptide-proteins interactions happening in the 
cancer cells than those in the normal cells. After being confirmed that the dual color 
system working in a good condition, we then carried on to do next for our formal 
experiments choosing 3 classical cancers cells: MCF7 (breast cancer, non-invasive), 
MDAMB-231 (breast cancer, highly invasive), HeLa (human cervical cancer); 2 different 
stages of colon cancer (early stage: SW480; late stage: SW620) and 1 normal cell 
(HEK293T) for our study. Firstly, we compared the 3 classical cancer cells to the normal 
cells. What we did was to firstly label cancer cell lysates with Cy3 dye and normal cell 
lysates with Cy5 dye, and then reversed the dye used, which was called reciprocal dual 
108 
color strategy. After labeling, they were run by the SDS-PAGE to establish each 
successful labeling and loading (Figure 5.13). 
 Upon mixing Cy3-cancer vs Cy5-normal cells, or Cy5-cancer vs Cy3-normal 
cells, they were applied to the different subgrids in one slide. Interestingly, to our 
pleasant surprise, we found that the fingerprints (Figure 5.14(a)) were almost green for 
Cy3-cancer cells vs Cy5-normal cells, or almost red for Cy5-cancer cells vs Cy3-normal 
cells, which indicated that bindings on the microarray were much stronger from the 
cancers than from the normal cells(Figure 5.14(b)), and suggested that there were much 
more binding proteins from the cancers than from the normal cells, which were consistent 




   
Figure 5.14 (a) Dual color labeling of the peptide microarray using 4 lysates; (b) 
Fingerprinting of the 4 cells (3 cancer and 1 normal cell). 
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Besides, we observed that peptide F24 (VVIALpYDYQTN) (Figure 5.14(a)) was 
always green for the profiling of MDA-MB231(breast cancer) vs HEK293T (normal) 
when we used the reciprocal dual color system, which suggested that F24 was probably 
false positive binding here, which could not been chosen as a potent probe for follow-up 
experiments. Therefore, our microarray profiling results here provided a highly 
reproducible and predictive set of signatures that reliably distinguished cancers from 
normal cells. Besides, one of the advantages of the reciprocal dual color microarray 
developed here over the traditional ones was that it can make you easily evaluate the 
results by your naked eyes to avoid the false positive results when you simultaneously 
compared the high throughput profiling of the different samples, which we could call it 
self-reporting character to filter false positive results. When we did the quantitative data 
analysis, we could also identify more selective peptide probes targeting the cancer cells 
than the normal cells. 
5.3.3.4 The Profiling is Based on Phosphopeptides-Proteins Interactions 
However, as there are some endogenous protein tyrosine phosphatases (PTPs) 
inside the cells, we are wondering whether it will dephosphorylate the phosphopepitdes 
on the microarray, thus causing the proteomes binding profiling not depending on the 
phosphopeptide-proteins interactions but dephosphorylated peptides-proteins interactions. 
To answer this haunting question, two experiments in the following sections were carried 
out to figure it out.  
The first was that we compared the ProQ image result (a phosphogroup specific 
dye) (Figure 5.15(a)) of 2 parallel spotted slides incubated with TBS buffer and the 
mammalian cell lysates. The result showed that the 2 slides were highly consistent with 
110 
pearson coefficient (r) more than 0.84 (Figure 5.15(a)), which indicated that there was no 
or little dephosphorylation within our experimental conditions (incubation time for 1hour 
in TBS buffer, not the commonly used PTPs activity buffer which also needed DTT to 
avoid the oxidization of the thiol group (–SH) in the active site of cysteine; and minimal 








Figure 5.15 Pro-Q image of the phosphopeptide microarray after incubation with TBS 
and MCF-7cancer cell lysate proteomes (without being labeled). (a) A. Incubation with 
TBS only; B. Incubation with lysates (10 μg lysates in TBS buffer for each subgrid); C. A 
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good pearson coefficient (r > 0.84) was obtained, which is to show that the two are quite 
similar before and after incubations with MCF7 lysates (b) The microarray spotting 
format in this microarray experiment. 
 
The second experiment was that we firstly dephosphorylated our phosphopeptide 
microarray into dephosphorylated peptide microarray (normal peptide microarray) using 
a well known alkaline phosphatase (ALP), which could remove the phosphate groups 
from phosphopeptide or proteins (Figure 5.16), and then incubated the mammalian cell 
lysates together with positive control (phosphopeptide microarray) under the same 
condition. The results showed that the bindings on the dephosphorylated peptides 
microarray almost disappeared or became very weak (Figure 5.17), while the 
phosphopeptide microarray still worked. These results suggested that the mammalian cell 
proteomic profiling greatly attributed to the phosphopeptides-proteins interactions. 
 
 
Figure 5.16 (a) ProQ
TM
 of the phosphopeptide (pY) microarray; (b) ProQ
TM
 of the 
peptide microarray(Y) (after treatment with alkaline phosphatase). This assay was to 
prove that the pY peptides on the microarray have been dephosphorylated by the alkaline 
phosphatase completely, which was then used for the next microarray experiments. 
 







Figure 5.17 Microarray experiments on the peptide (Y) microarray (After 
dephosphorylation). This is to show that there is no/weak binding after the 
phosphopeptides were dephosphorylated. 
 
5.3.3.5 Comparative Profiling of Different Stages of Colon Cancer  
 
Next, we applied our phosphopeptide microarrays to profile different stages of 
colon cancer named SW480 (early stage) and SW620 (late stage) as previous approach. 
Microarray fingerprintings (Figure 5.18) indicated that there was no obvious difference 
for these two different stages of colon cancer based on the naked eye analysis. However, 
we observed that there was subtle difference based on the quantitative data analysis. This 
could enable us to identify some selective peptide probes, which might help to unravel 
the potential protein biomarkers to differentiate different stages of colon cancer.  
   Cy3-MCF7                Cy3-HeLa 
Cy3-SW480            Cy3-MDAMB231 
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Figure 5.18 The dual color reciprocal fingerprintings of SW480/SW620, with 10 μg each 
cell per subgrid.  
   
5.3.4 Dual Color Pull Down Assays and MS for Biomarker Candidates 
Discovery 
5.3.4.1 Dual Color Pull Down and MS Assays  
To further evaluate the potential of the selective peptides identified from the array 
experiments, 2 peptide probes were selectively chosen for further dual color pull down 
assay: peptide D24 (YFMTEpYVATRW), one of the top selective peptides for MCF7 
cancers vs HEK293T; D07 (SESVVpYADIRK) for SW480 and SW620. The selective 
peptides were chosen with top ratio toward MCF7 (breast cancer) and SW620 (late stage 
of colon cancer) based on quantitative data analysis from the dual color microarray 
experiments. 
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(a)                                   (b) 
         
Figure 5.19 Dual color pull down and interesting bands for further MS analysis. (a) 
Pulled down using probe D24 (SESVVpYADIRK) with the lysates of (Cy3-MCF7 
/Cy5-HEK293T)(Proteins corresponding to Band 1 and 2 are identified from the whole 
pull down parallel lane cut, and proteins corresponding to Band 3 and 4 are identified 
from specific band cut); (b) Pulled down using probe D07 (SESVVpYADIRK) with the 
lysates of (Cy5-SW480 Vs Cy3-SW620)(The protein corresponding to Band 5 is 
identified from the specific band cut). 
 
Upon labeling the MCF7 with the Cy3 vs HEK293T with the Cy5, or the SW 480 
with Cy5 vs SW620 with Cy3, they were respectively incubated with their probes, 
followed by wash, and then suitable amount of beads were run the SDS gel followed by 
fluorescence scan. From the results in gel fluorescence (Figure 5.19), we could see some 
more interesting green bands from the Cy3 labeled MCF7 cancer (Figure 5.19(a)) and 
some green interesting bands from Cy3 labeled SW620 (Figure 5.17 (b)). By the 
quantitative data analysis, in the Figure 5.19 (a), we also obtained ratio of 1.7 (total 
green color intensity from the cancer cells vs total red intensity from the normal cells), 
which was also highly consistent with dual color microarray results. This also further 
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proved the accuracy of our dual color reciprocal phosphopeptide microarray platform. To 
further know the identity of these proteins, these interesting bands as well as the whole 
pull down (parallel sample) were exactly cut out, digested by trypsin and analyzed by 
mass spectrometry (MS). From the MS results, we obtained a proteins ID list with many 
proteins candidates. We then employed some stringent rules to shorten the interesting 
proteins candidates. Finally 5 proteins named PKM2, PTPN21, LDH-B, PRDX1 for 
MCF7 (breast cancer) and PHB for SW620 (colon cancer) (shown in Table 5.1) were 
identified and chosen based on MS results and some strict filter rules (molecular weight, 
score, peptide queries matched) for further validation.  
Table 5.1  MS results of the 5 biomarkers candidates. These results are for following up 
identification and validation of putative biomarkers overexpressed in cancer lysates. 
 
 
5.3.4.2 Validation for the Biomarker Candidates  
To further verify the 5 proteins (PKM2, PTPN21, PRDX1, LDH-B, PHB) 
identified from the dual color pull down and MS identification as a possible cancer 
biomarker candidates, we firstly should have to confirm the presence of these 5 proteins 
in the pull down samples. To prove that, western blotting experiments were carried out 
for the pull-down samples. The detailed results (Figure 5.20) were as below. From these 
results, they unambiguously confirmed the presence of these proteins in the 
corresponding pull down samples.  
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       (a)                         (b) 
D24       Uncoated               D24     Uncoated 
Agarose     Beads                Agarose     Beads 
           
 
          (c)                         (d) 
 
D24       Uncoated             D24       Uncoated 
Agarose      Beads             Agarose     Beads 
           
        (e) 
 
D07       Uncoated 
Agarose     Beads 
 
                  
 
Figure 5.20 Western blotting to validate the presence of 5 cancer biomarker candidates in 
the pulled down samples by their corresponding probes (use uncoated beads containing 
DMSO as negative control as peptide probes were dissolved in DMSO). (a) Anti-PKM2 
(58 kDa); (b) Anti-PTPN21(134 kDa); (c) Anti-LDH-B (37 kDa); (d) Anti-PRDX1 (22 
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Figure 5.21 Western blotting to validate the biomarker candidates more overexpressed in 
cancers than in normal cells( 30 μg lysates used here each, GAPDH as a loading control ). 
PKM2 















(a) Anti-PKM2 (58 kDa); (b) Anti-PTPN21 (134 kDa); (c) Anti-LDH-B (37 kDa); (d) 
Anti-PRDX1 (22 kDa); (e) Anti-PHB (29 kDa). 
 
To further validate the 5 proteins (PKM2, PTPN21, LDH-B, PRDX1, PHB) as the 
biomarkers candidates identified from the MS in the dual color pull down samples, they 
were then verified by the western blotting experiments to compare the expression level 
difference between the cancer cells and normal cells. 30 μg cell lysate each was used here 
with GAPDH as a loading control. The detailed experimental results were as shown in 
Figure 5.21, which suggested that these 5 proteins were more expressed in cancer cells 
than the normal cells, suggesting that they are highly possible cancer biomarkers 
candidates, which still need to be further validated by the clinical study in future. 
5.3.5 Antibodies Detection on the Microarrays 
Besides, to further prove the existence of the interaction between the 
phosphopeptides and the corresponding proteins, antibody detection on the microarray 
assay was employed here to show another evidence. What we did was to firstly incubate 
suitable MCF7 cell lysates (without being labeled) on the microarray, which had been 
washed and blocked by 1%BSA/TBS in advance. After the incubation, the slides were 
washed by H2O and then incubated the Cy3 labeled antibody for 1hour. After that, the 
slides were gently washed by H2O for 2 minutes each for 2-3 times and then scanned. The 
results showed that there are corresponding proteins binding with the corresponding pull 
down probes, which further proved the accuracy of the discovery here. Besides, we also 
found much more peptides, which also interacted with 5 proteins and could be helpful for 
inhibitor design for each biomarker candidate in future. 
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Figure 5.22 Antibody detection for the interactions between peptide probes of D24 
(YFMTEpYVATRW) (Boxed up in (a), (b), (c), (d)) and D07 (SESVVpYADIRK) 
(Boxed up in (e)) and the corresponding proteins (PKM2, PTPN21, LDH-B, PRDX1, 
PHB) on the microarray.  
 
5.4 Conclusion 
In summary, a novel dual color reciprocal phosphopeptide microarray platform 
was developed here for high throughput proteomic profiling of mammalian cell lysates. 
By using this phosphopeptide microarray platform and dual color approach, we could 
simultaneously compare different profiling of mammalian cell proteomes, which also 
could evaluate/avoid the false positive results by the naked eyes and can be much better 
than the conventional strategy—single color microarray analysis. Besides, this systematic 
strategy (combining dual color microarray, dual color pull down, MS, western blotting, 
antibody detection on the microarray) developed here could be used for the cancer 
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biomarker candidates discovery. The selective probes generated based on the dual color 
microarray data analysis helped us identify 5 cancer biomarkers candidates for MCF7 
(breast cancer) and SW620 (colon cancer) respectively. By targeting a class of proteins 
based on proteins-phosphopeptide affinity based on interactions while not depending on 
specific protein/biomarker-ligand interaction and not require much prior knowledge of 
expression level of the specific target protein in the mammalian cells, we could quickly 
identify much differences between the cancers cells and normal cells,  and also can even 
get some useful information and subtle differences between different kinds of cancers as 
well as different stages of cancers, thus possibly making phosphopeptide microarray 
based comparative proteomic profiling as a novel indicator/strategy shed light on the 
cancer differentiation and diagnosis in future. This useful and systematic strategy 
developed here should be also applicable for other post translational modification related 
biomarker discovery (such as methylation and so on) by changing the phosphopeptides 
into other small molecules. We would expect more applications of this phosphopeptide 
microarray based dual color system to the proteomics and “catalomics” study for 















6.1 General Procedures 
6.1.1 Materials 
  All chemicals were purchased at the highest grade and used without further 
purification, unless otherwise noted. Fmoc-amino acids, HOBT, HBTU, TIS, TFA were 
from GL Biochem (China). Piperidine was from Merck (USA). Plain glass slides were 
purchased from Sigma Aldrich (USA), and modified to generate the corresponding 
avidin-coated surface as previously described.1 Pro-Q™ Diamond dye was bought from 
Invitrogen (USA). All antibodies were purchased from Abcam or Santa Cruz. Active 
PTPs, PTPs mutants and SH2 domains were expressed and purified in house.
 
Plain glass 
slides were purchased from Sigma Aldrich (USA), and modified to generate the 
corresponding avidin-coated surface as previously described. Pro-Q
™
 Diamond dye was 
bought from Invitrogen (USA). All the SH2 domains bacterial constructsproteins are 




Microplates were scanned using a SpectraMax
TM
 Gemini XS fluorescence plate reader 
(Molecular Devices, USA). Where indicated, liquids were dispensed robotically using an 
automated liquid handler with 8-channel dispensing capability. (Precision XS, Biotek, 
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Vermont, USA). Microarrays were printed using a contact arrayer (Virtek Chipwriter, 
Ontario, Canada). Microarrays were scanned on an ArrayWoRx
TM
 microarray scanner 
(Applied Precision, USA) equipped with the relevant filters for Cy3 (λEx/Em:548/595 nm) 
and Cy5 (λEx/Em:633/685 nm), or scanned by Tecan Launch LS Reloaded Microarray 
Scanner (Tecan Trading AG, Switzerland) installing suitable laser channel: Cy3: λEx/Em= 
532/575 nm; Cy5: λEx/Em= 633/692 nm.. Gels were scanned on a Typhoon fluorescence 
gel scanner (GE Healthcare, USA). ESI mass spectra were acquired in both the positive 
and negative mode using a Finnigan/Mat TSQ7000 spectrometer. HPLC profiles and ESI 
mass spectra were acquired in the positive or negative mode by using a Shimadzu IT-TOF. 
Analytical and semi-preparative RP-HPLC separations were performed on Phenomex C18 
analytical (150 x 3.0 mm) and semi-preparative (250 x 21.2 mm) columns, respectively, 
using a Shimadzu Prominence HPLC system equipped with a Shimadzu SPD-20A 
detector. Eluents A (0.1 % TFA/acetonitrile) and B (0.1 % TFA/water) were used as the 
mobile phases.  
 
6.2 Solid Phase Peptide Synthesis of the Phosphopeptides 
Library 
The following procedures are used for all the peptide synthesis carried out in this thesis: 
the Peptide synthesis was performed by using standard Fmoc Strategy together with 
IRORI™ directed sorting technology. Rink amide resin was used as the solid support. 
Standard HOBT/HBTU/DIEA coupling method was used throughput the whole process. 
Each microreactor contains around 40 mg of rink amide resin and a unique Rf tag for 
sorting application. The resin was swelled in HPLC-grade DMF for 1 h at room 
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temperature. Subsequently the Fmoc group was deprotected by treatment of 20% 
piperidine for 1 h at room temperature. Following removal of the piperidine, the resin 
was washed extensively with DMF and DCM. The microreactors were then dried 
thoroughly under the high vaccum. Next, the microreactors were sorted and distributed 
into several reaction vessels, and each containing a unique Fmoc amino acid (4.0 eq), 
preactivated with HBTU/HOBt/DIEA (1/1/2 ratio relative to the amino acid). The resins 
were swelled in DMF for half an hour before coupling. The coupling reactions were 
carried out for 8 h at room temperature with shaking. At the end, the microreactors were 
collected and washed thoroughly with DMF and DCM. Any unreacted resin residue was 
capped with a solution of Ac2O (10 eq), DIEA (20 eq) in DCM (200 mL), and the 
reaction mixture was allowed to react for 2 h at room temperature, followed by extensive 
wash with DCM and DMF. Subsequently the resin was deprotected with 20% piperidine 
again and ready for next coupling cycle. Repeat the above cycle until the last amino acid 
has been coupled. (Biotin)-GG was attached at the N-terminus of peptides for microarray 
immobilization. After the whole coupling process was finished, the microreactors were 
collected, washed thoroughly and dried under high vaccum for 2 h at RT. The 
microreactors were then decoded and cleaved under 95% TFA, 2.5% TIS, 2.5% H2O for 4 
h at room temperature. For those peptides containing cysteine or methionine residue, the 
peptides were cleaved from the resin by using 94%TFA, 2.5% EDT, 2.5% H2O and 1% 
TIS. Following prolonged concentration in vacuo until >80% of cleavage cocktail was 
removed. Cold ether (chilled to -20 °C) was added to the liquid residue to precipitate the 
peptides. The peptides were allowed to precipitate at -20 °C for overnight. At the end, the 
ether layer was decanned and the precipitates were dried thoroughly in vacuo. This 
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process was repeated for a couple more times. The resulting peptide solids were dissolved 
in 1 ml DMSO and stored at -20 °C. LCMS was performed to ensure the peptides were of 
correct mass and sufficient purity for subsequent microarray experiments. 
 
6.3 Microarray-Based Enzyme Sreening and Proteomic 
Profiling 
6.3.1 Preparation of Avidin Slides 
25 mm × 75 mm glass slides (Sigma-Aldrich) were cleaned in piranha solution 
(sulfuric acid/hydrogen peroxide, 7:3). An amine functionality was incorporated onto the 
slides by silanization using a solution of 3% (aminopropyl) triethoxysilane in 2% water 
and 95% ethanol. After 1-2 h incubation, the slides were washed with ethanol and cured 
at 150 ºC for at least 2 h. The resulting amine slides were incubated in a solution of 180 
mM succinic anhydride in DMF for 30 min before being transferred to a boiling water 
bath for 2 min. The slides were rinsed with ethanol and dried under a stream of nitrogen. 
The carboxylic acid derivatized slide surface was activated with a solution of 100 mM of 
HBTU, 200 mM DIEA, and 100 mM N-hydroxysuccinimide (NHS) in DMF, thus 
generating the NHS-derivatized slides. These surfaces were reacted with a solution of 1 
mg/mL avidin in 10 mM NaHCO3 (pH 9) for 40 min, washed with water, air dried. The 
unreacted NHS groups were quenched with a solution of 2 mM aspartic acid in a 0.5 M 
NaHCO3 buffer, pH 9. These slides were washed with water, dried and stored at 4 ºC, 
ready for printing. 
6.3.2 Microarrays Spotting Preparation 
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All peptide stocks were prepared and diluted to final spotting concentration around 
1mM (or an appropriate concentration) in DMSO/PBS (1:1) spotting solution, and were 
distributed in 384-well plates. All peptides were shown to be completely soluble in this 
spotting solution. Slides were spotted on an ESI SMA arrayer (Ontario, Canada) with the 
print head installed with 4 Stealth SMP8B Microspotting pins (Telechem, U.S.A.). Spots 
generated were of approximately 350 μm diameter and were printed with a spot-spot 
spacing of 450 μm. The pins were rinsed in between samples using two cycles of wash 
(for 10 s) and sonication (for 10 s) in reservoirs containing 70% ethanol followed by 
drying under reduced pressure (for 10 s). The slides were allowed to stand for 1 h on the 
printer platform and stored at 4 ºC until use. For the microarray studies, all 
phosphopeptides were spotted on the same slide in duplicate. 
6.3.3 Proteins/Mammalian Cell Lysates Proteomes Labeling 
50 μg protein/lysates proteomes were minimally labeled with either 1.0 μL 
Cy5/Cy3-NHS ester, together with 10 μl NaHCO3 (0.5M, pH 9.0) in 50μl total solution 
(Monofunctional Cy5/Cy3 dye: Amersham, G.E. Healthcare) for 1 h on ice, following the 
manufacturer’s protocols and our previously published procedures 3. The unreacted dye 
was quenched with a 10-fold molar excess of hydroxylamine for a further 1 h. The 
unreacted dye was further removed by buffer exchange in a final TBS buffer solution 
with a Microcon
®
 centrifugal filter units (M3 Millipore, USA). The labeled proteomes 
was reconstituted in a final buffer volume of 100 μL TBS (pH 7.4) to dilute to be 0.5 
mg/mL to avoid precipitation. 
6.3.4 Peptide Microarrays Based Screening for Mutant and Active PTPs  
6.3.4.1 Pro-Q™ Assays 
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Pro-Q™ staining, which is capable of fluorescence-based measurement of 
pTyr/Ser/Thr residues present in peptides and proteins, was routinely carried out on 
spotted slides to ensure the consistency and quality of the slides by detection of the 
phosphopeptides. The slide was washed with H2O and stained with Pro-Q™ Diamond 
dye for 1 h at room temperature. Subsequently the slide was destained with a solution of 
20 % acetonitrile in sodium acetate (pH = 4) for 0.5 h and visualized with the microarray 
scanner under the Cy3 channel (λEx = 548 nm; λEm = 595 nm). 
6.3.4.2  Peptide Microarray Based Screening for Mutant PTPs 
PTP mutants were minimally labeled with the protocol described above. The excess 
dye was removed by extensive dialysis against TBS buffer due to the PTP mutants were 
trapped inside the G25 spin column. In a standard microarray experiment, the labeled 
protein was applied on microarray via marker pen method. For dual-color screening 
experiments, an equal amount of a Cy3-labeled protein and another Cy5-labeled protein 
was mixed and applied together to the slide. The samples were incubated with the array 
in a humidified chamber for 1 h at room temperature, before repeated rinses with TBS + 
0.05 % Tween 20, typically 3 x 10 min washes with gentle shaking. Slides were scanned 
using an ArrayWorx microarray scanner installed with the relevant filters (Cy3: λEx/Em = 
548/595 nm; Cy5: λEx/Em = 633/685 nm).            
6.3.5 Site Directed Mutagenesis of PTPs Mutants 
The PTP mutants were obtained by using QuickChangeTM XL Site-Directed 
Mutagenesis Kit (Strategene) described as above. The primers for constructing of different 
PTP mutants (C-S) were listed as followed: 
SDM-PTP1B-Fw (C215S)  
5’-CGG GCC CGT TGT GGT GCA CTC CAG TGC AGG CAT CGG CAG GT-3’ 
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SDM-PTP1B-Rv (C215S)  
5’-ACC TGC CGA TGC CTG CAC TGG AGT GCA CCA CAA CGG GCC CG-3’ 
 
SDM-TCPTP-Fw (C216S) 
5’-ATG GGC CTG CGG TGA TCC ACT CTA GTG CAG GCA TTG GGC GCT C-3’ 
 
SDM-TCPTP-Rv (C216S) 
5’-GAG CGC CCA ATG CCT GCA CTA GAG TGG ATC ACC GCA GGC CCA T-3’ 
 
SDM-SHP1-Fw (C453S) 
5’-CCC ATC ATC GTG CAC TCC AGC GCC GGC ATC GGC-3’ 
 
SDM-SHP1-Rv (C453S) 
5’-GCC GAT GCC GGC GCT GGA GTG CAC GAT GAT GGG-3’ 
 
SDM-SHP2-Fw (C459S) 
5’-CCG GTC GTG GTG CAC TCC AGT GCT GGA ATT GGC-3’ 
 
SDM-SHP2-Rv (C459S) 
5’-GCC AAT TCC AGC ACT GGA GTG CAC CAC GAC CGG-3’ 
 
SDM-LMW-Fw (C13S) 
5’-CAA GTC CGT GCT GTT TGT GTC CCT GGG TAA CAT TTG TCG ATC-3’ 
 
SDM-LMW-Rv (C13S) 
5’-GAT CGA CAA ATG TTA CCC AGG GAC ACA AAC AGC ACG GAC TTG-3’ 
6.3.6 Protein Expression and Purification 
Overnight cultures were diluted 1:100 in LB media supplemented with 100 μg/mL of 
ampicillin or 50 μg/mL kanamycin and grown at 37 °C. At OD600 ~0.6, expression was 
induced by addition of IPTG (isopropyl-β-Dthiogalactopyranoside) and Cultures were 
grown further at 15 °C for 18 hours. Successful overexpression of the proteins was 
verified by coomassie blue staining and immunoblot analysis with anti-His antibody 
(Amersham Biosciences). After cell harvest and lysis (at pH 7.4, 20 mM tris-HCl, 150 
mM NaCl) by sonication (6X pulses of 15 s each at half maximal power, on ice), the 
solution was clarified by centrifugation at 10000 g, 30 min, 4 °C and affinity purified 
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following vendor’s protocols. Fractions containing the desired fusion protein were pooled 
and dialyzed into a suitable buffer, and store at -20 °C with suitable glycerol. Protein 
concentration was determined using the Bradford protein assay (Bio-Rad). Protein purity 
was determined by separation on a 12 % SDS PAGE gel.  
6.3.7 His-Tag Protein Purification 
Protein purification was under the standard protocol of His tag purification Kit. Lysis 
Buffer: Phosphate Buffer, 300 mM NaCl, 10 mM imidazole (pH 8). Washing buffer: 
Phosphate Buffer, 20 mM imidazole (pH 8). Elution Buffer: phosphate buffer, 100 mM 
imidazole (pH 8). 200 ml cell culture was centrifuged down, resuspended into 2 ml ice 
cold lysis buffer and lysed by sonication method (Ultra sonic liquid processor model XL 
2020) on ice bath. The columns were prepacked with 200 µl Ni-NTA beads and washed 
with lysis buffer 3 times. The clarified cell lysate was incubated with column at 4 ºC for 1 
h with gentle agitation. Remove the bottom outlet cap and pass the flow through. Wash 
the beads with washing buffer with 0.5 ml each. Finally elute out the protein with 0.5 ml 
elution buffer containing 100 mM imidazole. Each step of purification was analyzed by 
SDS-PAGE and the eluted proteins were confirmed with western blotting with the 
anti-His antibody. 
6.3.8 Microplate PTPs Enzymatic Assays 
 
Substrate specificity in solution was measured in the transparent 384 well 
microplates.10 μM peptides were incubated with optimum concentration of PTPs in a 
total of 40 μL Hepes buffer (50 mM Hepes, 100 mM NaCl, 2 mM. EDTA, 0.01% Brij，1 
mM DTT, pH 7.0) for different time points (ranging from 0, 5 mins, 15 mins, 30 mins, 60 
mins to 120 mins) at 25 °C. The kinetic data for each peptide was determined in 
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duplicates. The reaction was stopped by addition of malachite green solution containing 
sulfuric acid. After incubation with the malachite green solution for 10 mins, the 
absorbance of the malachite green-phosphate complex was measured at 650 nm.  The 
microplate data was processed with the software Graphpad Prism v. 4.03 (GraphPad, San 
Diego, USA) and fitted with the following equation to derive the kinetic data. AbsObs 
represents the absorbance reading at time x. AbsMax represents the fitted constant which 
should correspond to the maximum absorbance obtained when the enzymatic reaction is 
complete. 
AbsObs=AbsMaxx(1-exp(-kobsxtime)). 
6.3.9 Peptide Microarrays Based Screening for Active PTPs 
6.3.9.1 Microarrays Assays 
The subgrids were treated with different enzyme on the same slides. Six grids of 
identical 144 phosphorylated peptides were spotted onto the same avidin-functionalized 
slide in DMSO:PBS (1:1) mixture (This concentration was tested to be ideal for substrate 
immobilization). The slide was then washed with H2O for 10 min at RT and incubated 
with 1% BSA in Hepes (pH = 7.4) for half an hour with gentle shaking. The slide was 
then washed with H2O and dried briefly to get rid of the water. Subsequently, suitable 
concentration of different PTPs were applied together with their own buffer to the 
different subgrids on the same slide. The enzyme reaction was allowed to incubate in a 
humid chamber at room temperature for 1 h. The slide was then washed with H2O and 
stained with ProQ Diamond Dye.  PTP1B/TCPTP working buffer: 50 mM Hepes, 
100mM NaCl, 2 mM. EDTA, 0.01% Brij,1 mM DTT, pH 7.0; SHP1 / SHP2 / ΔSHP1 / 
ΔSHP2/LMW working buffer: 50 mM NaOAc-HOAC, 2 mM EDTA, 0.01 % Brij, 1mM 
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DTT, pH 5.0), the slides were rinsed with TBS (pH 7.4) for 10 min and blocked with 
TBS-containing 1 % BSA for 1 h.  
6.3.9.2 Time-Dependent Experiment 
The time-dependent experiment was carried out similarly as described above except 
that the different grids were incubated with different PTPs (same concentration) for 
different periods of time (0, 5 min, 15 min, 30 min, 1 h, 2 h, respectively). 
 
6.3.10 Peptide Microarrays Based Proteomic Profiling for Mammalian 
Cell Lysates  
In a standard lysates microarray experiment, the labeled lysates (0.5 mg/mL; 40 μL) 
were applied under coverslip to the arrays (around 10μg lysates/grid). For the dual color 
reciprocal microarray screening experiments, an equal amount of Cy3 labeled SH2 
domain proteins (for SH2 domain screening) or a mixture of Cy3/Cy5-labelled proteomes 
A and a Cy5/Cy3-labelled proteomes B (for dual color reciprocal proteomic profiling) 
was applied together to the spotted microarray slides. The samples were incubated with 
the array in a humidified chamber for 1 h at room temperature, before repeating rinses 
with TBST (TBS containing 0.05% Tween
®
 20), typically 3×10 min washes with gentle 
shaking. Slides were scanned using a Tecan Launch LS Reloaded microarray scanner 
installed with the 2 relevant lasers (Cy3: λEx/Em= 532/575 nm; Cy5: λEx/Em= 633/692 nm). 
6.3.11 KD Microarrays Experiments 
Incubate the different concentration of the labeled proteins solution individually onto 
the subgrids on the microarrays, which have been drawn by the permanent marker pen to 
form rectangular frames, in a humid chamber for 0.5-1 hour. 
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6.3.12 Peptide Microarrays Based Screening for SH2 Domains 
In a standard microarray experiment, the labeled protein (1 μM/80 μL) was applied to 
the array. For denaturing experiments, the labeled protein was firstly boiled for 5 min, 
cooled before being applied to the peptide microarray. For dual-color screening 
experiments, an equal amount of a Cy3-labeled protein and a Cy5-labeled protein was 
mixed and applied together to the slide. The samples were incubated with the array in a 
humidified chamber for 1 h at room temperature, before repeated rinses with TBS + 
0.05% Tween 20, typically 3 x 10 min washes with gentle shaking. Slides were scanned 
using the Tecan Launch LS Reloaded microarray scanner installed with the 2 relevant 
lasers (Cy3: λEx/Em= 532/575 nm; Cy5: λEx/Em= 633/692 nm). 
 
6.4 Data Analysis 
6.4.1 Dephosphorylation Ratio Analysis 
Microarray data was extracted using the ArrayWoRx software. Values from duplicate 
points were background subtracted and averaged.  Points that were inconsistent across 
different slides were removed. The dataset showed a good consistency across triplicated 
experiments (Pearson correlation, r > 0.9). The combined dataset was scaled from 0% – 
60% by setting the contrast as 0.6. The dataset was presented in colored heatmaps, using 
the Treeview software (http://rana.lbl.gov/EisenSoftware.htm). The dataset was also 
subjected to cluster analysis to correlate specificity information from the library into 
hierarchical contributions, providing insights of the similarities across the enzyme 
towards the substrates. Averaged linkage clustering was performed using the Systat v11.0 
software (San Jose, CA, USA). For comparison, the active site domains of the enzymes 
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were retrieved from NCBI and aligned using ClustalW. 
 
The dephosphorylation ratio was calculated as followed: 
                                                         
 Dephosphorylation ratio of x=    
 
6.4.2 Kobs Analysis 
The time course experiment was carried out with the lambda phosphatase as the model. 
The optimum concentration of lambda phosphatase was applied onto array at different 
time points. And the data was extracted using the Array WoRx software and fitted with 
the following relationship. 
∆RF =RFInit x (1-exp(-kobs x time)) 
The observed intensity change (∆RF) was plotted over time by fitting the equation 
presented above with the software Graphpad Prism software v.4.03 (GraphPad, San 
Diego, USA). ∆RF (at time x) = Initial Fluorescence reading (at t = 0) – Fluorescence 
reading (at t = x). The dynamics curve reveals the kinetic constant kobs which could 
determine the enzyme substrate specificity. RFinit represents the fitted constant, which in 
theory should correspond to the relative fluorescence intensity of peptide spots prior to 
enzyme desphosphorylation (e.g. t = 0) 
6.4.3 Quantiative KD Analysis  
Peptides were spotted onto slides where up to 6 identical subarrays were generated on 
the same microarray, so as to allow consistent/uniform screening and comparison of 
different PTP mutants, or different concentrations of the same PTP mutants, or SH2 
domains, to be carried out concurrently on the same platform. Using dose-dependent 
experiments, we extracted binding data of against mutant PTPs, or SH2 domains proteins. 
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The corresponding KD was generated by fitting the data to the following equation, under 
the assumption that equilibrium is achieved during the incubation period: 
 
Observed fluorescence of x = [Maximum fluorescence, x] x [Protein concentration]  
                                                                       
KD + Protein concentration  
 
Saturation dynamics observed when plotting Observed fluorescence against the applied 
Protein concentration were then fitted to the above equation using the Graph pad Prism 
software v.4.03 (GraphPad, San Diego, USA) revealing the binding dissociation constant, 
KD.  
6.4.4 PTPs Substrate/SH2 Domain Binders Fingerprinting Analysis 
Microarray data was extracted using the ArrayWoRx software. Values from duplicated 
points were background subtracted and averaged (Duplicated spots with a standard 
deviation > 0.2 were rejected). The dataset was presented as colored heatmaps, using the 
Treeview software (http://rana.lbl.gov/EisenSoftware.htm). Venn diagrams were 
generated to identify the potent binders across PTP mutants. 
6.5 SH2 Domains Proteins Expression and Purification  
 
Overnight expression host bacterial cultures were diluted 1:100 in LB media 
supplemented with 50 μg/mL of kanamycin and grown at 37 °C. At OD600 reaching 
0.6-0.8, expression was induced by addition of IPTG 
(isopropyl-β-D-1-thiogalactopyranoside) with final concentration at 0.1mM, and cultures 
were grown further at 15°C overnight for 18h. Successful overexpression of the proteins 
was verified by coomassie blue staining and immunoblot analysis with anti-His antibody 
(Amersham Biosciences). After cell harvest and lysis at PBS buffer by sonication (6 
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times pulses of 15 s each at half maximal power, on ice), the solution was clarified by 
centrifugation at 13.2k rpm in an Eppendorf centrifuge, for 30 min at 4°C and affinity 
purified using vendor’s protocols. Fractions containing the desired fusion protein were 
pooled and dialyzed into a suitable buffer, and stored at -20 °C. Protein concentration was 
determined using the Bradford protein assay (Bio-Rad). Protein purity was determined by 
separation on a 15 % SDS-PAGE gel. 
6.6 Mammalian Cell Culture 
HeLa (human cervical cancer line), MCF7 (non-invasive breast cancer line), SW480 
(early stage of colon cancer line), SW620 (late stage of colon cancer line) and normal 
human cell line HEK293T (human embryonic kidney line) were cultured in growth 
medium (DMEM supplemented with 10% fetal bovine serum (FBS), 100 mg/L 
streptomycin, and 100 IU/mL penicillin); MDA-MB-231(invasive breast cancer cell) was 
cultured in RPMI 1640 growth medium. All cells were maintained in a humidified 
atmosphere of 5% CO2 at 37 °C, and grown to ~90% confluence. Cells were detached by 
trypsin digestion, washed by PBS for three times, centrifuged, and stored at -20 °C until 
required for use. 
6.7 Preparation of Cellular Lysates Proteomes  
Cell pellets were thawed on wet ice with PBS buffer added (one T75 cell pellet was 
resuspended with 200-400 µL PBS buffer). Pellets were resuspended, incubated on ice 
for 15 min. Lysis was performed by 30-50 passages through a 22G needle using a 1ml 
syringe, then samples were centrifuged at 13.2k rpm at 4°C for 30 min. Cleared 
supernatant was transferred to chilled Eppendorf tubes. Protein concentration was 
determined by Bradford assays (Bio-Rad). 
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6.8 Lysates Proteomes Pull Down Assays 
NeutrAvidin™ agarose beads (Pierce, USA) were pre-incubated with selected 
biotinylated peptide probes (final concentration 10μM) at room temperature for 1 h, then 
washed 3 times with TBS buffer to remove the excess unbound probes. After wash, beads 
were added into cellular lysate (2.5 mg) in TBS buffer containing phosphatase inhibitor 
(final concentration 2mM Na3VO4), and allowed to incubate at room temperature for 1 h 
with rocking. NeutrAvidin™ agarose beads were centrifuged for 5 min at 4000×g at room 
temperature and washed with TBST (0.05% Tween
®
20 in TBS buffer) 5-10 times. A 
negative control (same pull down procedures but without the probes, with DMSO as the 
negative control as phosphopeptides stocks were dissolved in DMSO solvent). Suitable 
amounts of the beads were taken, resuspended in 1×SDS loading dye buffer, and 
analyzed by Western blotting as described below. 
6.9 Western Blotting (WB) 
Primary antibody GRB2 (Cat.#:ab-28164) was bought from Abcam, and others such as  
LDH-B (Cat.#:sc-100775), PRDX1(Cat.#:sc-7381), PHB (Cat.#:sc-18198), 
GAPDH-HRP (Cat.#:sc-25778), c-SRC (Cat.#:sc-130074), and secondary antibody 
donkey anti-goat IgG-HRP (Cat.#: sc-2020), goat anti-rabbit IgG-HRP (Cat.#:sc-2004) 
were bought from Santa Cruz. Secondary antibody goat anti-mouse HRP (Cat.#:1858112) 
was obtained from Pierce. Briefly, suitable amount of proteomes or proteins (the exact 
amount of proteins/lysates proteomes will be specified in each parallel group of the 
experiments) were loaded and separated by SDS-PAGE and transferred onto PVDF 
membrane, blocked for 1 h at room temperature or overnight at 4 °C in blocking buffer 
(4% BSA in TBS containing 0.1% Tween
®
20). After that, membranes were incubated 
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with primary antibody for 1 h at room temperature in primary antibody blocking buffer 
(3% BSA in TBS containing 0.1% Tween
®
20). Following 3 washes (5-10 minutes each) 
in TBST (TBS containing 0.1% Tween
®
20), the blot was then incubated with 
HRP-conjugated secondary antibody for 1 h at room temperature in the buffer same as 
primary antibody blocking buffer. At the end of this period, it was again washed three 
times with 10-15 min each in TBST (TBS containing 0.1% Tween
®
20) and detected by 
chemiluminescence using the Super Signal West Pico/Dura Kit (Pierce, Thermo 
Scientific). 
6.10 Antibodies Detection on the Microarrays  
All the antibodies used for the detection on the microarray platform were firstly 
labeled with Cy3 monofunctional dye (Amersham, G.E. Healthcare). The labeling 
procedure was as follows: 40 μL antibodies solution about 8 μg (only 4 μg of anti-LDH-B 
was used) were mixed with 0.3 μL Cy3 dye and 10 μL NaHCO3 (0.5M, pH = 9.0). After 
reaction for 1 h in ice, the unreacted dye was quenched with 5μL hydroxylamine solution 
(0.21 g hydroxylamine (Cat.#:25558-0, Sigma Aldrich) dissolved in 1ml 2.5M NaOH) for 
another 1 h. After that, the mixture was separated with G25 column (Cat.#: 27-5325-01, 
G.E. Healthcare) to remove unreacted dyes. Next the slides were washed for 10 min with 
H2O and then blocked with 1% BSA/TBS for 30 min to maximally reduce non-specific 
bindings in next experiment. After blocking, the slides were incubated with 30μg MCF7 
cell lysates or SW620 cell lysates (only for anti-PHB detection) in TBS buffer per 
subgrid for 1 h, and then briefly washed with H2O. Slides were incubated with labeled 
antibodies for another 1 h, and then washed with H2O for 2-3 times, for 2 min each time. 
Finally, slides were dried and scanned using the microarray scanner. 
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6.11 Mass Spectrometric Analysis 
The LTQ-FT ultra (Thermo Electron, Bremen, Germany) was coupled with an online 
Shimadzu UFLC systems utilizing nanospray ionization. Peptides were first enriched 
with a Zorbax 300SB C18 column (5 mm × 0.3 mm, Agilent Technologies, Santa Clara, 
CA) followed by elution into an integrated nanopore column (75 μm × 100 mm, New 
Objective, Woburn, MA) packed with C18 material (5 μm particle size, 300 Å pore size, 
Macho BioResources, Inc.). Mobile phase A (0.1% formic acid or TFA, H2O) and mobile 
phase B (0.1% formic acid or TFA, acetonitrile) were used to establish the 90-min 
gradient comprised of 3 min of 0-5 % B, then 52 min of 5 - 30% B, followed by 12 min 
of 30 - 60% B; maintained at 80% B for 8 min, before re-equilibrating at 5% B for 15 
min. Sample was injected into the MS with an electrospray potential of 1.8 kV without 
sheath and auxiliary gas flow, ion transfer tube temperature of 180 °C, and collision gas 
pressure of 0.85 mTorr. A full survey MS scan (350-2000 m/z range) was acquired in the 
7-T FT-ICR cell at a resolution of 100,000 and a maximum ion accumulation time of 1s. 
Precursor ion charge state screening was activated. The linear ion trap was used to collect 
peptides where 10 most intense ions were selected for collision induced dissociation (CID) 
in MS
2
, which were performed concurrently with a maximum ion accumulation time of 
200 ms. Dynamic exclusion was activated for this process, with a repeat count of 1 and 
exclusion duration of 30 s. For CID, the activation Q was set at 0.25, isolation width (m/z) 
2.0, activation time 30 ms, and normalized collision energy of 35%. The Extract_Msn 
(version 4.0) program found in Bioworks Browser 3.3 (Thermo Electron, Bremen, 
Germany) was used to extract tandem MS spectra in the dta format from the raw data of 
LTQ-FT ultra. These dta files were then converted into MASCOT generic file format 
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using an in-house program. Intensity values and fragment ion m/z ratios were not 
manipulated. This data was used to obtain protein identities by searching against the 
corresponding database by means of an in-house MASCOT server (version 2.2.03) 
(Matrix Science, Boston, MA). Mass tolerances of 10 ppm for peptide precursors; and 0.8 
Da mass tolerance for fragment ions. Only proteins with a MOWSE score higher than 39, 
corresponding to p < 0.05 were considered significant. The peptide/protein list(s) 





























Herein I have described several array-based systematic approaches by integration 
of microarray, microplate and other enabling platforms capable of facilitating 
high-throughput enzyme screening and proteomic profiling. With the assistance of these 
platforms, they could be used to examine and address a lot of chemical biology 
challenges, such as physiological roles, substrate specificity and downstream targets of 
these enzymes as well as what specific proteins are associated with cancer states, which 
are called biomarkers. 
In chapter 2, by making use of PTP substrate trapping mutants, a phosphopeptide 
array together with dual labeling approach was used to efficiently high-throughput screen 
and identify the strong and selective peptide substrates between highly homologous PTPs. 
We were able to identify several candidate peptides showing selectivity towards SHP1 
and PTP1B over their homologous pairs. However, this strategy also had its own 
limitation, because the substrates fingerprints were based on affinity based interactions, 
while not depending on the exactly actual enzymatic activity of the PTPs and their 
putative substrates, which may generate some false-positive hits when designing PTPs 
inhibitors.   
To overcome the inner limitation of the strategy presented in chapter 2, we then in 
chapter 3 developed an activity based microarray approach for mapping the substrate 
140 
specificity of PTPs, thus truly reflecting how the enzyme carries out dephosphorylation 
reaction under in vitro settings, which was more close to reflect the in vivo case. 
In chapter 4, we presented an array based systematic approach for 
high-throughput screening and identification of several potent and selective SH2 domains 
binders, which could be of great use and importance for the design of selective SH2 
domains inhibitors in future. 
In chapter 5, a 176-member dual color reciprocal phosphopeptide microarray was 
developed for high throughput comparative profiling of mammalian cell lysates 
proteomes. Combined with dual color pull down, MS identification, antibody validation 
on the microarray and western blotting, this new systematic strategy could be used to 
identify and preliminarily validate several cancer biomarker candidates for breast cancer 
(MCF7) and colon cancer (SW620), which would shed light on the cancer differentiation 
and diagnosis in future. 
Overall high-throughput strategies described in this thesis have led to some 
interesting discovery and also solved several challenging chemical biology problems. In 
this thesis, due to limited time for the Ph.D. training, I only used limited examples and 
space to prove these useful platforms developed here; however, they should also be 
readily expanded to other classes of enzymes screening and proteomic profiling as well 
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9.1 Supplemental tables 
 
 
Table 9.1 List of 144 peptides used in the peptide microarray. The table below shows the identify of each peptide sequences，
molecular weight(MW) and original protein sources in this study. (
a
Most peptides (>98%) were shown to possess the expected 
molecular weight and have sufficient purity (>85%) as judged by LCMS analysis. 
b











Original protein  
source (pTyrsite) 
A01 AEKPFpYVNVEF 1762 PTP1B BCR(177) 
A02 AEMTGpYVVTRW 1732  Mitogen kinase 
A03 AENAEpYLRVAP 1652 Shp1 EGF receptor(1197) 
A04 DEELHpYASLNF 1757 Shp1 CD33(340) 
A05 DEGIHpYSELIQ 1723 Shp1 Siglec2(822) 
A06 DEKVDpYVQVDK 1757 Shp1, Shp2 Gab2(643) 
A07 DERVDpYVVVDQ 1756 Shp2 Gab1(689) 
A08 DESVDpYVPMLD 1702 Shp2, TCPTP PDGF(751) 
A09 DKQVEpYLDLDL 1770 Shp2 GAB1(657) 
A10 DSGGFpYITSRT 1623  Src-1 
A11 DTETVpYSEVRK 1746 Shp1 CD31(713) 
A12 EANSHpYGHNDD 1678 Shp1 CD31(663) 
A13 EDEDYpYKASVT 1739 Type 12 
A14 EDGGVpYSSSGL 1489 Photooncogene FER kinase 
A15 EDGISpYTTLRF 1721 Shp1 SIGLEC2(762) 
A16 EDSTYpYKASKG 1668 Fak chick kinase 
A17 EDTLTpYADLDM 1706 Shp2 SIRP(470) 
165 
A18 EGVATpYAAAVL 1484 Shp1 CATENIN(654) 
A19 EGDNDpYIIPLP 1665 TCPTP PDGF(1021) 
A20 ENGLNpYIDLDL 1698 Shp2,PTP1B IRS1(1179) 
A21 EPNVSpYICSRY 1750  Kinase gsk3 
A22 ESDGSpYQKPSY 1680 Shp2 SELECTIN E(603) 
A23 ESDGGpYMDMSK 1638 Shp2 PDGF(740) 
A24 ETDKEpYYTVKD 1810 TCPTP 
JANUS 
KINASE1(1022) 
B01 FEEDDpYESPND 1779 Shp1 SLP76(113) 
B02 FGMTRpYVLDDE 1765 Tyrosine kinase TXK 
B03 FLFNMpYLTRER 1909 Shp1 HOAX1(343) 
B04 FMMTPpYVVTRY 1827  JNK-2 kinase 
B05 GFLTEpYVATRW 1762 PTP1B ERK2(187) 
B06 GNNYVpYIDPTQ 1703 Shp1 KIT(570) 
B07 GSAAPpYLKTKF 1602 TCPTP STAT3(705) 
B08 GWMEDpYDYVHL 1847 P130cas 
B09 GWMVHpYTSKDT 1744 protein kinase c 
B10 HNSALpYSQVQK 1694 p62dok 
B11 HRQLNpYIQVDL 1818 Shp2 FRS2(436) 
B12 IEDNEpYTAREG 1716 Shp1 LYN(397) 
B13 IEDEDpYYKASV 1751 Type 12 
B14 IEDNEpYTARQG 1715 Shp1,type 18, C-SRC(419) 
166 
TCPTP 
B15 IESDIpYAEIPD 1684 Type 12 
B16 IESSNpYMAPYD 1709 PTP1B,TCPTP PDGF(771) 
B17 IRYHRpYHGRSA 1835 Protooncogene kinase, PIM 1 
B18 IYETDpYYRKGG 1784 TCPTP INSULIN(1189) 
B19 KAVDGpYVKPQI 1637 Shp2, PTP1B STAT5B(699) 
B20 KDRMSpYHVRSH 1835  Myc  Zinc  protein 
B21 KKRCPpYTKHQT 1809 Shp1 HOAX10(326) 
B22 KVVALpYDYMPM 1749  BTK kinase 
B23 LISSDpYELLSD  1674 TCPTP JAK3(785) 
B24 LNSDGpYTPEPA 1583 LMW ZAP70(292) 
C01 LNSKGpYTKSID 1645  Erk kinase 
C02 LPPEGpYVVVVK 1619 Shp2 PTK2B(906) 
C03 MDTSVpYESPYS 1698 Tyrosine kinase Zap 70 
C04 MKDEEpYEQMVK 1849 type 13 
C05 MTGDTpYTAHAG 1544 type 12 ABL 
C06 NNHTEpYASIQT 1697 shp1, Shp2 SIRP(453) 
C07 NQSSGpYRYGTD 1667  Fyn kinase 
C08 NSDVQpYTEVQV 1701 shp1, Shp2 CD31(690) 
C09 NSKRDpYTGCST 1651 Shp2 MYELIN(200) 




C11 PEGLNpYACLTH 1637 shp1 ROS1(2334) 
C12 PEGHEpYpYRVRE 1934 PTP1B TYK2(1054) 
C13 PEQDEpYDIPRH 1818 P130cas 
C14 PGSLEpYLCLPA 1582 Shp1, Shp2 
INTERLUKIN 3 
RECEPTOR (628) 
C15 PKGTGpYIKTEL 1626 Shp2,TCPTP STAT1(701) 
C16 PLDKDpYpYVVRE 1896 TCPTP JAK3(981) 
C17 PPDHQpYYNDFP 1812 TCPTP SHC(349) 
C18 PQDKEpYYKVKE 1846 Shp2,PTP1B 
JANUS 
KINASE2(1007) 
C19 PSFSEpYASVQV 1633 Shp2 SIRP(496) 
C20 PSTRDpYEIQRE 1813  Fak kinase 
C21 PQDKEpYpYKVKE 1926  JAK kinase 
C22 QGPVIpYAQLDH 1660 Shp2 MYELIN(241) 
C23 QKQPIpYIVMEL 1781  FES kinase 
C24 QQQEVpYGMMPR 1786 LMW SPECTRIN(1176) 
D01 RNEGVpYTAIAV  1612 Type 12  
D02 REGLNpYMVLAT 1686 Shp1 ROS1(2274) 
D03 SAEPQpYQPGDQ 1639 Photooncogene FGR kinase 
D04 SDDVRpYVNAFK 1733 Shp2 VEGF (1213) 
D05 SDGHEpYIYVDP 1714 TCPTP PDGF(579) 
D06 SEEPIpYIVTEY 1762 Shp1   C-SRC(338) 
168 
D07 SESVVpYADIRK 1686 Shp2 MYELIN(263) 
D08 SETDDpYAEIID 1690 Type 12  
D09 SPPALpYAEPLD 1592  P62dok 
D10 SSNPEpYLSASD 1589 TCPTP INSULIN(999) 
D11 SSSSEpYGSVSP 1505 Mitogen kinase  
D12 SSTVQpYSTVVH 1627 Shp2 
INTERLUKIN 6 
RECEPTOR(759) 
D13 STEPQpYQPGEN 1669 Shp1,PTP1B C-SRC(530) 
D14 TDKEYpYTVKDD 1796 TCPTP 
JANUS KINASE 
1(1023) 
D15 TGGSVpYTEDND 1576 Type 3  
D16 TNDITpYADLNL 1672 Shp2 SIRP(429) 
D17 TSKLI pYDFIED 1763 Type 12  
D18 TSSVLpYTAVQP 1585 Shp2 PDGF(1009) 
D19 VDADEpYLIPQQ 1710 Shp2, PTP1B EGFR(1016) 
D20 VDTPHpYPRWIT 1804  PKC Kinase 
D21 VNTTLpYEKFTY 1798 Shp2 TEK KINASE(1108) 




D23 YETDYpYRKGGK 1799 PTP1B,TCPTP INSULIN(1190) 
D24 YFMTEpYVATRW 1886  Mitogen kinase 
E01 AEGSApYEEVPT 1572 PLC-r 
169 
E02 AENPEpYLSEFS 1705  Erb2 receptor 
E03 FDNLYpYWDQDP 1895  Erb2 receptor 
E04 AFGTVpYKGIWI 1674  Erb2 receptor 
E05 AFQFSpYTAVFG 1657  CAAX Protease 
E06 AKIQDpYHILTR 1777  Jak2 
E07 APAEMpYDIMKT 1689 
Stem cell growth 
factor 
 
E08 ASEQGpYEEMRA 1690  Erb3 




E10 AYRQLpYLNPKG 1742 Chromosomal associate protein 
E11 CPEKVpYELMRA 1758  Abl 1 
E12 DINSLpYDVSRM 1732 PLC-r 
E13 DRFIQpYANPAF 1761 Camp Phosphodiesterase 
E14 DVSRMpYVDPSE 1717  PLC-r 
E15 EDIKSpYYTVRQ 1821 PTP1B  
E16 EEIRFpYQLGEE 1832 Potassium gate 
E17 EKIQDpYEKMPE 1829  IL-1 
E18 ELGYEpYMDVGS 1682  Erb-3 
E19 AELEFpYMDYEA 1800  Alanine scanning 
E20 FGAKPpYDGIPA 1555  Erb2 receptor 
E21 GPQDIpYDVPPV 1619  P130cas 
170 
E22 GQESEpYGNITY 1680 PTN6  




E24 IGEGTpYGTVFK 1591 Cell division kinase 5  
F01 IYIHRpYENVSI 1826  ATP cyclase 
F02 KAEDEpYVNEPL 1726 Erb2 receptor 
F03 KPKQEpYLNPVE 1764 Erb4 
F04 LARDMpYDKEYY 1886  Met growth factor 
F05 LDSTFpYRSLLE 1763  Erb2 receptor 




F07 LLANApYIYVVQ 1686 Neural cell adhesion   
F08 LMGHEpYMEMKN 1802 
Cell division cycle 
protein 23 
 
F09 LNKQGpYKCRQC 1760 Protein kinase C 
F10 NKPTVpYGVSPN 1595 Abl 
F11 PPDHQpYYNDFP 1812 SHC transforming protein 
F12 PEDTFpYFDPEF 1826  ISPK-1 Kinase 
F13 PEPGPpYAQPSV 1561  Adaptor crk 
F14 RHDSGpYEVHHQ 1784 Alzheimer's disease 
F15 RNPGFpYVEANP 1683  PLC-r 



















Table 9.2 Table below shows the dephosphorylation ratio of the 144 phosphopeptides against 4 phosphatases.
F17 SSDPTpYTSSLG 1534 Tyrosine kinase receptor  
F18 EEEPVpYEAEPE 1728 
Hematopoietic 
lineage cell specific 
protein1(HS1) 
 
F19 STKYFpYKQNGR 1811 Erb4 
F20 TAEPDpYGALYE 1648 PLC-r 
F21 VCAERpYSQEVF 1750 Apoptosis Protein cd27 
F22 VDSSLpYNLPRS 1670  Grb2 associated 
F23 VSSTHpYYLLPE 1728 Activated cdc42 kinase  
F24 VVIALpYDYQTN 1718 T cell specific kinase 
172 
ID Sequence 
Dephosphorylation Ratio of Each PPase 
PTP1B TCPTP ΔSHP1 ΔSHP2 LMW 
A01 AEKPFpYVNVEF 0.61 0.37 0.10 0.44 0 
A02 AEMTGpYVVTRW 0.53 0.56 0.15 0.20 0.05 
A03 AENAEpYLRVAP 0.44 0.29 0.33 0.29 0.07 
A04 DEELHpY ASLNF 0.59 0.79 0.51 0.58 0.14 
A05 DEGIHpYSELIQ 0.62 0.63 0.56 0.51 0.13 
A06 DEKVDpYVQVDK 0.50 0.79 0.43 0.49 0.12 
A07 DERVDpYVVVDQ 0.48 0.54 0.52 0.42 0.11 
A08 DESVDpYVPMLD 0.57 0.55 0.39 0.51 0.13 
A09 DKQVEpYLDLDL 0.43 0.33 0.38 0.35 0.09 
A10 DSGGFpYITSRT 0.56 0.90 0.34 0.47 0.12 
A11 DTETVpYSEVRK 0.59 0.37 0.33 0.41 0.1 
A12 EANSHpYGHNDD 0.27 0.36 0.30 0.32 0.08 
A13 EDEDYpY KASVT 0.52 0.60 0.36 0.31 0.08 
A14 EDGGVpYSSSGL 0.46 0.60 0.35 0.47 0.12 
A15 EDGISpYTTLRF 0.40 0.27 0.06 0.30 0.07 
A16 EDSTYpYKASKG 0.43 0.61 0.20 0.38 0.1 
A17 EDTLTpYADLDM 0.44 0.29 0.41 0.36 0.09 
A18 EGVATpYAAAVL 0.40 0.52 0.19 0.38 0.1 
173 
 A19 EGDNDpYIIPLP 0.42 0.09 0.31 0.29 0.07 
A20 ENGLNpYIDLDL 0.42 0.47 0.14 0.46 0.11 
A21 EPNVSpYICSRY 0.31 0.33 0.10 0.22 0.05 
A22 ESDGSpYQKPSY 0.31 0.60 0.15 0.38 0.1 
A23 ESDGGpYMDMSK 0.35 0.35 0.20 0.29 0.07 
A24 ETDKEpYYTVKD 0.32 0.53 0.35 0.36 0.09 
B01 FEEDDpYESPND 0.36 0.29 0.00 0.48 0 
B02 FGMTRpYVLDDE 0.40 0.62 0.23 0.38 0.09 
B03 FLFNMpYLTRER 0.41 0.43 0.22 0.39 0.1 
B04 FMMTPpYVVTRY 0.41 0.50 0.10 0.10 0.03 
B05 GFLTEpYVATRW 0.33 0.41 0.01 0.45 0.11 
B06 GNNYVpYIDPTQ 0.36 0.69 0.27 0.37 0.09 
B07 GSAAPpYLKTKF 0.40 0.31 0.08 0.40 0.1 
B08 GWMEDpYDYVHL 0.13 0.54 0.38 0.36 0.09 
B09 GWMVHpYTSKDT 0.46 0.45 0.21 0.39 0.1 
B10 HNSALpYSQVQK 0.50 0.00 0.10 0.10 0.03 
B11 HRQLNpYIQVDL 0.21 0.46 0.13 0.37 0.09 
B12 IEDNEpYTAREG 0.34 0.52 0.31 0.30 0.08 
B13 IEDEDpYYKASV 0.38 0.48 0.24 0.39 0.1 
B14 IEDNEpYTARQG 0.34 0.67 0.08 0.25 0.06 
174 
B15 IESDIpYAEIPD 0.33 0.49 0.00 0.36 0.09 
B16 IESSNpYMAPYD 0.46 0.64 0.17 0.26 0.07 
B17 IRYHRpYHGRSA 0.23 0.18 0.14 0.37 0.09 
B18 IYETDpYYRKGG 0.18 0.47 0.07 0.32 0.08 
B19 KAVDGpYVKPQI 0.33 0.51 0.06 0.00 0 
B20 KDRMSpYHVRSH 0.12 0.40 0.12 0.14 0.04 
B21 KKRCPpYTKHQT 0.36 0.34 0.05 0.35 0.09 
B22 KVVALpYDYMPM 0.10 0.57 0.00 0.70 0.18 
B23 LISSDpYELLSD 0.54 0.51 0.36 0.53 0.13 
B24 LNSDGpYTPEPA 0.17 0.54 0.00 0.23 0.06 
C01 LNSKGpYTKSID 0.43 0.33 0.10 0.39 0 
C02 LPPEGpYVVVVK 0.51 0.35 0.10 0.00 0 
C03 MDTSVpYESPYS 0.64 0.56 0.57 0.52 0.13 
C04 MKDEEpYEQMVK 0.03 0.57 0.05 0.17 0.04 
C05 MTGDTpYTAHAG 0.48 0.71 0.20 0.44 0.11 
C06 NNHTEpYASIQT 0.22 0.66 0.00 0.34 0.09 
C07 NQSSGpYRYGTD 0.27 0.50 0.16 0.27 0.07 
C08 NSDVQpYTEVQV 0.50 0.56 0.08 0.39 0.1 
C09 NSKRDpYTGCST 0.28 0.33 0.33 0.30 0.08 
C10 NVVPLpYDLLLE 0.27 0.48 0.28 0.29 0.07 
175 
C11 PEGLNpYACLTH 0.12 0.17 0.23 0.42 0.1 
C12 PEGHEpYpYRVRE 0.33 0.44 0.22 0.22 0.06 
C13 PEQDEpYDIPRH 0.30 0.41 0.28 0.35 0.09 
C14 PGSLEpYLCLPA 0.24 0.50 0.17 0.21 0.05 
C15 PKGTGpYIKTEL 0.21 0.18 0.12 0.29 0.07 
C16 PLDKDpYpYVVRE 0.38 0.45 0.31 0.26 0.06 
C17 PPDHQpYYNDFP 0.34 0.34 0.26 0.15 0.04 
C18 PQDKEpYYKVKE 0.28 0.49 0.26 0.41 0.1 
C19 PSFSEpYASVQV 0.00 0.23 0.25 0.10 0.02 
C20 PSTRDpYEIQRE 0.33 0.43 0.30 0.40 0.1 
C21 PQDKEpYpYKVKE 0.01 0.17 0.17 0.29 0.07 
C22 QGPVI pYAQLDH 0.24 0.38 0.09 0.33 0.08 
C23 QKQPIpYIVMEL 0.13 0.60 0.00 0.10 0.03 
C24 QQQEVpYGMMPR 0.32 0.58 0.11 0.24 0.06 
D01 RNEGVpYTAIAV 0.00 0.30 0.10 0.15 0 
D02 REGLNpYMVLAT 0.39 0.85 0.20 0.10 0.03 
D03 SAEPQpYQPGDQ 0.00 0.00 0.00 0.00 0 
D04 SDDVRpYVNAFK 0.41 0.72 0.00 0.00 0 
D05 SDGHEpYIYVDP 0.88 0.46 0.29 0.10 0.03 
D06 SEEPIpYIVTEY 0.00 0.17 0.00 0.00 0 
176 
D07 SESVVpYADIRK 0.50 0.22 0.00 0.00 0 
D08 SETDDpYAEIID 0.28 0.48 0.00 0.16 0.04 
D09 SPPALpYAEPLD 0.44 0.34 0.04 0.00 0 
D10 SSNPEpYLSASD 0.16 0.53 0.20 0.28 0.07 
D11 SSSSEpYGSVSP 0.41 0.40 0.15 0.17 0.04 
D12 SSTVQpYSTVVH 0.10 0.56 0.11 0.19 0.05 
D13 STEPQpYQPGEN 0.35 0.52 0.26 0.43 0.11 
D14 TDKEYpYTVKDD 0.14 0.51 0.05 0.21 0.05 
D15 TGGSVpYTEDND 0.03 0.39 0.50 0.31 0.08 
D16 TNDITpYADLNL 0.31 0.72 0.00 0.36 0.09 
D17 TSKLI pYDFIED 0.40 0.46 0.00 0.40 0.1 
D18 TSSVLpYTAVQP 0.16 0.39 0.00 0.00 0 
D19 VDADEpYLIPQQ 0.29 0.30 0.00 0.18 0.05 
D20 VDTPHpYPRWIT 0.17 0.29 0.09 0.09 0.02 
D21 VNTTLpYEKFTY 0.23 0.30 0.00 0.23 0 
D22 VYESPpYSDPEE 0.30 0.75 0.01 0.20 0.05 
D23 YETDYpYRKGGK 0.05 0.31 0.00 0.19 0 
D24 YFMTEpYVATRW 0.02 0.31 0.00 0.11 0.03 
E01 AEGSApYEEVPT 0.00 0.32 0.18 0.10 0 
E02 AENPEpYLSEFS 0.31 0.43 0.14 0.22 0.06 
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E03 FDNLYpYWDQDP 0.50 0.20 0.26 0.28 0.07 
E04 AFGTVpYKGIWI 0.03 0.00 0.00 0.21 0 
E05 AFQFSpYTAVFG 0.39 0.36 0.18 0.32 0.08 
E06 AKIQDpYHILTR 0.15 0.36 0.00 0.18 0.04 
E07 APAEMpYDIMKT 0.45 0.57 0.30 0.29 0.07 
E08 ASEQGpYEEMRA 0.27 0.26 0.10 0.27 0.07 
E09 ATVGHpYTAVQN 0.19 0.22 0.29 0.44 0.11 
E10 AYRQLpYLNPKG 0.26 0.41 0.13 0.21 0.05 
E11 CPEKVpYELMRA 0.00 0.23 0.06 0.24 0.06 
E12 DINSLpYDVSRM 0.26 0.35 0.06 0.36 0.09 
E13 DRFIQpYANPAF 0.15 0.27 0.02 0.20 0.05 
E14 DVSRMpYVDPSE 0.38 0.59 0.07 0.30 0.08 
E15 EDIKSpYYTVRQ 0.01 0.41 0.00 0.09 0.02 
E16 EEIRFpYQLGEE 0.26 0.26 0.00 0.23 0.06 
E17 EKIQDpYEKMPE 0.39 0.28 0.10 0.33 0 
E18 ELGYEpYMDVGS 0.34 0.46 0.11 0.27 0.07 
E19 AELEFpYMDYEA 0.25 0.40 0.13 0.32 0 
E20 FGAKPpYDGIPA 0.29 0.55 0.11 0.34 0.09 
E21 GPQDIpYDVPPV 0.27 0.45 0.27 0.40 0.1 
E22 GQESEpYGNITY 0.36 0.48 0.14 0.42 0.11 
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E23 GRETIpYPNASL 0.32 0.47 0.35 0.34 0.09 
E24 IGEGTpYGTVFK 0.38 0.35 0.00 0.30 0.07 
F01 IYIHRpYENVSI 0.00 0.26 0.00 0.13 0.03 
F02 KAEDEpYVNEPL 0.40 0.50 0.00 0.00 0 
F03 KPKQEpYLNPVE 0.34 0.37 0.00 0.00 0 
F04 LARDMpYDKEYY 0.00 0.32 0.00 0.00 0 
F05 LDSTFpYRSLLE 0.27 0.47 0.00 0.13 0.03 
F06 LGQRIpYQYIQS 0.00 0.45 0.00 0.24 0.06 
F07 LLANApYIYVVQ 0.00 0.30 0.00 0.00 0 
F08 LMGHEpYMEMKN 0.24 0.54 0.07 0.23 0 
F09 LNKQGpYKCRQC 0.20 0.46 0.00 0.00 0 
F10 NKPTVpYGVSPN 0.49 0.56 0.26 0.14 0.03 
F11 PPDHQpYYNDFP 0.27 0.56 0.13 0.23 0.06 
F12 PEDTFpYFDPEF 0.43 0.64 0.14 0.11 0.03 
F13 PEPGPpYAQPSV 0.55 0.48 0.05 0.12 0.03 
F14 RHDSGpYEVHHQ 0.27 0.66 0.30 0.14 0.03 
F15 RNPGFpYVEANP 0.26 0.52 0.00 0.00 0 
F16 SADHLpYVNVSE 0.00 0.41 0.03 0.12 0.03 
F17 SSDPTpYTSSLG 0.30 0.45 0.00 0.26 0 

















F19 STKYFpYKQNGR 0.00 0.54 0.00 0.19 0 
F20 TAEPDpYGALYE 0.34 0.65 0.19 0.37 0.09 
F21 VCAERpYSQEVF 0.17 0.56 0.00 0.10 0 
F22 VDSSLpYNLPRS 0.34 0.67 0.03 0.09 0 
F23 VSSTHpYYLLPE 0.21 0.71 0.08 0.16 0 
F24 VVIALpYDYQTN 0.20 0.22 0.00 0.26 0.07 
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Table 9.3 List of 176 peptide sequences, molecular weight (MW) and original protein sources of 176 phosphopeptides used in this study. 
 
 
NO. 384 well plate Peptide Sequence MW
a
 Original protein source(pYsite) 
1 Plate1_A01 AEKPF-pY-VNVEF 1761.7 BCR(177) 
2 Plate1_A02 AEMTG-pY-VVTRW 1731.7 Mitogen kinase 
3 Plate1_A03 AENAE-pY-LRVAP 1651.7 EGF receptor(1197) 
4 Plate1_A04 DEELH-pY-ASLNF 1756.6 CD33(340) 
5 Plate1_A05 DEGIH-pY-SELIQ 1722.6 SIGLEC2 (822) 
6 Plate1_A06 DEKVD-pY-VQVDK 1756.7 Gab2(643) 
7 Plate1_A07 DERVD-pY-VVVDQ 1755.7 Gab1(689) 
8 Plate1_A08 DESVD-pY-VPMLD 1701.6 PDGF(751) 
9 Plate1_A09 DKQVE-pY-LDLDL 1769.7 GAB1(657) 
10 Plate1_A10 DSGGF-pY-ITSRT 1622.6 Src-1 
11 Plate1_A11 DTETV-pY-SEVRK 1745.6 CD31(713) 
12 Plate1_A12 EANSH-pY-GHNDD 1677.5 CD31(663) 
13 Plate1_A13 EDEDY-pY-KASVT 1738.6 Type 12 
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14 Plate1_A14 EDGGV-pY-SSSGL 1489.5 Photo-oncogene FER kinase 
15 Plate1_A15 EDGIS-pY-TTLRF 1720.7 SIGLEC2(762) 
16 Plate1_A16 EDSTY-pY-KASKG 1667.6 Fak chick kinase 
17 Plate1_A17 EDTLT-pY-ADLDM 1705.6 SIRP(470) 
18 Plate1_A18 EGVAT-pY-AAAVL 1483.6 CATENIN(654) 
19 Plate1_A19 EGDND-pY-IIPLP 1664.6 PDGF(1021) 
20 Plate1_A20 ENGLN-pY-IDLDL 1697.7 IRS1(1179) 
21 Plate1_A21 EPNVS-pY-ICSRY 1749.6 Kinase gsk3 
22 Plate1_A22 ESDGS-pY-QKPSY 1679.6 Selectin E(603) 
23 Plate1_A23 ESDGG-pY-MDMSK 1638.5 PDGF(740) 
24 Plate1_A24 ETDKE-pY-YTVKD 1809.7 Janus kinase 1(1022) 
25 Plate1_B01 FEEDD-pY-ESPND 1778.5 SLP76(113) 
26 Plate1_B02 FGMTR-pY-VLDDE 1764.6 Tyrosine kinase TXK 
27 Plate1_B03 FLFNM-pY-LTRER 1908.8 HOAX1(343) 
28 Plate1_B04 FMMTP-pY-VVTRY 1826.7 JNK-2 kinase 
29 Plate1_B05 GFLTE-pY-VATRW 1761.7 ERK2(187) 
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30 Plate1_B06 GNNYV-pY-IDPTQ 1702.6 KIT(570) 
31 Plate1_B07 GSAAP-pY-LKTKF 1601.7 STAT3(705) 
32 Plate1_B08 GWMED-pY-DYVHL 1846.6 P130cas 
33 Plate1_B09 GWMVH-pY-TSKDT 1743.6 Protein kinase c 
34 Plate1_B10 HNSAL-pY-SQVQK 1693.7 p62dok 
35 Plate1_B11 HRQLN-pY-IQVDL 1817.8 FRS2(436) 
36 Plate1_B12 IEDNE-pY-TAREG 1715.6 LYN(397) 
37 Plate1_B13 IEDED-pY-YKASV 1750.6 Type 12 
38 Plate1_B14 IEDNE-pY-TARQG 1714.6 C-Src(419) 
39 Plate1_B15 IESDI-pY-AEIPD 1683.6 Type 12 
40 Plate1_B16 IESSN-pY-MAPYD 1708.6 PDGF(771) 
41 Plate1_B17 IRYHR-pY-HGRSA 1834.8 Protooncogene kinase, PIM 1 
42 Plate1_B18 IYETD-pY-YRKGG 1783.7 Insulin(1189) 
43 Plate1_B19 KAVDG-pY-VKPQI 1636.7 STAT5B(699) 
44 Plate1_B20 KDRMS-pY-HVRSH 1834.7 Myc zinc protein 
45 Plate1_B21 KKRCP-pY-TKHQT 1808.8 HOAX10(326) 
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46 Plate1_B22 KVVAL-pY-DYMPM 1748.7 BTK kinase 
47 Plate1_B23 LISSD-pY-ELLSD 1673.6 JAK3(785) 
48 Plate1_B24 LNSDG-pY-TPEPA 1582.6 ZAP70(292) 
49 Plate1_C01 LNSKG-pY-TKSID 1644.7 Erk kinase 
50 Plate1_C02 LPPEG-pY-VVVVK 1618.7 PTK2B(906) 
51 Plate1_C03 MDTSV-pY-ESPYS 1697.6 Tyrosine kinase Zap 70 
52 Plate1_C04 MKDEE-pY-EQMVK 1848.7 type 13 
53 Plate1_C05 MTGDT-pY-TAHAG 1543.5 ABL 
54 Plate1_C06 NNHTE-pY-ASIQT 1696.6 SIRP(453) 
55 Plate1_C07 NQSSG-pY-RYGTD 1666.6 Fyn kinase 
56 Plate1_C08 NSDVQ-pY-TEVQV 1700.6 CD31(690) 
57 Plate1_C09 NSKRD-pY-TGCST 1650.6 Myelin(200) 
58 Plate1_C10 NVVPL-pY-DLLLE 1706.8 Estrogen receptor(537) 
59 Plate1_C11 PEGLN-pY-ACLTH 1636.6 ROS1(2334) 
60 Plate1_C12 PEGHE-pY-pY-RVRE 1933.7 TYK2(1054) 
61 Plate1_C13 PEQDE-pY-DIPRH 1817.7 P130cas 
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62 Plate1_C14 PGSLE-pY-LCLPA 1581.6 Interlukin receptor (628) 
63 Plate1_C15 PKGTG-pY-IKTEL 1625.7 STAT1(701) 
64 Plate1_C16 PLDKD-pY-pY-VVRE 1895.7 JAK3(981) 
65 Plate1_C17 PPDHQ-pY-YNDFP 1811.6 SHC(349) 
66 Plate1_C18 PQDKE-pY-YKVKE 1845.8 Janus kinase 2(1007) 
67 Plate1_C19 PSFSE-pY-ASVQV 1632.6 SIRP(496) 
68 Plate1_C20 PSTRD-pY-EIQRE 1812.7 Fak kinase 
69 Plate1_C21 PQDKE-pY-pY-KVKE 1925.8 JAK kinase 
70 Plate1_C22 QGPVI-pY-AQLDH 1659.7 Myelin(241) 
71 Plate1_C23 QKQPI-pY-IVMEL 1780.8 FES kinase 
72 Plate1_C24 QQQEV-pY-GMMPR 1785.7 Spectrin(1176) 
73 Plate1_D01 RNEGV-pY-TAIAV 1611.7 Type 12 
74 Plate1_D02 REGLN-pY-MVLAT 1685.7 ROS1(2274) 
75 Plate1_D03 SAEPQ-pY-QPGDQ 1638.6 Photooncogene FGR kinase 
76 Plate1_D04 SDDVR-pY-VNAFK 1732.7 VEGF (1213) 
77 Plate1_D05 SDGHE-pY-IYVDP 1713.6 PDGF(579) 
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78 Plate1_D06 SEEPI-pY-IVTEY 1761.7 C-Src(338) 
79 Plate1_D07 SESVV-pY-ADIRK 1685.7 Myelin(263) 
80 Plate1_D08 SETDD-pY-AEIID 1689.6 Protein tyrosine kinase 2 beta Type 12 
81 Plate1_D09 SPPAL-pY-AEPLD 1591.6 P62dok 
82 Plate1_D10 SSNPE-pY-LSASD 1588.5 Insulin (999) 
83 Plate1_D11 SSSSE-pY-GSVSP 1505.5 Mitogen kinase 
84 Plate1_D12 SSTVQ-pY-STVVH 1626.6 Interlukin 6 receptor (759) 
85 Plate1_D13 STEPQ-pY-QPGEN 1668.6 C-Src(530) 
86 Plate1_D14 TDKEY-pY-TVKDD 1795.7 Janus kinase1(1023) 
87 Plate1_D15 TGGSV-pY-TEDND 1576.5 Type 3 
88 Plate1_D16 TNDIT-pY-ADLNL 1671.6 SIRP(429) 
89 Plate1_D17 TSKLI-pY-DFIED 1762.7 Type 12 
90 Plate1_D18 TSSVL-pY-TAVQP 1584.6 PDGF(1009) 
91 Plate1_D19 VDADE-pY-LIPQQ 1709.7 EGFR(1016) 
92 Plate1_D20 VDTPH-pY-PRWIT 1803.7 PKC kinase 
93 Plate1_D21 VNTTL-pY-EKFTY 1797.7 Tek kinase(1108) 
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94 Plate1_D22 VYESP-pY-SDPEE 1733.6 Tyrosine kinase zap-70 
95 Plate1_D23 YETDY-pY-RKGGK 1798.7 Insulin (1190) 
96 Plate1_D24 YFMTE-pY-VATRW 1885.7 Mitogen-activated protein kinase 7 
97 Plate1_E01 AEGSA-pY-EEVPT 1571.5 PLC-r 
98 Plate1_E02 AENPE-pY-LSEFS 1704.6 Erb2 receptor 
99 Plate1_E03 FDNLY-pY-WDQDP 1894.6 Erb2 receptor 
100 Plate1_E04 AFGTV-pY-KGIWI 1673.7 Erb2 receptor 
101 Plate1_E05 AFQFS-pY-TAVFG 1656.6 CAAX Protease 
102 Plate1_E06 AKIQD-pY-HILTR 1776.8 Jak2 
103 Plate1_E07 APAEM-pY-DIMKT 1688.6 Stem cell growth factor 
104 Plate1_E08 ASEQG-pY-EEMRA 1689.6 Erb3 
105 Plate1_E09 ATVGH-pY-TAVQN 1579.6 Cyclin kinase activator 
106 Plate1_E10 AYRQL-pY-LNPKG 1741.8 Chromosomal associate protein 
107 Plate1_E11 CPEKV-pY-ELMRA 1757.7 Abl 1 
108 Plate1_E12 DINSL-pY-DVSRM 1731.7 PLC-r 
109 Plate1_E13 DRFIQ-pY-ANPAF 1760.7 Camp phosphodiesterase 
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110 Plate1_E14 DVSRM-pY-VDPSE 1716.6 PLC-r 
111 Plate1_E15 EDIKS-pY-YTVRQ 1820.7 PTP1B 
112 Plate1_E16 EEIRF-pY-QLGEE 1831.7 Potassium gate 
113 Plate1_E17 EKIQD-pY-EKMPE 1828.7 IL-1 
114 Plate1_E18 ELGYE-pY-MDVGS 1681.6 Erb-3 
115 Plate1_E19 AELEF-pY-MDYEA 1799.6 Alanine scanning 
116 Plate1_E20 FGAKP-pY-DGIPA 1554.6 Erb2 receptor 
117 Plate1_E21 GPQDI-pY-DVPPV 1618.6 P130cas 
118 Plate1_E22 GQESE-pY-GNITY 1679.6 PTN6 
119 Plate1_E23 GRETI-pY-PNASL 1639.7 Carcinoembroyonic antigen 
120 Plate1_E24 IGEGT-pY-GTVFK 1590.6 Cell division kinase 5 
121 Plate1_F01 IYIHR-pY-ENVSI 1825.8 ATP cyclase 
122 Plate1_F02 KAEDE-pY-VNEPL 1725.7 ERB2 receptor 
123 Plate1_F03 KPKQE-pY-LNPVE 1763.8 ERB4 
124 Plate1_F04 LARDM-pY-DKEYY 1885.7 Met growth factor 
125 Plate1_F05 LDSTF-pY-RSLLE 1762.7 Erb2 receptor 
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126 Plate1_F06 LGQRI-pY-QYIQS 1787.8 Dual specificity regulated kinase 
127 Plate1_F07 LLANA-pY-IYVVQ 1685.7 Neural cell adhesion 
128 Plate1_F08 LMGHE-pY-MEMKN 1801.6 Cell division cycle protein 23 
129 Plate1_F09 LNKQG-pY-KCRQC 1759.7 Protein kinase C 
130 Plate1_F10 NKPTV-pY-GVSPN 1594.6 Abl 
131 Plate1_F11 PPDHQ-pY-YNDFP 1811.6 SHC transforming protein 
132 Plate1_F12 PEDTF-pY-FDPEF 1825.6 ISPK-1 kinase 
133 Plate1_F13 PEPGP-pY-AQPSV 1560.6 Adaptor crk 
134 Plate1_F14 RHDSG-pY-EVHHQ 1783.6 Alzheimer's disease 
135 Plate1_F15 RNPGF-pY-VEANP 1682.6 PLC-r 
136 Plate1_F16 SADHL-pY-VNVSE 1652.6 Tumor necrosis factor 
137 Plate1_F17 SSDPT-pY-TSSLG 1533.5 Tyrosine kinase receptor 
138 Plate1_F18 EEEPV-pY-EAEPE 1727.7 Hematopoietic lineage cell specific 
protein1(HS1) 
139 Plate1_F19 STKYF-pY-KQNGR 1810.7 Erb4 
140 Plate1_F20 TAEPD-pY-GALYE 1647.6 PLC-r 
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141 Plate1_F21 VCAER-pY-SQEVF 1749.6 Apoptosis Protein cd27 
142 Plate1_F22 VDSSL-pY-NLPRS 1669.7 GRB2 associated 
143 Plate1_F23 VSSTH-pY-YLLPE 1727.7 Activated cdc42 kinase 
144 Plate1_F24 VVIAL-pY-DYQTN 1717.7 T cell specific kinase 
145 Plate1_G01 LV-pY-LNVMELV 1610.7 Protein tyrosine kinase 2 beta 
146 Plate1_G02 PE-pY-VNQPDVR 1634.6 Receptor tyrosine- 
protein kinase erbB-2 precursor 
147 Plate1_G03 NQ-pY-GNVLSLP 1539.6 B-lymphocyte antigen CD19 precursor 
148 Plate1_G04 PS-pY-VNVQNLD 1566.6 SHC-transforming protein 1(317) 
149 Plate1_G05 VR-pY-VNAFKFM 1692.7 Vascular endothelial growth factor receptor 
1 precursor 
150 Plate1_G06 EL-pY-SNALPVG 1480.6 Beta platelet-derived growth factor receptor 
precursor 
151 Plate1_G07 NI-pY-VEVEDEG 1584.6 SH2 domain protein 2A 
152 Plate1_G08 VI-pY-DFIEKTG 1602.7 Neural Wiskott-Aldrich syndrome protein 
153 Plate1_G09 VL-pY-TEVIPML 1595.7 Olfactory receptor 9Q1 
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154 Plate1_G10 PE-pY-EEEEVAI 1625.6 Ras GTPase-activating protein 1 
155 Plate1_G11 PL-pY-VLVEYAA 1555.7 Fibroblast growth factor receptor 3 
precursor 
156 Plate1_G12 AI-pY-EEIDAHQ 1606.6 TOM1-like 1 protein 
157 Plate1_G13 EL-pY-FLIARYL 1718.8 Bromodomain and WD repeat 
domain-containing protein 1 
158 Plate1_G14 PP-pY-RHIDPFD 1674.6 Macrophage-stimulating protein receptor 
precursor 
159 Plate1_G15 KP-pY-DGIPASE 1494.6 Epidermal growth factor receptor 
precursor(pY 891) 
160 Plate1_G16 NP-pY-CNIYLNS 1618.6 Ras GTPase-activating protein 1 
161 Plate1_H01 DI-pY-AEIPDET 1583.6 Protein tyrosine kinase 2 beta 
162 Plate1_H02 PV-pY-EEPVYEE 1671.6 Centaurin-delta 3 
163 Plate1_H03 SD-pY-ENPDEHS 1610.5 B-cell linker protein 
164 Plate1_H04 EV-pY-DVPPSVE 1551.6 Breast cancer anti-estrogen resistance 
protein 1 
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165 Plate1_H05 PI-pY-ELTSQFT 1616.6 Caspase-8 precursor 
166 Plate1_H06 EV-pY-DTPPMAV 1539.6 Breast cancer anti-estrogen resistance 
protein 1 
167 Plate1_H07 GW-pY-EGVCNRV 1600.6 Abl interactor 1 
168 Plate1_H08 NT-pY-DVVYLKV 1631.7 Discs large homolog 4 
169 Plate1_H09 PV-pY-EEVGAFP 1525.6 Centaurin-delta 3 
170 Plate1_H10 AL-pY-DNVPECA 1512.5 Enhancer of filamentation 1 
171 Plate1_H11 PH-pY-EKVSGDY 1612.6 Ephrin-B2 precursor 
172 Plate1_H12 DS-pY-ENMDNPD 1617.5 B-lymphocyte antigen CD19 precursor 
173 Plate1_H13 DV-pY-ENLHTKN 1650.6 Tyrosine-protein phosphatase non-receptor 
type 6 
174 Plate1_H14 PI-pY-ENVNPEY 1655.6 Receptor-type tyrosine-protein 
phosphatase beta precursor 
175 Plate1_H15 EQ-pY-ELYCEMG 1682.5 E3 ubiquitin-protein ligase CBL 
176 Plate1_H16 QG-pY-EEMRAFQ 1676.6 Receptor tyrosine-protein kinase erbB-3 
precursor 
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Table 9.4 LC-MS results of representative library members. 
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